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Abstract 
The herpes simplex virus type 1 (HSV-1) UL25 protein (pUL25) is a minor capsid 
protein that is essential for packaging the full-length viral genome into 
preformed precursor capsid.  It is also important in virus entry and recently has 
been implicated in the egress of the virus from the cell (Coller et al., 2007, 
Preston et al., 2008).  The crystallographic structure of an N-terminally 
truncated form of pUL25 (residues 134-580) has been determined to 2.1 Å, 
revealing a protein with a novel fold that consists mostly of α-helices and a few 
minor β-sheets (Bowman et al., 2006).  An unusual feature of the protein is the 
presence of numerous flexible loops extending out from the stable core and its 
distinctive electrostatic distribution.  Five of the extended loops contain 
unstructured regions, L1-L5, with three additional unstructured amino acids, L6, 
located at the carboxyl terminus of the protein (Bowman et al., 2006). Four 
potentially functional clusters of residues, C1-C4, were identified on the surface 
of the protein using evolutionary trace analysis (Lichtartge & Sowa, 2002).   
To examine the function of the protein in relation to its structure, site-directed 
mutations were engineered into the UL25 gene in a protein expression plasmid.  
A series of mutant proteins was generated, each protein containing a deletion of 
the unstructured residues in one of the six regions, L1-L6.  Another set of mutant 
proteins were constructed with each member containing substitutions of 
selected amino acids within one of the four potentially functional clusters, C1-
C4, or substitutions of the three disordered amino acids in L6.  The amino acid 
substitutions were generally to alanine, but in one case where the SIFT program 
predicted alanine would not affect the function of the protein an alternative 
residue was substituted.  To determine the functional significance of the 
uncrystallised part of pUL25, residues 1-133, three deletion mutant proteins that 
spanned this region (pUL25Δ1-45, pUL25Δ1-59 and pUL25Δ1-133) were included 
in the study.   
Although an existing UL25 null mutant, KUL25NS, was available at the beginning 
of the project for analysis of the mutant proteins, it had been made by the 
insertion of multiple stop codons in the UL25 ORF and as a result some UL25 
sequences were still present within the virus genome.  Consequently, during 
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complementation assays recombination between the UL25 sequences in the 
KUL25NS genome and the transfected expression plasmid generated low levels of 
wild-type (wt) progeny virus.   To improve the sensitivity of the assay, a new 
deletion mutant, ΔUL25MO, was created that lacked the entire UL25 gene.  This 
mutant failed to form plaques in non-permissive Vero cells and grew well in the 
complementing cell line, 8-1.  However, contrary to previously published work, 
electron microscopic (EM) analysis revealed that DNA-containing capsids as well 
as A- and B-capsids were present in the nuclei of both ΔUL25MO- and KUL25NS-
infected cells.  As expected, none of the progeny from ΔUL25MO-infected Vero 
cells expressing the wt pUL25 formed plaques on non-permissive cells.  Of the 17 
mutant UL25 proteins screened in the complementation assay, nine failed to 
complement the growth of ΔUL25MO in Vero cells.  
Three of the non-complementing mutant proteins, pUL25-C4A, pUL25-L3 and 
pUL25-L6, altered the phenotype of ΔUL25MO in a transient DNA packaging 
assay, allowing the mutant virus to package full-length genomes in U2OS cells 
co-infected with ΔUL25MO and a mammalian baculovirus vector containing the 
mutant UL25 gene.  These results indicate that viral assembly was disrupted in 
these cells following DNA packaging.  Five mutant proteins, pUL25-C3B, pUL25-
L5, pUL25Δ1-45, pUL25Δ1-59 and pUL25Δ1-133 did not change the pattern of 
DNA encapsidation of ΔUL25MO in this system, suggesting that C3, L5 and the N-
terminal region are critical for packaging virus DNA.  Since C3 and L5 regions are 
on different sides of pUL25, it is likely that these regions and possibly the N-
terminal domain of pUL25 represent different interfaces for protein-protein 
interactions important for DNA packaging.  To determine at which point in the 
virus growth cycle these post-packaging blocks occurred, EM was used to 
investigate the pattern of virus assembly in ΔUL25MO-infected cells expressing 
pUL25-C4A, -L3 or –L6 and fluorescent in-situ hybridisation (FISH) analysis was 
performed to establish the distribution of virus DNA in these cells.  The results 
showed that in ΔUL25MO-infected cells expressing pUL25-C4A or –L3, the C-
capsids failed to exit the nucleus, whereas in the cells expressing pUL25-L6 the 
C-capsids were seen in both the nucleus and the cytoplasm.  The FISH data 
confirmed the EM observations, and viral DNA was detected only in the nuclei of 
ΔUL25MO–infected cells expressing the C4 or L3 mutant proteins, but in the 
nuclei and cytoplasm of the mutant virus-infected cells expressing pUL25-L6.  
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These studies show that the C4 and L3 regions of pUL25 are important for egress 
of the C-capsids from the nuclei, whereas the L6 region is essential for virus 
assembly after the C-capsids are released into the cytoplasm.  The C4 and L3 
regions of pUL25 are situated in close proximity to each other on the surface of 
pUL25, with the wt residues mutated in pUL25-C4A lying along a loop adjacent 
to L3.  The similar phenotypes of the mutant proteins generated for the C4 and 
L3 suggest that these two regions may represent a single functional interface of 
pUL25 that is critical for nuclear egress of C-capsids during HSV-1 infection.  The 
62 carboxyl-terminal region of the UL36 gene product (pUL36) has previously 
been shown to contain a capsid-binding domain (CBD) that interacts with pUL25 
(Coller et al., 2007).  A GST-pull down assay was used to determine whether the 
mutations in the post-packaging mutant proteins, pUL25-C4A, -L3, –L6, or the 
control packaging-competent mutant protein, pUL25-L5, disrupted the 
interaction of pUL25 with the CBD of pUL36.  However, all of these mutant 
proteins and the wt pUL25 bound to the pUL36 CBD GST fusion protein.   
In summary, three different classes of pUL25 mutants, each of which affect a 
different essential function of pUL25, have been identified, revealing that pUL25 
is indeed a versatile viral protein.  These mutants provide the first evidence that 
this DNA packaging protein is crucial for virus assembly at two different stages 
after DNA encapsidation, one in nuclear egress of C-capsids and the other in the 
assembly of the virus in the cytoplasm.   
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Glutamic acid Glu   E  Acidic  
Glycine  Gly   G  Polar (neutral) 
Histidine  His   H  Basic 
Isoleucine  Ile   I  Non-polar (hydrophobic)  
Leucine  Leu   L  Non-polar (hydrophobic) 
Lysine   Lys   K  Basic 
Methionine  Met   M  Non-polar (hydrophobic) 
Phenylalanine Phe   F  Non-polar (hydrophobic) 
Proline  Pro   P  Non-polar (hydrophobic) 
Serine   Ser   S  Polar (neutral) 
Threonine  Thr   T  Polar (neutral) 
Tryptophan  Trp   W  Non-polar (hydrophobic) 
Tyrosine  Tyr   Y  Polar (neutral) 
Valine   Val   V  Non-polar (hydrophobic) 
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Nucleotide abbreviations 
 
Base      One letter code 
 
Adenine (Purine)     A 
Cytosine (Pyrimidine)    C 
Guanine (Purine)     G 
Thymidine (Pyrimidine)    T 
Uracil (Pyrimidine)     U   
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1 Introduction 
1.1 Introduction to herpesviruses 
1.1.1 Classification of herpesviruses 
Herpesviruses are a large diverse group of double-stranded DNA (dsDNA) viruses 
with a wide range of host species, including most vertebrate and at least one 
invertebrate.  Few herpesviruses naturally infect more than one species and it is 
likely that the 200 herpesviruses identified so far only reflects a small proportion 
of the probable number in existence (Pellet & Roizman, 2007).  Historically, 
members of the herpesvirus family were identified by their virion morphology, 
which consists of four distinct layers (Section 1.2) (Davison, 2002, Pellet & 
Roizman, 2007).  In addition to virion structure, members of the family exhibit 
the following common biological characteristics:  
• They all encode a large range of enzymes and proteins involved in nucleic 
acid metabolism, DNA synthesis and the processing of proteins.   
• Viral DNA replication, capsid assembly and encapsidation of viral DNA 
occur in the nucleus, while further viral maturation takes place in the 
cytoplasm of the infected cell.   
• The production of infectious viral progeny invariably leads to destruction 
of the infected cell.   
• They all share the ability to maintain a dormant or latent persistent 
infection throughout the lifetime of the host.  Latent viruses express only 
a subset of viral genes and retain the capacity to replicate and cause 
disease on reactivation.   
Although family members share these features, different herpesviruses also 
display considerable variation with respect to other biological properties:  they 
differ in the clinical manifestations of the diseases they cause, their host cell 
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range in vitro and the length of their replicative cycle.  In addition, the specific 
cell type in which the different herpesviruses remain latent varies.   
Since the advent of DNA sequencing technology, the traditional approach for 
classifying family members on biological criteria has been replaced by 
classification based primarily on DNA sequence homology and genome 
organisation (Davison, 2002, McGeoch et al., 2006).  On this basis a new order 
has been established, Herpesvirales, which has divided the former Herpesviridae 
family into three distinct lineages (Davison et al., 2009).  The revised 
Herpesviridae family retains the herpesviruses that infect mammals, birds and 
reptiles, while the new family Alloherpesviridae comprises viruses with fish or 
amphibian hosts and the other new family Malacoherpesviridae currently 
includes a single virus that infects marine bivalves (Davison et al., 2005, 
McGeoch et al., 2006).  The family Herpesviridae has been further          
classified into the subfamilies Alphaherpesvirinae, Betaherpesvirinae and 
Gammaherpesvirinae.  Eight distinct human herpesviruses have been identified 
so far and there are representatives from each of the three subfamilies (Table 
1.1).   
Currently there is an extensive catalogue of sequence data for herpesvirus 
genomes, which range in size from 124-241 kilo base pairs (kbp) with an 
estimated one gene per 1.5-2 kbp of herpesvirus genome (Davison et al., 2003, 
McGeoch et al., 2006).  The DNA sequence information allowed the reassessment 
of herpesvirus classification on the basis of gene conservation, positioning and 
arrangement of gene clusters relative to one another, the arrangement of 
terminal sequences or the presence of nucleotides subject to methylation 
(McGeoch et al., 2006, McGeoch et al., 2005, Pellet & Roizman, 2007).  In the 
light of these data the original system proved to be remarkably accurate, since 
only a few viruses had to be re-classified.  Two human herpesviruses, HHV-6 and 
HHV-7, were reassigned to the Betaherpesvirinae subfamily following amino acid 
and DNA sequence comparisons.  In addition, DNA sequence information enabled 
the construction of a phylogenetic tree illustrating the common ancestral origin 
of the herpesvirus family (Figure 1.1).       
Virus Common Name  Abbreviation Subfamily Genera Genome Size (kb) Disease 
HHV-1 Herpes simplex virus type 1 HSV-1 Alphaherpesvirinae Simplexvirus 152 Cold sores  
HHV-2 Herpes simplex virus type 2  HSV-2 Alphaherpesvirinae Simplexvirus 152 Genital ulcers 
HHV-3 Varicella-zoster virus  VZV Alphaherpesvirinae Varicellovirus 125 Chicken pox, shingles 
HHV-4 Epstein-Barr virus  EBV Gammaherpesvirinae Lymphocryptovirus 172 
Infectious mononucleosis, 
Burkitt’s lymphoma, 
Hodgkin’s disease. 
HHV-5 Human cytomegalovirus  HCMV Betaherpesvirinae Cytomegalovirus 236 
Disseminated disease in 
neonates and in immuno-
compromised individuals  
HHV-6 Human herpesvirus 6 HHV-6 Betaherpesvirinae Roseolovirus 160 Exanthema subitum (Infant rash) 
HHV-7 Human herpesvirus 7 HHV-7 Betaherpesvirinae Roseolovirus 145 Exanthema subitum (Infant rash) 
HHV-8 Kaposi’s sarcoma-associated herpesvirus  KSHV Gammaherpesvirinae Rhadinovirus 170 
Associated with Kaposi’s 
sarcoma 
 
 
Table 1.1 Human herpesviruses and their classification and associated diseases (Pellet & Roizman, 2007; Davison et al., 2009)  
Figure 1.1 Phylogenetic relationships and taxonomy of major herpesviruses
The diagram shows branching patterns and not evolutionary relationships (adapted from 
Pellet & Roizman 2007).
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1.1.1.1 Alphaherpesvirinae 
The main features for members of this subfamily are: they display a variable 
host range in vitro, with the ability to infect a variety of cell lines in culture; 
they have a relatively short replicative cycle of less than 24 hours (h); spread 
rapidly in tissue culture; show a strong cytopathic effect (CPE) in infected cells 
and establish latency primarily in sensory ganglia.  The subfamily is further 
divided into the four genera: Simplexvirus, which includes herpes simplex virus 
type 1 (HSV-1) and type 2 (HSV-2); Varicellovirus, which includes varicella-zoster 
virus (VZV); Mardivirus and Iltovirus, members of which infect avian hosts 
(Pellet & Roizman, 2007).   
1.1.1.2 Betaherpesvirinae   
Members of this subfamily have a restrictive host range in vitro and in vivo.  The 
reproductive cycle is long, infection progresses slowly in culture and infected 
cells often become enlarged (cytomegalia).  Carrier cultures can be readily 
established in which cells survive following infection.  In the natural host the 
virus is maintained in the latent form in a wide range of cell types including 
secretory glands, lymphoreticular cells, kidneys and other tissues.  This 
subfamily contains the genus Cytomegalovirus, which includes human 
cytomegalovirus (HCMV) and the genus Roseoloviruses, which include human 
herpesvirus type 6 (HHV-6) and type 7 (HHV-7) (Pellet & Roizman, 2007).     
1.1.1.3 Gammaherpesvirinae 
Herpesviruses within this subfamily are characterised by a limited experimental 
host range, restricted to the family or order to which the natural host belongs.  
In culture all members replicate in lymphoblastoid cells and are usually specific 
for either T or B lymphocytes.  Latent infections also occur frequently within 
lymphoblastoid tissue.  However, some viruses in this group produce a 
productive or lytic infection in other cell types, such as epithelioid and 
fibroblastic cells.  Two genera in this subfamily have viruses that infect humans.  
The Epstein-Barr virus (EBV) as a member of Lymphocryptovirus, whereas 
Rhadinovirus includes human herpesvirus type 8 (HHV-8), also known as Kaposi’s 
sarcoma-associated herpesvirus (KSHV).  Recent evidence indicates that 
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members of the genus Lymphocryptovirus consist of two major lineages that 
have coevolved with their hosts: viruses of the Old World (humans, chimpanzees) 
and New World (marmosets) primates (Gerner et al., 2004, McGeoch et al., 
2005, Pellet & Roizman, 2007).  
1.1.2 Human herpesviruses and disease 
So far eight human herpesviruses have been identified and characterised (Table 
1.1). Generally symptoms in infected individuals are asymptomatic and 
consequently lead to widespread transmission of the virus in early life.  
Exceptions to these are infections with VZV, which is the causative agent of 
chicken pox, or HSV-2 causing neonatal, disseminated herpes infections.  In most 
other cases symptoms are largely the consequences of the re-emerging latent 
virus.  The most extensively studied herpesvirus is HSV-1, and in populations that 
have been analysed usually 50-90% of individuals are infected.  Primary infection 
by HSV-1 can occur at a number of sites, but the classic route is through mucosal 
membranes of the mouth and nose, leading to latent infection of the trigeminal 
ganglia.  Reactivation of the latent virus is often associated with stress, 
exposure to UV light, fever, tissue damage or immuno-suppression, resulting in 
the appearance of the characteristic cold sore lesions at, or close to, the site of 
primary infection (Roizman et al., 2007).  In some cases the reactivated virus 
can cause more severe conditions such as HSV-1 encephalitis, which can be fatal, 
or keratoconjunctivitus that can result in blindness.  In the case of latent VZV 
infections, reactivation is restricted to a single nerve tract where it causes the 
painful condition referred to as shingles.  Immuno-compromised individuals, such 
as transplant or AIDS patients, are particularly at risk from infections due to 
reactivated virus, including life-threatening conditions from reactivated HCMV.  
In addition, two gammaherpesviruses, EBV and KSHV, have been linked to 
neoplastic transformations that include Burkitt’s lymphoma (EBV) and Kaposi’s 
sarcoma (KSHV) (Pellet & Roizman, 2007).  Since the work carried out in this 
thesis relates to the prototypical herpesvirus, HSV-1, the following discussions 
will focus predominately on this virus.   
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1.2 HSV-1 virion architecture 
The mature or infectious virion consists of four morphologically distinct 
structural components.  The central core comprises the linear dsDNA genome, 
which is enclosed within a protective icosahedral capsid that together form the 
nucleocapsid.  The capsid in turn is embedded in a protein matrix known as the 
tegument and, finally, the tegument is surround by a lipid bilayer or envelope 
containing several viral glycoproteins (Roizman et al., 2007, Wildy et al., 1960).  
A generalised representation and a detailed electron micrograph of the 
herpesvirus structure are shown in Figure 1.2.     
1.2.1 Genome 
The HSV-1 genome consists of a single linear dsDNA molecule, which is 
approximately 152 kbp in length, has a GC content of 68% and contains at least 
75 open reading frames (ORFs) (McGeoch et al., 1993).  The viral genome 
consists of two covalently linked regions designated long (L) and short (S), which 
each contain unique sequences, termed UL and US, respectively.  The UL region is 
107.9 kbp and the Us region is 13 kbp long, and both regions are bordered by 
inverted repeat sequences.  The terminal and internal repeats flanking UL are 
referred to as TRL and IRL, respectively, whilst those flanking US are known TRS 
and IRS, respectively.  Genes in the unique and repeated sequences have prefixes 
UL, US, RL or RS and are numbered according to their relative position in the 
genome (Roizman et al., 2007).  Each of the inverted repeats flanking the UL or 
US regions are composed of various combinations of repeat elements termed a, b 
and c.  The a and b repeats are found in TRL and their inversions (a’ and b’) in 
IRL, and the a and c elements are found in TRS and their inversions (a’ and c’) in 
IRS.  Multiple a sequences are frequently found in TRL and also at the junction of 
IRL and IRS, but in the opposite orientation to the terminal a sequences (McGeoch 
et al., 1988).  Thus the HSV-1 genome can be written as anb-UL-b’a’mc’-US-ca, 
where n and m represent variable copies of the a sequence (Roizman et al., 
2007).  An illustrated version of the HSV-1 genome is shown Figure 1.3.  As a 
consequence of the inverted repeats at either end of the UL and US 
recombination can occur during viral replication, resulting in the inversion of 
one region relative to the other and the formation of four genome isomers 
Figure 1.2 Structure of the HSV-1 virion
The HSV-1 virion is composed of four structural elements.  The 
double-stranded DNA genome is packaged into the icosahedral 
capsid.  The tegument surrounds the capsid and consists of a 
collection of proteins that are organised into at least two layers, one 
which interacts with the envelope proteins and one that is closely 
associated with the capsid.  The envelope is a lipid bilayer infused 
with viral glycoproteins and encloses both the tegument and the 
DNA containing capsid.
Envelope
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Figure 1.3 The HSV-1 genome structure
The HSV-1 genome (A) consists of the L and S domains, shown in (B).  The L and S 
domains each contains a unique sequence, UL and US, respectively, which is flanked 
by inverted repeats (TRL/IRL and TRS/IRS).  The genome contains the a sequence at 
the end of each terminal repeat (aL and aS) and this sequence is also present at the L-S 
junction in an inverted orientation (a').  The TRL has a variable number of a sequences 
(an) and there is also a variable number at the L-S junction (a'm).  The b sequence is 
only present in TRL and in an inverted position in IRL.  Similarly, the c sequence is only 
found in TRS and in an inverted orientation in IRS.  (C) The arrows indicate the relative 
orientation of the four possible genomic isomers of HSV-1 that result from inversion of 
the L and S domains during DNA replication.  P indicates the prototype and no inversion 
of either L or S domains, IL indicates inversion of the L region and IS indicates inversion 
of the S region, while ILS signifies that both L and S domains are inverted.    
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(Figure 1.3), which exist in equimolar amounts in HSV-1 populations.  The role of 
the various genome isomers during viral replication is unknown, since HSV-1 
mutants with specific repeat sequences removed and their genomes frozen in 
any given isomeric form still remained viable in culture (Roizman et al., 2007).  
Herpesvirus genomes in general can be divided into seven groups on the basis of 
the overall arrangement of their repeat sequences and unique regions, and the 
HSV-1 genome is typical member of group 6 (Davison & McGeoch, 1995).  An 
illustration of the various genome structures found in herpesvirus and a summary 
of their salient features are shown in Figure 1.4.   
  
1.2.2 The capsid  
The virus genome is packaged into an icosahedral capsid, consisting of protein 
subunits that self-assemble around a scaffold core in the nuclei of infected cells.  
The proteins required for capsid formation are conserved within the 
Herpesviridae and a list of the genes that encode them in HSV-1 are shown in 
Table 1.2 (Steven et al., 2005).   
 
Gene Protein MW (kDa) Description 
UL18 VP23 34 Structural component of triplexes 
UL19 VP5 15 Structural component of hexons and pentons 
UL26 VP21 40 Minor scaffolding protein 
UL26 VP24 26.5 Maturational protease 
UL26.5 VP22a 34 Major scaffolding protein 
UL35 VP26 12 Accessory protein located on hexon tips 
UL38 VP19C 50 Structural component of triplexes  
 
Table 1.2 HSV-1 genes encoding proteins involved in capsid assembly 
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Figure 1.4 Herpesvirus genome structures
The genome structures of herpeviruses, defined by Roizman (1992) and Davison & 
McGeoch (1995), are illustrated.  The unique regions are indicated by the letter U, with 
the long and short unique regions denoted as UL and US, respectively .  The repeat 
units are depicted by boxes and their orientation is indicated by the arrowheads.  Group 
0 genomes each consists of a single unique coding region and no repeat units.  An 
example is tree shrew herpesvirus (Koch et al., 1985).  The group 1 genomes each 
consists of a single unique region and single direct repeat sequences at each terminus.  
An example being channel catfish virus (Davison, 1992).  Each group 2 genome also 
contains a single unique region, but has multiple copies of repeat units at each terminus.  
An example is herpesvirus saimiri (Albrecht et al., 1992).  The group 3 genomes each 
has multiple repeat units located at each terminus and an internal repeat unit in the 
opposite orientation at the junction of the UL and US domains.  An example is the 
cottontail rabbit herpesvirus (Cebrian et al., 1989).  Group 4 genomes are similar to 
group 3 genomes, but the internal repeats show no similarity to the end terminal repeats  
and the gammaherpesvirus EBV has a genome with this arrangement (Baer et al., 
1984).  Group 5 genomes each has two unrelated inverted repeats flanking the UL and 
US regions respectively, however, the ones at either end of the UL domain are much 
smaller than those at each end of the US domain.   An example of this group is VZV 
(Davison & Scott, 1986).  Group 6 genomes are similar to group 5 genomes, but they 
contain additional repeat units termed a sequences that are located at each terminus of 
the genome and at the junction of the UL and US region in the opposite orientation.  In 
addition, the inverted repeats flanking the UL domain are much larger than those 
contained in group 5 genomes.   Both HSV-1 and HSV-2 have genomes of this type 
(Roizman, 1979).            
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1.2.2.1 Icosahedral symmetry  
Crick & Watson (1956) were the first to point out that due to the limited coding 
capacity of the viral genome, it was economical to construct capsids from a 
small number of protein subunits.  In the case of the spherical viruses, a closed 
shell could be achieved by using the symmetry of Platonic polyhedra, for 
example tetrahedron, octahedron or icosahedron.  So far only examples of 
icosahedral capsids have been found, perhaps because the most economical way 
to build a symmetric shell, of maximal internal volume using nonsymmetric 
protein molecules, is to arrange the proteins in identical equilateral triangular 
structures that can be joined to form an icosahedron.    An icosahedron has 20 
triangular faces and 12 vertices related by two-, three- and fivefold axes of 
rotational symmetry (Figure 1.5).  In the simplest packing arrangement, each 
triangular face of the capsid comprises three identically placed proteins (x 20 
faces = 60), with each of the 60 subunits (asymmetric units) interacting with 
their neighbour in an identical (equivalent) environment.  Consequently, 
although the volume in such a capsid depends on the size of the protein, it is 
still quite small and can only package a small genome.  Larger genomes, such as 
HSV-1, require larger capsids and therefore must contain more than 60 protein 
subunits.  The apparent contradiction of the structural properties of larger 
particles was accounted for by the theory of quasi-equivalence developed by 
Caspar & Klug (1962).  They proposed that when a capsid contained more than 
60 subunits, each subunit occupied a quasi-equivalent position, where the 
bonding properties of subunits in different structural environments are similar, 
but not identical as in the case of the 60-subunit structure.  In a larger 
structure, such as the HSV-1 capsid, five subunits make fivefold symmetric 
contact at each of the 12 vertices, forming the pentons.  The additional subunits 
are interposed between the pentons and arranged with six-fold symmetry, 
forming the hexons.  The addition of the hexons allows the size of the shell to 
increase without disrupting the basic geometry of the icosahedral capsid.   In 
such a structure, each subunit can be present in one of three different structural 
environments.  Nevertheless, all subunits bond to their neighbours in similar 
ways.  Another important concept introduced by Caspar & Klug (1962) was the 
triangulation number, T, a mathematical means used to describe the number of 
5-fold symmetry
2-fold symmetry
3-fold symmetry
Figure 1.5 Icosahedron
An icosahedron has 20 equilateral triangular faces and 
12 vertices related by 2-, 3- and 5-fold symmetry.
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structural units required per triangular face that would be needed to assemble 
an icosahedron in a given structure. 
1.2.2.2 Capsid structure 
A reconstruction of the HSV-1 capsid has been determined to a resolution of 8.5 
Å and is illustrated in Figure 1.6 (Zhou et al., 2000).  The capsid has a diameter 
of 125 nm and is approximately 15 nm thick.  The genes encoding the major 
proteins of the capsid are summarised in Table 1.2.  Three viral proteins, VP5, 
VP23 and VP19C, are essential for HSV-1 capsid formation.  The major capsid 
protein, VP5, assembles into 161 subunits or capsomers, which are connected to 
each other at the innermost layer of the shell cavity to form the capsid floor 
(Baker et al., 1990).  Capsomers can be subdivided into two populations of 150 
hexons and 11 pentons, which form the structural units of the T=16 icosahedral 
capsid (Wildy et al., 1960).  Eleven of the 12 vertices of the HSV-1 capsid are 
occupied by pentons, each comprising identical populations of five VP5 
molecules.  The twelfth capsid vertex is occupied by a cylindrical portal made 
up of 12 molecues of UL6, forming a channel through which viral DNA is 
packaged into the capsid and possibly released (Chang et al., 2007, Deng et al., 
2007, Homa & Brown, 1997, Newcomb et al., 2001, Valpuesta & Carrascosa, 
1994).  The hexons, composed of six VP5 molecules, form the edges and faces of 
the icosahedron and are decorated by the small non-essential protein VP26 
(Zhou et al., 1994).  In contrast to pentons, there are three quasi-equivalent 
populations of hexons (Figure 1.7).  The hexons lying adjacent to the pentons 
are known as peripentonal or P hexons, while those located on the faces of the 
icosahedron are termed C hexons and ones situated on the edges are referred to 
as E hexons.  The hexons and pentons are interconnected by a heterotrimeric 
complex of proteins known as the triplex, composed of two copies of VP23 and 
one copy of VP19C, which form their connections by interacting with the middle 
and floor domains of the surrounding capsomers (Newcomb et al., 1993, Trus et 
al., 1995).  Triplexes, like hexons, can be divided into quasi-equivalent 
populations (termed Ta, Tb, Tc, Td, Te and Tf) based on their location within 
the icosahedral lattice (Zhou et al., 1994).  The positions of the quasi-equivalent 
hexons and triplexes on the surface lattice of the capsid are illustrated in Figure 
1.7.    
o
Figure 1.6 Reconstruction of the HSV-1 capsid to 8.5 A
Shaded surface view of the T=16 HSV-1 capsid, which has a 
diameter of 1250 A and is 150 A thick.  The capsid shell 
consists of 161 capsomers, with 150 hexons (blue) forming 
the faces and edges, 11 pentons (red) forming the vertices, 
and 320 triplexes (green) lying between adjacent capsomers 
(adapted from Zhou et al., 2000).                                                                                              
o o
Figure 1.7 Surface lattice of HSV-1
T h e  p o s i t i o n  o f  t h e  q u a s i - e q u i v a l e n t  
capsomers and triplexes.  The peripentonal, 
edge and central hexons (pale blue circles) 
a re  denoted by  the  le t te rs  P,  E and C,  
respectively.  The pentons are positioned at 
the vertices and are indicated by the dark 
blue circ les and the number 5.   The six 
triplexes Ta-Tf (green triangles) are denoted 
a-f (adapted from Heyman et al., 2003).
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1.2.2.3 Capsid scaffold 
Assembly of the HSV-1 capsid requires not only the structural proteins VP5, 
VP19C and VP23, but involves the participation of the scaffolding proteins, 
VP22a and VP21, which form the scaffold, or core, and the maturational 
protease, VP24.  The scaffolding proteins direct the fidelity of the maturing 
capsid’s assembly, with the structural proteins co-assembling with and around 
the core, which interacts directly with VP5 (Hong et al., 1996, Thomsen et al., 
1995).  In contrast to the other capsid proteins, which are encoded in separate 
transcriptional units, the scaffolding proteins are encoded by two in-frame 
overlapping genes, UL26 and UL26.5 (Liu & Roizman, 1991), the arrangement of 
which is illustrated in Figure 1.8.  As a consequence of their gene organisation, 
the UL26.5 gene product preVP22a (the major scaffolding protein) has an 
identical sequence to the C-terminal 329 amino acids of the UL26 precursor 
protein, preVP21/VP24 (Figure 1.8).  The 635 amino acid preVP21/24 has an N-
terminal protease fragment (VP24), several oligomerisation domains, and a VP5 
binding site located at the C-terminus (Deckman et al., 1992, Hong et al., 1996, 
Liu & Roizman, 1992).  During capsid assembly, the UL26 protein is incorporated 
into the structure and the intrinsic protease activity (VP24) it contains cleaves 
either autoproteolytically or in trans (Liu & Roizman, 1993, Preston et al., 
1983).  Cleavage at the R site (A247-S248) of the UL26 precursor molecule 
releases two products, the N-terminally located functional protease, VP24 (M1-
S247), and the C-terminal encoded scaffolding protein preVP21 (S248-R635).  A 
second cleavage event is initiated by the maturational protease at the 
maturation or M site (A610-S611) present in the C-terminal portion of the 
scaffolding proteins, preVP21 and preVP22a, which are attached to the inner 
capsid shell via the VP5 binding domains located in each protein at the C-
terminus (Hong et al., 1996, Robertson et al., 1996).  Although the scaffolding 
proteins participate in capsid assembly, they are removed during capsid 
maturation by cleavage at the M site of preVP21 and preVP22 to release VP21 
(S348-A610) and VP22 (M307-A610), respectively, while the protease (VP24) 
remains in the capsid shell (Figure 1.8) (Homa & Brown, 1997, Roizman et al., 
2007).  Activity of the protease, VP24, is required for the assembly of DNA-
containing capsids (Preston et al., 1983; Gao et al., 1994).    
-Figure 1.8 Structural organisation of the HSV-1 scaffolding genes and their proteolytic products  
(A) The scaffolding proteins are encoded by two overlapping genes, UL26 and UL26.5.  As a 
consequence of their gene organisation, the UL26.5 gene product, pre-VP22a, has an identical 
sequence to the C-terminal 329 amino acids of the UL26 encoded protein (M307-R635).  For 
convenience these residues are also labelled as M307-R635 in the UL26.5 illustration and are 
highlighted in both scaffolding proteins in green and red.  The red portion indicates the VP5 binding 
domain.  (B) During capsid maturation the UL26 encoded protein is cleaved at the R site to release the 
VP24 maturational protease (residues M1-A247) and preVP21 (S248-R610).  Cleavage of preVP21 at 
the M site results in removal of the VP5 binding domain (S611-R635) and releases the minor 
scaffolding protein VP21 (S248-A610) from the capsid.  (C) Cleavage of preVP22a at the M site 
removes the VP5 binding domain (S611 – R635) and releases the major scaffolding protein VP22a 
(M307-A610) from the capsid.    
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1.2.2.4 Capsid forms                          
In the nuclei of infected cells, electron microscopic studies have identified three 
forms of angularised HSV-1 capsids, which have been classified as A-, B- and C-
capsids (Gibson & Roizman, 1972).  Although the capsids have the same basic 
icosahedral structure that was described previously, they can be separated by 
sucrose density gradient ultracentrifugation.  The differences in density and 
morphology between the three capsid forms are due to the material contained in 
the cavity of their shells.  C-capsids, which contain the virus genomes, are the 
successful end product of DNA packaging that will eventually form part of the 
infectious virion.  A- and B-capsids are considered the abortive or dead-end 
products of failed DNA packaging events.  A-capsids are empty shells that lack 
DNA and scaffolding proteins, while B-capsids also lack DNA but are filled with a 
core of cleaved scaffolding proteins, primarily VP22a (Homa & Brown, 1997, 
Newcomb et al., 1996, Rixon & McNab, 1999, Sherman & Bachenheimer, 1988, 
Trus et al., 1996).  An additional capsid form has been identified, the procapsid, 
which is the precursor of the other three types and will be discussed in detail in 
Section 1.3.4.  An illustration of all four capsid forms is shown in Figure 1.9    
1.2.2.5 Accessory capsid proteins 
Maturation of the procapsid to the angularised capsid involves large cooperative 
conformational changes (Section 1.3.4).  In addition to providing increased 
stability, these changes create new binding sites that are required for 
downstream reactions and optimal infectivity.  Reconfiguration of the hexons 
during maturation generates new binding sites on the outer surface of the 
mature capsid shell that VP26 interacts with.  The precise role of this protein is 
unclear, since it is dispensable and does not appear to confer additional stability 
to the assembling capsid.  However, its absence does reduce infectious virion 
production (Desai et al., 1998, Newcomb et al., 1993).  In addition to the 
structural and scaffolding proteins, a number of viral proteins have been 
identified as minor components of the HSV-1 capsid.  Most of these minor capsid 
constituents are involved in DNA packaging and include the proteins encoded by 
the UL6, UL15, UL17, UL28, UL25 and UL33 genes, which will be discussed 
further in Section 1.3.5.2.   
VP5
VP19C + VP23
pUL6
pUL26.5 (preVP22a)
pUL26 (VP24 + preVP21)
VP26
Procapsid
B-capsid
A-capsid
C-capsid
DNA packaging and 
capsid maturation
Figure 1.9 Alternative HSV-1 capsid forms
The procapsid is the immature spherical form that during viral DNA packaging and maturation 
switches to the more angularised capsid.  C-capsids are the successful end product of DNA 
encapsidation.  B-capsids are dead-end products that lack DNA but are filled with a core of 
cleaved scaffolding proteins.  A-capsids are empty shells that lack DNA and scaffolding proteins 
and are considered the abortive products of failed DNA packaging events.  The hexons on the 
procapsid shell, highlighted in light blue, and the pentons (mid-blue) are coordinated by the 
triplexes made up of heterotrimers of VP19C and VP23 (green).  The inner shell of the procapsid 
is composed of the scaffolding proteins pUL26.5 (red) and pUL26 (red and grey).  During 
maturation, the protease is released by autoproteolysis from pUL26 and processes the C termini 
of the scaffolding proteins attached to the inner capsid shell wall.  The conformational switch in 
capsid morphology creates binding sites for VP26, which are located at the tips of hexons 
(yellow).  The UL6 gene product is arranged as a single dodecamer at the portal (pink) and is the 
channel where viral DNA is inserted into the capsid during encapsidation (adapted from Trus et 
al., 2007).
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1.2.3 The tegument  
In contrast to the symmetrical uniformity of the capsid, the tegument is a 
largely unstructured proteinaceous layer that is located between the capsid and 
outer envelope (Figure 1.2).  More than 15 viral proteins are present in the 
tegument and there is some evidence that cellular components are also 
incorporated (Del Rio et al., 2005, Grünewald et al., 2003).  Many of the 
tegument proteins share no sequence homology between alpha-, beta- and 
gammaherpesviruses and their origin and evolution remains unclear.  Indeed, 
many can be deleted without obviously affecting virion structure (Homa & 
Brown, 1997, Mettenleiter, 2002, Steven & Spear, 1997).    An important 
function of the tegument is to carry with it an assortment of already synthesised 
viral proteins that following infection can assist the virus in managing the host 
environment.  These proteins include, the UL41 encoded virion host shut off 
protein (vhs) that acts by shutting off host cell protein synthesis, and VP16, 
which is encoded by UL48 and that stimulates expression of HSV-1 immediate-
early genes (Cambell et al., 1984, Pellet & Roizman, 2007).  
Information from cryo-EM and 3D reconstructions have revealed that the 
tegument, although regarded as largely amorphous, is composed of at least two 
distinct layers referred to as the inner and outer tegument layers.  The outer 
layer is asymmetrically organised, heterogeneous and interacts with the 
cytoplasmic domains of viral membrane proteins, while the inner layer is tightly 
associated with the vertices of the capsid and displays a more ordered 
icosahedral morphology (Gibson & Roizman, 1972, Zhou et al., 1999).  One of the 
constituents of the inner tegument layer is the UL36 encoded protein (pUL36), 
which is highly conserved among the herpesviruses and is essential for viral 
morphogenesis (Desai, 2000, Klupp et al., 2002).  Since pUL36 has been 
demonstrated to be tightly associated with the capsid at the pentons and also 
directly interacts with VP5, the protein was suggested as a good candidate for 
the icosahedrally ordered tegument observed in cryo-EM reconstructions (Gibson 
& Roizman, 1972, Zhou et al., 1999).  Subsequently, a functionally conserved 
capsid-binding domain (CBD), located in the last 62 amino acids of HSV-1 and PrV 
pUL36, was identified, which specifically bound to the minor capsid protein 
pUL25 that is predicted to be situated adjacent to the capsid vertices (Coller et 
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al., 2007, Trus et al., 2007).  More recently this interaction was confirmed, and 
a second domain in pUL36 (residues 2037–2353) that interacts with pUL25 has 
also been identified (Pasdeloup et al., 2009).  Indications that these interactions 
may act as the link that binds the capsid to the tegument in the infectious virion 
has been provided using an HSV-1 UL36 null mutant (Roberts et al., 2009), since 
in cells infected with the pUL36 deletion mutant, C-capsids lacking tegument 
accumulated in the cytoplasm and no enveloped capsids were observed in the 
cytosol.    
1.2.4 The envelope 
The outer boundary of the virion is formed by the envelope (Figure 1.2), a lipid 
bilayer that is created from host cell membranes during viral assembly, and 
which is thought to originate at the trans-Golgi network (Mettenleiter, 2002).  
The envelope contains numerous protrusions of virally encoded glycoproteins 
that function during viral entry, egress and cell-to-cell spread (Beitia Ortiz de 
Zarate et al., 2004, Farnsworth & Johnson, 2006, Farnsworth et al., 2007).  HSV-
1 encodes at least 11 glycoproteins (Table 1.3) and the total copy number of 
these proteins can exceed 1,000 per virion (Pellet & Roizman, 2007). 
1.2.5 L-particles 
L-particles resemble virions in size and shape, but are simply enveloped 
tegument structures that lack capsids (Szilágyi & Cunningham, 1991).  They have 
been detected in all alphaherpesviruses examined for their presence and their 
existence indicates that tegument proteins have an intrinsic ability to self-
assemble in the absence of capsids (McLauchlan & Rixon, 1992).  L-particles are 
formed in productive infections and in instances where virus assembly is blocked 
and can be easily purified (Rixon et al., 1992).  Since they have an envelope, L-
particles retain the capacity to penetrate cells and have proved to be a useful 
experimental tool for analysing the viral constituents of the tegument.  Their 
existence in nature has been hypothesised to facilitate HSV-1 infections, for 
example, by acting as decoys during the host’s immune response, by 
complementing partially defective co-infecting virions, or by enhancing 
reactivation of latent virus (Dargan et al., 1995, McLauchlan et al., 1992).          
Gene Protein Function of protein 
UL1 gL Interacts with gH and is required for membrane fusion and viral entry. 
UL10 gM Forms a complex with UL49A and is present in cellular and virion membranes.  It is thought to be involved in secondary envelopment. 
UL22 gH Interacts with gL and is required for membrane fusion and viral entry.  It is also thought to play a role during egress and cell-to-cell spread.  
UL27 gB Forms dimers and is required for membrane fusion and the initial attachment of the virus via heparan sulphate. 
UL44 gC Involved in the initial attachment of the virus to the cell membrane via heparan sulphate.  
UL53 gK Involved in cell fusion and required for efficient virus exocytosis. 
US4 gG Involved in egress and cell-to-cell spread. 
US5 gJ Non-essential for virus replication in cell culture. 
US6 gD Involved in cell receptor binding, cell fusion and viral entry. 
US7 gI Involved in the acquisition of the viral envelope during secondary envelopment and forms a complex with gE. 
US8 gE Involved in the acquisition of the viral envelope during secondary envelopment and forms a complex with gI. 
 
Table 1.3 HSV-1 glycoproteins  
Chapter 1 32
1.3 HSV-1 replication  
Productive infection by HSV-1 can be divided into several stages, which are 
described below and are summarised in Figure 1.10.  In permissive tissue culture 
cells, from initial infection to the release of infectious progeny, HSV-1 
replication takes approximately 18–20 h.   
1.3.1 Entry 
1.3.1.1 Cell binding and fusion   
HSV-1 can enter cells in two ways.  The primary pathway involves fusion of the 
envelope with the plasma membrane and transport of released capsids to the 
nuclear pore.  The secondary pathway involves endocytosis of the enveloped 
capsid and although this auxiliary pathway has been defined experimentally in a 
few cell lines, its role in natural infections is unclear (Roizman et al., 2007).  
However, both routes of entry share an initial and reversible attachment of the 
virion to the cell surface that is mediated by the viral glycoproteins.  HSV-1 first 
attaches to the cells by the interaction of gC, and to a lesser extent gB, to cell-
surface glycosaminoglycans (GAGs) such as heparan sulphate (Herold et al., 
1991, Shieh et al., 1992, WuDunn & Spear, 1989).  HSV-1 gD then binds to 
specific cell receptors to stabilise the virion-cell interaction.  At least three 
different types of receptors have been identified.  These are nectins, herpes 
virus entry mediator (HVEM), and a selected form of 3-O-sulphated heparan 
sulphate, none of which act as co-receptors during entry.  Finally, gD together 
with gB, gH and gL, enable the viral envelope to fuse with the cellular plasma 
membrane to allow penetration of the viral capsid and tegument into the cell 
(Cai et al., 1988, Campadelli-Fiume et al., 2000, Forrester et al., 1991, Ligas & 
Johnson, 1988, Spear & Longnecker, 2003, Turner et al., 1998).  Binding and 
fusion appear to be distinct events, since binding has been demonstrated to be 
reversible and viruses eluted from the cell surface are still infectious (Bender et 
al., 2005).   
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Figure 1.10 Lytic replication cycle of HSV-1 
(1) The virion binds to the host cell membrane via specific interactions between the viral glycopro-
teins and the plasma membrane.  The viral envelope then fuses with the host cell membrane 
releasing the capsid and tegument proteins into the cytoplasm.  (2)  The capsid containing the 
inner tegument proteins is transported via microtubules to the nucleus where the capsid binds to 
the nuclear pore complex and releases the viral DNA into the nuclear compartment.  (3) The outer 
tegument is released into the cytoplasm and virion host shut-off (vhs) protein causes degradation 
of host messenger RNA (mRNA).  (4) Another component of the outer tegument, VP16, localises 
to the nucleus where it activates HSV-1 gene expression and where viral genes are expressed in 
a tightly regulated cascade.  (5) Viral DNA circularises in the nucleus prior to replication and gene 
expression.  (6) The viral DNA is transcribed by host RNA polymerase II to give first the IE gene 
transcripts (α mRNA), a process which is stimulated by VP16.  The viral mRNAs are exported to 
the cytoplasm for translation on cellular ribosomes and five of the six IE or α proteins act to 
regulate viral gene expression in the nucleus.  (7)  The IE proteins transactivate the E (β) gene 
products.  (8) The E  proteins are involved in replicating the viral DNA molecule, with the vast 
majority of progeny DNA genomes forming concatemers.  (9) Viral DNA synthsis stimulates L (γ) 
gene expression.  (10) The L  proteins are mainly structural proteins involved in assembling the 
procapsid in the nucleus.  (11) The concatemeric progeny DNA is cleaved into monomeric unit-
length genomes that are packaged into the preformed procapsids.  During DNA encapsidation the 
procapsid undergoes extensive conformational remodelling to form the mature angularised DNA-
containing C-capsid.  (12) The C-capsid exits the nucleus by budding into the perinuclear space 
and then fuses with the outer nuclear membrane and is released into the cytoplasm.  Tegument is 
assembled around the capsid and is initiated by an interaction of the UL36 protein with the capsid 
vertices.  The tegumented capsids subsequently acquire an envelope by budding into the trans-
golgi network, a process that involves the interaction of the tegument with the cytoplasmic tails of 
the viral glycoproteins gD, gE/gI and gM.  The enveloped virion finally exits the cell via the 
secretory pathway, a stage that is thought to involve the viral glycoprotein gK (adapted from 
Roizman et al., 2007).          
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1.3.1.2 Capsid translocation to the nucleus 
Following penetration, the outer layer of tegument proteins quickly dissociates 
from the capsid and the tegument proteins involved in host-cell management are 
transported to the appropriate cellular compartments (Luxton et al., 2005).  Vhs 
localises in the cytoplasm, while VP16 makes its way to the nucleus 
independently of the capsid (Batterson & Roizman, 1983, Taddeo et al., 2006).  
The capsid, containing the residual inner layer of tegument proteins comprising 
pUL36 and pUL37, is transported along microtubules from the periphery of the 
cell to the nuclear pore complex (NPC).  This process is mediated by an 
interaction between as yet unknown capsid-associated protein and the cellular 
motor protein dynein, together with the co-factor dynactin (Dohner et al., 2002, 
Sodeik et al., 1997).  Sodiek et al. (1997) reported that the microtubules 
interact with the pentons on incoming capsids.  Several HSV-1 proteins have 
been proposed as the interaction sites for dynein, but the prime candidates are 
likely to be the inner tegument or outer capsid proteins.  Strong contenders are 
the large tegument protein, pUL36 and the minor capsid protein encoded by 
UL25 (pUL25) that is located on the external shell (Newcomb et al., 2006, 
Thurlow et al., 2006, Trus et al., 2007).  In PrV, pUL36, pUL37 and pUL25 remain 
linked with the capsid during its transport across the cytoplasm to the NPC 
(Granzow et al., 2005, Kaelin et al., 2000, Luxton et al., 2005).   
Once the capsid arrives at the nucleus it docks at the NPC.  The component 
proteins of the NPC are termed nucleoporins and these multiprotein structures 
selectively control the passage of material through the nuclear envelope 
(reviewed in Lim & Fahrenkrog, 2006).  The first evidence that virus DNA is 
uncoated at the nuclear pores came from studies with a temperature-sensitive 
(ts) mutant of UL36, tsB7.  At the non-permissive temperature (NPT), cells 
infected with tsB7 accumulate capsids containing DNA at the NPC.  When the 
infected cells are shifted to the permissive temperature (PT), DNA is released 
from the capsids and virus gene expression follows (Batterson et al., 1983, Knipe 
et al., 1981).  Subsequently, protolytic cleavage of pUL36 has been 
demonstrated to be required for release of the HSV-1 DNA into the nucleus 
(Jovasevic et al., 2008).  A second HSV-1 ts mutant, ts1249, which has a 
mutation in the essential DNA packaging gene UL25, has a phenotype similar to 
that of tsB7, suggesting that pUL25 is required for uncoating the genome 
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(Preston et al., 2008).  Recently, Pasdouloup et al. (2009) identified the 
nucleoporin CAN/Nup214 as the nuclear receptor for incoming HSV-1 capsids in 
infected cells and showed, using an immunoprecipitation assay, that pUL25 
interacted directly with the protein.  In addition, they demonstrated binding of 
pUL25 to the large tegument protein pUL36 and the portal protein pUL6, both of 
which have key roles in virus DNA release (Batterson et al., 1983, Jovasevic et 
al., 2008, Newcomb et al., 2007).  Taken together these results suggest that 
pUL25 is the interface on the capsid that binds incoming capsids to the NPC and 
triggers the release of virus DNA into the nucleus.  It is in the infected cell 
nucleus that HSV-1 gene expression, DNA replication, capsid assembly, DNA 
packaging and egress takes place (Shahin et al., 2006, Strang & Stow, 2005, 
Strang & Stow, 2007).          
1.3.2 Gene expression 
Upon entering the nucleus the linear HSV-1 genome rapidly circularises with the 
help of cellular factors and virus gene expression is initiated.  During the lytic 
cycle of infection a molecular hallmark of herpesviruses is the temporally 
ordered sequence of RNA polymerase II-directed gene transcription (reviewed in 
Roizman et al., 2007).  The virus genes can be divided into three classes, named 
immediate early (IE or α), early (E or β) and late (L or γ), depending on their 
pattern of transcription.  Although the precise kinetics of viral gene expression is 
dependent on the cell type infected and the MOI, in general the initiation of 
expression of the IE genes starts approximately 30 minutes post-infection (hpi) 
at 37oC.  The IE proteins produced are responsible for propelling the 
transcription cascade forward by activating expression of the next set of virus 
genes.  There are six IE proteins, designated ICP0, ICP4, ICP22, ICP27, ICP47 and 
US1.5.  The ICP0, ICP4, ICP22 and ICP27 products each play important regulatory 
roles in viral gene expression of E and L gene products, but IE proteins are also 
involved in modulating the host antiviral defence system or exploiting the cell’s 
machinery for productive virus infection.  Transcription of IE genes does not 
require prior viral protein synthesis, since their promoters are recognised by host 
transcription factors and RNA polymerase II.  The HSV-1 protein VP16, however, 
has an important role in expression of IE genes following its interaction with two 
host cell proteins.  On its release from the incoming capsids, VP16 binds to a 
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cellular protein called host cell factor (HCF) and is transported to the nucleus.  
Within the infected cell nucleus, the VP16-HCF complex binds to a cellular 
transcription factor, Oct-1 (octomer DNA-binding protein), and the stable 
interaction of VP16 with Oct-1 promotes Oct-1 binding to viral DNA (Hughes et 
al., 1999).  Oct-1 binds to the octomer core sequence present in the promoters 
of all IE genes, while VP16 binds to Oct-1 and the adjacent HSV-1 sequences, 
forming an activator complex (Gaffney et al., 1985, O'Hare et al., 1988).  ICP0 is 
a transcriptional activator that stimulates viral gene expression and viral 
infection, which has been proposed to be involved in controlling the balance 
between lytic and latent HSV-1 infection, such that in its absence the latent 
state is favoured (Hagglund & Roizman, 2004, Preston & Nicholl, 1997, 
Samaniego et al., 1998).  There is accumulating evidence to suggest that  blocks 
the infected cell’s repression of viral transcription by disrupting nuclear 
substructures known as ND10 domains.  The disruption of ND10 sites during HSV-
1 infection is caused by the -induced degradation of cellular proteins, which are 
important components of ND10 sites, by  interacting with the ubiquitin-
proteasome pathway (Everett et al., 2007, Everett et al., 2006).     
Expression of the E genes requires the IE transactivator, ICP4, and in its absence 
the synthesis of E and L virus gene transcripts is blocked (DeLuca et al., 1985).  
The mechanism that ICP4 uses to activate E and L gene transcription is unclear, 
although it does contain a DNA binding site that is essential for its 
transactivation function (DeLuca & Schaffer, 1988).  In addition, evidence 
suggests it functions by enhancing the assembly of transcription complexes onto 
the viral promoters (Grondin & DeLuca, 2000).  If unrestrained, IE transcription 
would be expected to compete with E gene expression during viral replication 
and overwhelm the initiation of E mRNA translation.  Three mechanisms are 
thought to play a role in shutting off of IE gene expression.  First, ICP4 represses 
its own transcription by binding to specific sequences located across its own 
transcription initiation site (Faber & Wilcox, 1986).  Second, during the 
productive infection, E gene products down-regulate IE expression, and finally, 
one of the functions of vhs is to synchronise sequential viral gene expression.   
Expression of E genes reaches a peak at approximately 4-8 hpi and the products 
generated are required during DNA replication and nucleotide metabolism.  Two 
groups of E proteins, β1 and β2, have been identified.  The β1 proteins are 
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expressed a short time after the onset of IE protein synthesis, while the β2 
proteins are transcribed later and include DNA polymerase.  Since the β2 proteins 
require ICP27 for their activation, this may explain their expression kinetics 
(McCarthy et al., 1989).  ICP27 is a multifunctional IE regulatory protein that not 
only initiates viral gene expression but also represses it in the presence of ICP4 
(Panagiotidis et al., 1997).  In addition, it contributes to the shut-off of host 
protein synthesis during productive infection by preventing mRNA splicing of host 
gene transcripts and has a role in promoting nuclear export of viral mRNA 
(reviewed in Roizman et al., 2007).    
L genes are also activated by IE proteins, but it is only after DNA replication that 
their expression reaches its peak at approximately 8–10 hpi, with their gene 
products being required for virion assembly, DNA packaging and egress.  Similar 
to E genes, the L genes can be divided into two groups termed γ1 (leaky/late) 
and γ2 (true late) genes.  The γ1 proteins are expressed prior to viral DNA 
synthesis, while the onset of viral DNA replication is required prior to the 
expression of the proteins encoded by the true late genes.  The ultimate goal of 
L gene expression is to express large amounts of structural proteins for the 
assembly of progeny viral particles.  The relatively abundant major capsid 
protein, VP5, is a product of both γ1 and γ2 L gene transcripts during infection, 
while the tegument protein pUL36 is expressed by a true late gene (Roizman et 
al., 2007).   
1.3.3 DNA replication 
DNA replication initiates on the circular viral DNA molecules that accumulate in 
the infected cell nucleus in specialised structures known as replication 
compartments, which are located next to sub-nuclear structures termed ND10 
domains (Qinlan et al., 1984).  New ND10 domains also assemble around 
incoming viral genomes and these are thought to play an essential part in the 
cell’s defence mechanism against viral infection (Everett, 2006, Everett & 
Murray, 2005, Everett et al., 2006).  However, as infection progresses the ND10 
structures are degraded by a mechanism involving the IE viral protein .  In 
addition to the E gene products required during DNA synthesis, replication 
compartments also contain the HSV-1 proteins necessary for capsid assembly and 
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DNA packaging and as a consequence are thought to be the sites of viral DNA 
cleavage and encapsidation (de Bruyn Kops et al., 1998, Lamberti & Weller, 
1998).  
 
Herpesvirus genomes contain three origins of replication that consist of two 
copies of oriS, located in the IRS and TRS regions of the viral genome, and one 
oriL that is situated in the centre of the UL region.  The apparent reason(s) for 
these three potential origins of replication in the viral genome is currently 
unclear, since mutant viruses lacking oriL or both copies of oriS are still viable 
(Polvino-Bodnar et al., 1987, Roizman et al., 2007).  In addition to the cis-acting 
origins of replication, seven trans-acting proteins are required during viral DNA 
replication.  Three of these proteins, encoded by UL5, UL8 and UL52, are 
components of the heterotrimeric helicase-primase complex.  Two of the 
proteins form a heterodimeric DNA polymerase complex, comprising the 
catalytic subunit encoded by UL30 and its processivity factor encoded by UL42.  
The remaining two trans-acting replication proteins are the single-stranded DNA 
binding protein expressed by UL29, also referred to as ICP8, and the origin-
binding protein encoded by UL9 (pUL9).  
 
A model based on the current information available for HSV-1 DNA replication 
has been proposed and is illustrated in Figure 1.11.  After the viral DNA 
molecules have entered the cell nucleus, the circular genomes generated serve 
as templates for DNA synthesis.  Binding of pUL9 in association with ICP8 to the 
origin sequences initiates the preliminary theta (bi-directional) mode of 
replication that quickly switches to a sigma or rolling-circle form by an unknown 
mechanism.  Evidence that replication is initially bi-directional comes from 
observations that viral DNA accumulates with nonlinear kinetics during early DNA 
synthesis and that cellular topoisomerase II is also required at this stage, 
suggesting a need for decatenation of circular progeny molecules (Hammarsten 
et al., 1996).  Following binding, the ATP-dependent helicase activity of pUL9 is 
stimulated by its interaction with ICP8, inducing a distortion in the DNA and the 
formation of a single-stranded stem loop structure that is subsequently coated 
with ICP8.  Separation of the two DNA strands then permits access of the 
helicase-primase complex, which is recruited to the origin by its interaction with 
pUL9, ICP8 or both, and the DNA polymerase complex to establish a replication 
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Figure 1.11 Model for HSV-1 DNA replication
(1) Input DNA is circularised on entry into the nucleus.  (2) pUL9, 
the origin binding protein, initially binds to specific elements in the 
origin (either oriL or oriS) and begins to unwind the DNA. pUL9 
then recruits ICP8, the ssDNA binding protein, to the unwound 
ssDNA. (3) pUL9 and ICP8 recruit the five remaining viral DNA 
replication proteins to the replication fork.  (4) The helicase-primase 
proteins and the viral polymerase complex assemble at each 
replication fork for initial rounds of theta form replication.  (5) 
Replication switches to the rolling circle mode by an unknown 
mechanism.  pUL9 is not necessary for rolling circle replication, 
because this process is origin independent.  (6) Rolling circle DNA 
replication produces long head-to-tail concatemers of viral DNA, 
which are the substrates for DNA cleavage and packaging 
(adapted from Roizman et al., 2007).   
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fork (reviewed in Lehman & Boehmer, 1999 and Roizman et al., 2007).  
However, once DNA replication is initiated the origin binding protein is no longer 
required (Schildgen et al., 2005).  The origin-dependent theta replication 
switches to an origin-independent rolling-circle and/or recombination-mediated 
replication mechanism that produces progeny DNA in the form of head-to-tail 
concatemers (Jacob et al., 1979).   
 
1.3.4 Capsid assembly  
A feature of herpesviruses is that DNA replication, capsid assembly and DNA 
encapsidation all occur in the nucleus of the infected cell.  Therefore, prior to 
capsid assembly the structural and scaffolding proteins that are translated in the 
cytoplasm must be transported to the nucleus.  However, only VP19C and 
preVP22a can localise to the nucleus independently, which suggests that these 
proteins contain a nuclear localisation signal (NLS).  The other structural 
proteins, VP5, VP23 and VP26, are transported to the nuclear compartment via 
direct or indirect interactions with either or both VP19C and preVP22a (Desai & 
Person, 1996, Nicholson et al., 1994, Rixon et al., 1996).  The distribution of the 
capsid proteins in the nucleus during virus infection has been studied using 
confocal microscopy techniques (de Bruyn Kops et al., 1998, Ward et al., 1996).  
This has revealed that capsid proteins accumulate at punctate foci within 
nucleus known as replication compartments.   
A possible common ancestry between herpesviruses and dsDNA bacteriophages, 
such as T4, P22 and λ, has been revealed by similarities in their capsid structure 
and in the way capsids are formed (Baker et al., 2005, Booy et al., 1991, 
Davison, 1992, Trus et al., 2004).  Since the process of capsid assembly and DNA 
encapsidation has been extensively studied and is well defined in the large 
dsDNA bacteriophages (Baker et al., 2005, Hendrix, 2005, Johnson & Chiu, 2007, 
Rixon, 2008, Steven et al., 2005), this information has provided a framework for 
studying these processes in HSV-1.  In its basic features the pathway for capsid 
assembly and DNA packaging in HSV-1 resembles that in the large dsDNA 
bacteriophage.  In both systems the capsid proteins and internal scaffolding 
proteins co-assemble to form a spherical and mechanically fragile intermediate 
empty shell, termed the procapsid.  Following DNA replication, the 
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concatemeric viral DNA molecules formed are cleaved into unit-length genomes.  
The sequence of events that yield progeny virions proceeds through the 
overlapping events of capsid maturation, DNA packaging and the release of 
cleaved scaffolding proteins from the maturing capsid.  The procapsid is the key 
site of maturation and its surface shell undergoes a morphological transition into 
the mature capsid, which stabilises the particle and enables it to withstand the 
increasingly high pressure that is imposed on it as the viral genome is inserted 
during encapsidation.   
1.3.4.1 Procapsid assembly 
An understanding of the mechanism of how the structural and scaffolding 
components of the capsid assemble advanced significantly with the development 
of the baculovirus expression system.  Baculoviruses naturally infect anthropods 
and baculovirus vectors that express foreign genes at high levels in cultured 
insect cells, such as Spodoptera frugiperda (Sf cells) have been developed.  By 
analysing the structures formed in Sf cells infected with various combinations of 
baculoviruses expressing the capsid shell proteins and the products of the 
scaffolding genes, the essential viral proteins required during capsid assembly 
were identified (Tatman et al., 1994, Thomsen et al., 1994).  Closed icosahedral 
capsids were detected in insect cells co-infected with baculoviruses expressing 
the capsid shell proteins VP5, VP19C, VP23 and the scaffolding proteins encoded 
by either UL26 or UL26.5.  These experiments revealed that the expression of 
UL35 (encoding VP26) was not essential for capsid formation.  Omission of the 
UL26 gene product from the system resulted in a high number closed icosahedral 
capsids with large internal cores, due to the presence of intact preVP22a, which 
was not cleaved in the absence of the maturational protease.  In cells expressing 
preVP22a alone, a large number of core-like structures formed indicating that 
this scaffolding protein could self-assemble in the absence of other capsid 
proteins, a property not observed when preVP21 was expressed on its own 
(Preston et al., 1994).  In the absence of preVP22a, fewer capsids were detected 
in the baculovirus expression system and no distinct core was apparent.    
Nevertheless, in mammalian cells infected with an HSV-1 mutant that did not 
express preVP22a, infectious virions were still produced but at significantly 
reduced yields relative to the wt virus (Gao et al., 1994).  These results 
suggested that although the UL26 polypeptide could still serve as a scaffold 
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during capsid formation, it formed a less effective one than those containing 
preVP22a.  However, no intact capsids were formed when both UL26 and UL26.5 
gene products were absent, indicating that the presence of a scaffolding protein 
was required for the assembly of a closed icosahedral capsid (Gao et al., 1994, 
Preston et al., 1994, Tatman et al., 1994, Thomsen et al., 1994).                 
The baculovirus expression system and analysis of the capsid protein interactions 
from recombinant baculovirus-infected cell extracts led to the development of 
an in vitro based model for capsid assembly (Desai & Person, 1996, Newcomb et 
al., 1999, Newcomb et al., 1994, Preston, 2002, Rixon et al., 1996). In the in 
vitro system, closed angularised icosahedral capsids formed in samples of mixed 
cell extracts containing capsid shell proteins and the scaffolding proteins 
incubated at 27oC for 12 h (Newcomb et al., 1994).  The requirements for cell-
free assembly, in terms of input viral gene products, were the same as for 
assembly in insect cells co-infected with multiple baculovirus vectors expressing 
HSV-1 structural proteins.  Optimal assembly required the major capsid protein, 
the triplex proteins and the major scaffolding protein.  By immunoprecipitating 
the complexes formed in the in vitro assembly reaction mixtures and analysing 
them under the electron microscope, several intermediate capsid forms were 
identified (Newcomb et al., 1996).  During progressively longer periods of 
incubation, partial capsids, followed by closed spherical capsids, termed 
procapsids, and finally angularised icosahedral capsids were observed.  While 
the various capsid structures all contained VP5, VP19C, VP23 and the scaffolding 
proteins preVP22a and VP21, procapsids were found to be more labile at low 
temperatures than the angular capsids formed.  In addition, upon continued 
incubation of purified procapsids in vitro they underwent an energy-independent 
conformational change and spontaneously formed angularised capsids.  These 
observations, which were consistent with the prohead maturation events 
reported in dsDNA bacteriophages, led Newcomb et al. (1996) to propose a 
model for HSV-1 capsid assembly.  The capsid assembly model is illustrated in 
Figure 1.12 and begins with formation of the partial capsid that consists of 
angular segments of the closed structure, and then proceeds through the more 
fragile and closed spherical procapsid intermediate to the stable and mature 
icosahedral capsid.   
Figure 1.12 Model for HS-1 capsid assembly
The major events in HSV-1 viral assembly are illustrated and show the relationship between capsid assembly, maturation 
and DNA packaging.  The open boxes represent the major capsid protein (VP5) that makes up the hexons and pentons, 
the triplexes are denoted by crescents and the scaffolding proteins by triangles.  Similar to bacteriophage systems, HSV-1 
capsids contain a portal vertex, which is known to associate with scaffold.  These observations have prompted the 
suggestion that the capsid assembly in HSV-1 is initiated through an interaction between the portal complex and the major 
scaffolding protein, UL26.5 (Newcomb et al., 2003).  Although not precisely defined, the cleavage and release of the 
scaffolding proteins is concomitant with DNA packaging.  On completion of DNA encapsidation the portal channel is 
sealed by an unkown mechanism, followed by the final stages of viral assembly (adapted from Rixon and Chiu, 2003). 
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1.3.4.2 Procapsid structure and maturation 
The procapsids identified in the cell free capsid assembly system were confirmed 
as intermediates in HSV-1 capsid assembly by characterising capsids formed in 
cells infected with the HSV-1 temperature-sensitive (ts) protease mutant, ts1201 
(Rixon & McNab, 1999).  Cryo-EM analysis and image reconstruction techniques 
showed that procapsids were spherical with a T=16 icosahedral symmetry and 
had a looser architecture than the more angularised mature HSV-1 capsid (Figure 
1.13) (Heymann et al., 2003, Newcomb et al., 1999, Newcomb et al., 2000, Trus 
et al., 1996).  In the procapsid there is little interaction between the 
neighbouring VP5 hexon and penton subunits, with contact between the 
capsomers being coordinated exclusively by the surrounding triplexes.  Within a 
given capsomer the main intersubunit contacts take place in the innermost layer 
of the capsid cavity, where the VP5 subunit floor domains form rings.  The result 
is that the trans-hexonal channel, which is a small circular opening in the 
mature capsid, is considerably wider in the procapsid.  The more porous and 
fragile architecture of the procapsid is a consequence of this loose association 
between its components (Newcomb et al., 1996, Newcomb et al., 2000).  As the 
procapsid matures, the conformational changes that take place results in 
enhanced interactions between the floor domains of neighbouring capsomers.  
These contacts are reinforced by the triplexes, which transform into molecular 
clamps overlying the trigonal points at which three capsomers come together in 
the floor domains.  In addition, the highly asymmetric hexons present in the 
procapsid are transformed into the symmetric configurations detected in the 
mature capsid (Heymann et al., 2003).  The precise kinetics of capsid maturation 
in vivo is unknown, but thin sections of infected cells do not reveal procapsids 
except when the protease is inactivated, implying that they mature shortly after 
assembly (Rixon et al., 1988). 
Capsid maturation overlaps with viral DNA packaging and is initiated by the 
protease clipping the terminal peptide at the M site in the assembled scaffolding 
proteins, disrupting their interaction with the outer shell (Section 1.2.2.3). The 
successful end product of procapsid maturation is the mature angularised 
nucleocapsid, which has lost its internal scaffold and contains a viral genome.  
Although the link between DNA packaging and loss of the scaffold has been 
shown, the prompt that initiates scaffold cleavage and expulsion is still unclear 
Procapsid CapsidA
B
Figure 1.13 Comparison of the HSV-1 procapsid and capsid
(A) The colour illustration show the difference in shape between the spherical 
procapsid and the more angularised capsid. The capsomers are highlighted in 
blue and the triplexes in green.  (B) Outside (1 and 2) and inside (3 and 4) views 
of reconstructions of the HSV-1 procapsid (1 and 3) and capsid (2 and 4).  All 
views are shown looking along a 3-fold icosahedral axis.  The procapsid retains 
some icosahedral symmetry, which is apparent by the hexagonal arrangement of 
the capsomers seen in the internal view (3).  The procapsid subunits are less 
clearly defined than those of the capsid.  In addition, the contacts between the 
individual subunts are looser and the continuous floor is absent, since there are is 
no contact at the bases of the capsomers in the procapsid.    
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(Church & Wilson, 1997, Dasgupta & Wilson, 1999, Preston et al., 1983, Rixon & 
McNab, 1999).  In bacteriophage systems the transformation from procapsid to 
mature capsid is promoted by the electrostatic repulsive forces exerted by 
packaged DNA on the inner capsid surface (Conway et al., 2001).  In the HSV-1 
system, it has been suggested that these forces alter the ionic environment 
within the capsid cavity, triggering the dissociation of the scaffold from the shell 
(McClelland et al., 2002).   In addition, the physical force exerted on the capsid 
shell as more DNA is packaged during encapsidation would be expected to 
facilitate changes in procapsid maturation.     
1.3.5 DNA encapsidation 
DNA encapsidation requires two linked events, cleavage of the replicated head-
to-tail concatemeric viral DNA into unit-length genomes and packaging of these 
DNA molecules into capsids (Ladin et al., 1980, Ladin et al., 1982).  As well as 
the maturational protease, seven trans-acting virus-encoded proteins, UL6, 
UL15, UL17, UL25, UL28, UL32 and UL33 are essential during the process 
(reviewed in Baines & Weller, 2005).  When cells are infected with HSV-1 
mutants lacking the function of any of these genes, apart from UL25, capsid 
formation and DNA replication takes place, but no DNA packaging occurs.  By 
analogy to the extensively studied bacteriophage system, it is presumed that 
HSV-1 encodes a multicomponent enzyme, the terminase, which links the DNA to 
the procapsid and cleaves the DNA precisely into unit-length genomes.  After the 
initial cleavage of the concatemeric viral DNA, the cleaved DNA is inserted 
through the unique vertex, or portal, and is driven into the maturing capsid by 
the terminase complex and ATP hydrolysis, with concomitant loss of the internal 
scaffold.  A second cleavage event occurs to release a monomeric viral genome 
that is stably encapsidated as a consequence of the interaction of viral gene 
products with the maturing capsid, resulting in the successful production of the 
precursor of the infectious virion (reviewed in Baines & Weller, 2005).    
1.3.5.1 Cleavage and packaging signals 
In addition to the essential trans-acting viral proteins that direct the site-
specific DNA cleavage and packaging process, cis-acting viral DNA sequences 
termed Pac1 and Pac2 are also involved and have been mapped to the Ub and Uc 
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domains of the a sequences, respectively (Varmuza & Smiley, 1985).  In various 
herpesvirus strains the sequences within the a region consist of a series of direct 
repeat units (DR) and unique regions (Uc or Ub), arranged as DR1-Uc-DR4m-DR2n-
Ub-DR1, where m and n designate variable numbers of repeats (Figure 1.14).  
The size of these components and the type of direct repeat units (DR1, DR2 or 
DR4) present can vary between strains, but are thought to be consistent within a 
strain.  In HSV-1 strain 17 syn+ the a sequence encompasses a region of 
approximately 400 base pairs (bp) in length, containing only the DR1 and DR2 
direct repeat units (Figure 1.14).  A single a sequence is flanked by DR1, while 
junctions containing more than one a sequence share a single intervening DR1 
(Davison & Wilkie, 1981, Mocarski & Roizman, 1981, Mocarski & Roizman, 1982).  
Lying internally to the DR1 repeats are two unique regions, Ub and Uc, which 
contain highly conserved packaging elements termed Pac1 and Pac2, 
respectively (Deiss et al., 1986, Nasseri & Mocarski, 1988).   
Upon entry, the linear viral genomes fuse at their terminal sequences and 
generate the circular DNA molecules that are the substrate for viral DNA 
replication.  Fusion at the terminal a sequences creates a Uc-DR1-Ub junction 
(Figure 1.14) that has been demonstrated to be the minimal packaging signal 
required during DNA encapsidation (Hodge & Stow, 2001, Nasseri & Mocarski, 
1988, Stow, 2001).  Cleavage of the concatemeric viral DNA occurs within the 
DR1 repeat, although the actual sequence of DR1 is not important.  The cleaved 
concatemeric end consists of a truncated DR1 with 18 of its 20 bp plus a single-
nucleotide 3’ overhang and in HSV-1 strain 17 syn+ this is followed by Uc (Pac2), 
DR2, Ub (Pac1), DR1 and UL sequences (Mocarski & Roizman, 1982).  After 
association of the cleaved DNA termini with the capsid portal the viral genome is 
inserted into the capsid shell in the direction of the UL to Us region.  The second 
cleavage is dependent on the Pac1 motif and occurs in such a way that the DNA 
being packaged is terminated by a single bp of DR1 with a 3’ nucleotide 
overhang.  Consequently, the terminus of the unpackaged cleaved concatemeric 
DNA is identical to the terminus generated following the first cleavage event and 
as a result would be expected to initiate the next round of DNA packaging (Stow, 
2001).     
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Figure 1.14 HSV-1 genome and structure of the a sequences
(A)The positions of the a sequences in the HSV-1 genome are highlighted in red and their relative 
orientations are indicated by the arrowheads.  For simplicity only a single a sequence is shown at the L 
terminus and L/S junction.  (B) Generation of the minimal cleavage/packaging signal Uc-DR1-Ub upon 
fusion of a sequences.  (C) The cleavage site in concatemeric DNA is situated close to one end of the 
DR1 sequence as indicated.
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1.3.5.2 Components of the packaging machinery 
Mutational analysis of the seven essential packaging genes, UL6, UL15, UL17, 
UL25, UL28, UL32 and UL33, provided evidence that, although DNA cleavage and 
DNA packaging were linked, they were distinct events in the process of DNA 
encapsidation.  In cells infected with null mutants of UL6, UL15, UL17, UL28, 
UL32 or UL33 the concatemeric DNA produced is neither cleaved or packaged 
into capsids, resulting in an accumulation of B-capsids that contain processed 
scaffolding proteins (Lamberti & Weller, 1996, Lamberti & Weller, 1998, Patel et 
al., 1996, Reynolds et al., 2000, Salmon & Baines, 1998, Yu et al., 1997).  In 
contrast in cells infected with a UL25 null mutant, DNA cleavage occurs and DNA 
packaging is initiated but less than unit-length viral genomes are stably 
encapsidated and there is an overrepresentation of empty A-capsids (Stow, 
2001).   
1.3.5.2.1 The portal vertex (UL6) 
 
In the dsDNA bacteriophages, such as Φ29, T4, P22 and epsilon15, the portal 
complex is located at a unique vertex on the icosahedral capsid shell and 
consists of a dodecameric ring of portal protein (Chang et al., 2006, Jiang et al., 
2006, Lander et al., 2006).  Evidence has accumulated that indicates the UL6 
gene product (pUL6) forms the portal or channel through which viral DNA is 
inserted into the capsid and presumably is released during HSV-1 entry.  The 
protein is a component not only of the procapsid, but also of the angularised A-, 
B- and C-capsid forms and the mature virion, which suggests that pUL6 is an 
integral part of the capsid shell and its association is unaffected by capsid 
maturation or DNA packaging (Patel et al., 1996, Sheaffer et al., 2001).  
Subsequently, immunogold-labelling experiments revealed that HSV-1 pUL6 was 
present at one of the twelve vertices of B-capsids from HSV-1 infected cells 
(Newcomb et al., 2001).  To determine if pUL6 could actually form ring-like 
structures that resembled portals, soluble pUL6 was purified from insect cells 
infected with recombinant baculovirus expressing the protein (Newcomb et al., 
2001).  The samples were examined by EM and revealed a uniform population of 
rings with an internal diameter of 5 nm and external diameter of 16.4 nm.  The 
dimensions of the ring-like structures corresponded closely to the diameters 
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observed of the portal complexes of the dsDNA bacteriophages, which range in 
size from 14.5 nm – 17.5 nm externally and 2.5 nm – 4.5 nm internally (Bazinet & 
King, 1985, Valpuesta & Carrascosa, 1994).  Further analysis to determine the 
mass of the individual pUL6 rings using dark-field scanning electron microscopy, 
revealed a homogenous population with an oligomeric state that equalled 12, 
the same number determined for bacteriophage dodecameric portal complexes 
(Bazinet & King, 1985, Valpuesta & Carrascosa, 1994).  Similar to the portal 
proteins of the bacteriophage T4, pUL6 associates with the scaffolding proteins.  
Newcomb et al. (2005) used an in vitro capsid assembly assay to demonstrate 
that pUL6’s interaction with the scaffold protein was essential for incorporation 
of the portal into the capsid.  However, from the data discussed in Section 
1.3.4.1 it is clear that capsid assembly can occur in the absence of pUL6.  
Newcomb et al. (2005) also showed that capsids containing portals only formed 
when portals were present at the initiation of capsid assembly, any delay in the 
availability of portals at this stage resulted in the formation of capsids lacking 
portals.   
The mass of a single portal subunit in HSV-1 is 74 KDa, making the entire mass of 
the portal approximately 888 kDa, which is similar in size to the 747 KDa penton 
(Newcomb et al., 2001, Zhou et al., 2000).  The equivalent size of the vertices 
has presented a challenge in determining the location and structure of the portal 
in the HSV-1 capsid using electron microscopy coupled with 3-dimensional (3D) 
reconstruction.  A recent study used electron cryotomography to reveal the 
organisation of the HSV-1 portal in B-capsids treated with 6 M urea, which does 
not remove the portal protein but selectively removes proteins associated with 
the other 11 vertices (Chang et al., 2007).  The portal in HSV-1 appears to be 
organised in a similar manner to those observed in some of the dsDNA 
bacteriophage capsids, specifically P22 and Epsilon15.  In these systems the 
majority of the portal extends inwards into the interior of the capsid shell, while 
the remainder of the structure does not extend far but lies predominately flat 
against the external capsid shell (Figure 1.15).  Since the structure is lodged 
deep within the shell, this may explain the difficulties that have been 
encountered until recently in detecting the HSV-1 portal. 
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Figure 1.15 The HSV-1 portal
(A) The HSV-1 portal structure (magenta) is shown in the context of the 
icosahedral averaged tomographic map of the capsid shell (green).  The 
density represented by magenta is 14 nm tall and 11 nm wide.  (B) 
Various views of a 3D reconstruction of the 12 mer HSV-1 portal at 16 Å 
resolution.  (C) Interior view of a capsid model at 18 Å resolution.  A 
penton of VP5, the major capsid protein, was computationally excised 
and replaced by the portal shown in magenta (adapted from Trus et al., 
2004 and Chang et al., 2007). 
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1.3.5.2.2 Putative terminase complex (pUL15, pUL28 and pUL33) 
 
By analogy with the muticomponent terminases of the bacteriophage systems, 
the HSV-1 terminase would be predicted to specifically recognise DNA ends 
within the viral genomes, and have the ability to cleave and link these DNA 
molecules to the capsid at the portal.  Since the encapsidation of DNA requires 
energy, the putative HSV-1 terminase would also be expected to mediate the 
DNA packaging process by translocating the DNA into the capsid cavity by ATP 
hydrolysis (Dasgupta & Wilson, 1999).  The first indication that the UL15 gene 
product (pUL15) was involved in DNA packaging and may form part of the HSV-1 
terminase complex came from observations that the gene shared sequence 
homology with the ATP binding motif of the bacteriophage T4 terminase subunit, 
gp17 (Davison, 1992, Davison et al., 1992).  Confirmation that the UL15 gene 
product was essential during DNA encapsidation was provided by analysis of two 
UL15 null viruses, in which the UL15 gene was either truncated or replaced by a 
LacZ insertion (Baines et al., 1997, Yu et al., 1997).  These studies revealed that 
in non-permissive cells infected with the mutant virus, viral DNA cleavage or 
packaging did not occur.  The idea that the UL15 gene product formed the 
ATPase subunit of the HSV-1 terminase was reinforced when a mutant pUL15, 
encoding a mutation in the putative ATP binding domain, failed to support DNA 
encapsidation when expressed in HSV-1 UL15 null mutant-infected non-
permissive cells (Yu & Weller, 1998b).  More recent evidence that UL15 encodes 
a terminase function has been provided by mutational analysis of the conserved 
UL15 sequences shared with the ATPase subunits of phage terminase, which 
revealed that DNA encapsidation was impaired in cells infected with HSV-1 
mutant viruses expressing pUL15 with a point mutation in one of the four 
conserved regions (Przech et al., 2003).  Since the mutated pUL15s associated 
with capsids localised to replication compartments, these residues are likely to 
be directly required for cleavage and packaging of viral DNA.  
 
The components of the putative HSV-1 terminase have been identified by protein 
interaction studies, which have established that pUL15 interacts with two other 
essential DNA packaging proteins encoded by UL28 (pUL28) and UL33 (pUL33) 
(Abbotts et al., 2000, Beard et al., 2002, Koslowski et al., 1999, Yu & Weller, 
1998b).  These observations led to the suggestion that in contrast to the two 
subunit bacteriophage terminases, the putative HSV-1 terminase is a 
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heterotrimeric complex of pUL15, pUL28 and pUL33.  Direct binding between 
pUL15 and pUL28 was originally demonstrated when HSV-1 pUL15 was shown to 
relocate PrV pUL28 to the nucleus when the proteins were transiently expressed 
together in un-infected cells (Koslowski et al., 1997).  A study using co-
immunoprecipitation assays subsequently showed pUL33 also formed a complex 
with pUL15 and pUL28 in virus-infected cells (Beard et al., 2002).  A further 
study using immunoprecipitation assays demonstrated that pUL28 was required 
for the interaction of pUL15 with pUL33, while the presence of pUL33 enhanced 
the binding of pUL15 to pUL28 (Yang & Baines, 2006).  An indirect interaction 
between pUL15 and pUL33 was confirmed by co-immunoprecipitation analysis on 
HSV-1 UL28 null mutant-infected cells (Jacobson et al., 2006).  In addition, 
experiments have revealed that the putative heterotrimeric terminase of HSV-1 
was assembled in the cytoplasm of infected cells, and that a nuclear localisation 
signal present in pUL15 was necessary for the import of the complex into the 
nucleus (Yang et al., 2007).    
 
A potential terminase complex would be predicted to interact with capsids and 
indeed components of the putative HSV-1 terminase have been found to 
associate with the different capsid forms.  Both pUL15 and pUL28 have been 
detected on procapsids, the capsid substrate required during the DNA cleavage 
and packaging process, and on A-, B- and C-capsids (Sheaffer et al., 2001).  In 
addition, pUL33 has been observed on all three forms of angularised capsid, but 
its association with capsids is independent of that of pUL15 or pUL28 (Beard & 
Baines, 2004).  Although the location of the pUL15 and pUL28 on the HSV-1 
capsid is not known, both proteins have been shown to interact with the UL6 
portal protein, an observation that supports the suggestion that pUL15 and 
pUL28 form part of the terminase complex (White et al., 2003).  Studies have 
shown that as the capsid matures in infected cells, decreasing concentrations of 
pUL15, pUL28 and pUL33 are detected, suggesting that the putative terminase’s 
association with the capsid may be transient (Beard et al., 2004, Salmon et al., 
1998, Sheaffer et al., 2000, Sheaffer et al., 2001, Taus et al., 1998, Yu & Weller, 
1998a).  Approximately about the time of the first cleavage event during DNA 
encapsidation, epitopes encoded by the first 35 aa of pUL15 are proteolytically 
removed (Salmon et al., 1999).  Sequence analysis of this portion of UL15 has 
revealed that it has a potential coiled-coil motif that may mediate protein-
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protein interactions, removal of this segment during DNA encapsidation could 
release the protein and mediate the terminase activity (Baines & Weller, 2005, 
McGeoch et al., 1988). 
 
An in vitro DNA binding activity for the putative pUL28 terminase subunit was 
suggested, when the purified protein bound to a novel ssDNA structure formed 
by the HSV-1 DNA Pac1 cleavage signal.  In addition, pU28 also bound to the DNA 
structures induced by the Pac1 motif of HCMV with only slightly less affinity, and 
mutations in sequence elements within the HMCV Pac1 motif eliminated DNA 
cleavage and packaging and prevented DNA binding by HSV-1 pUL28 (Adelman et 
al., 2001).  Consequently, it was claimed that this provided indirect evidence 
that HSV-1 pUL28 recognises Pac1 sequences in vivo.  However, the DNA binding 
activity associated with pUL28 has not been confirmed, and these experiments 
could not be repeated (Dr N. Stow, personal communication).  In addition, since 
the Pac1 sequence is required for the second cleavage event and the correct 
production of S-termini during HSV-1 DNA encapsidation, the observations 
suggested that Pac1 DNA binding by pUL28 occurs later during cleavage and 
packaging (Hodge & Stow, 2001).  However, there is evidence that pUL28 may 
also be required during the early stages of encapsidation, since mutants lacking 
UL28 demonstrate defects in the initiation of the DNA cleavage and packaging 
reaction (Addison et al., 1990, Tengelsen et al., 1993).  No in vitro DNA 
packaging system exists to verify that pUL15, pUL28 and pUL33 comprise the 
HSV-1 terminase.  Nevertheless, a substantial body of evidence does exist to 
suggest these proteins possess the predicted functional profiles of the 
constituents of such a complex.  
1.3.5.2.3 UL32 
 
Characterisation of two UL32 mutants, tsN20 and hr64, confirmed that the gene 
was essential for HSV-1 cleavage and packaging (Lamberti & Weller, 1998, 
Schaffer et al., 1973).  The UL32 protein (pUL32) is a cysteine rich, zinc-binding 
protein, which although required for encapsidation has an indirect role during 
DNA cleavage and packaging, since it is not directly associated with capsids (Al-
Kobaisi et al., 1991, Chang et al., 1996, Lamberti & Weller, 1998, Reynolds et 
al., 2000).  In the absence of pUL32, capsids did not appear to accumulate in 
replication compartments and this observation led to suggestions that the 
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protein functioned during capsid transport (Lamberti & Weller, 1998).  However, 
subsequent experiments in our laboratory do not support this suggestion (Dr V. 
Preston, personal communication).    
1.3.5.2.4 UL17 
 
UL17 was first recognised as an essential HSV-1 DNA cleavage and packaging 
protein following analysis and characterisation of a UL17 null mutant.  In 
contrast to wt virus-infected cells where B-capsids are dispersed within the 
nucleus, in the HSV-1 UL17 null-infected cells the B-capsids accumulated in large 
aggregates around the periphery of the nuclei (Roizman et al., 2007, Salmon & 
Baines, 1998, Taus et al., 1998).  On the basis of these observations it was 
suggested that the UL17 protein (pUL17) was involved in pathways that either 
directly transported capsids through the nucleus or produce capsids competent 
for intranuclear transport.  Initially, it was proposed that pUL17 was a 
component of the tegument since it was readily detected L-particles (Section 
1.2.5) and virions, and this finding was later confirmed using a more potent anti-
pUL17 antibody in Western blot analysis of virions and related particles (Salmon 
et al., 1998, Thurlow et al., 2005).  Subsequently pUL17 was identified as a 
minor component of the procapsid and the angularised A-, B- and C-capsids 
(Goshima et al., 2000, Thurlow et al., 2005).  Thus, it appears that UL17 is 
present in two different structural components of the mature virus particle, the 
capsid and the tegument.  A recent report demonstrated that pUL17 was present 
at higher concentrations on C-capsids compared to B-capsids and that its 
presence on capsids was required for efficient binding of the DNA packaging 
protein encoded by UL25 (Thurlow et al., 2006).  Additional viral proteins have 
been implicated in delaying the transformation of the spherical procapsid to the 
angularised capsid in infected cells, since in vitro procapsids formed from the 
capsid shell and major scaffolding proteins angularise more readily than in vivo 
procapsids (Newcomb et al., 1999, Newcomb et al., 2000, Rixon & McNab, 1999).  
In addition, in virus-infected cells and in the absence of DNA packaging, the HSV-
1 procapsid spontaneously angularises.  Given that UL17 is an essential DNA 
packaging gene and appears to be required at an earlier stage of DNA 
encapsidation than pUL25, Thurlow et al. (2006) suggested that pUL17 was a 
strong candidate for preventing premature angularisation by stabilising the 
procapsid during DNA encapsidation.  
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1.3.5.2.5 UL25 
 
The HSV-1 UL25 gene product is a minor capsid protein that, in contrast to the 
other essential DNA packaging genes, functions during the later stages of the 
process.  UL25 was initially classified as an essential DNA encapsidation gene 
following characterisation of two ts mutants, ts1204 and ts1208 (Addison et al., 
1984).  One mutant, ts1208, failed to produce C-capsids at the NPT, while ts1204 
had two defects, a reversible defect during the initial stages of infection and 
another that was evident during DNA packaging.  Because ts1204 contained two 
ts lesions, one of which lay outside the UL25 ORF, the UL25 ts mutation was 
transferred into wt virus and the mutant ts1249 was isolated.  Indirect 
immunofluorescence assays and in-situ hybridisation analysis of virus-infected 
cells revealed that ts1249 was not impaired in penetration of the host cell but 
had an uncoating defect at the NPT.  When ts1249-infected cells were initially 
grown at the PT to allow uncoating of the viral genome and subsequently 
transferred to the restrictive temperature, a DNA packaging defect was 
observed, suggesting that pUL25 was involved not only during viral entry but also 
during DNA encapsidation (Preston et al., 2008).  
 
Confirmation that UL25, unlike the other essential cleavage/packaging genes, 
was involved in DNA encapsidation during the later stages came from studies 
involving the UL25 null mutant, KUL25NS (McNab et al., 1998, Stow, 2001).  In 
virus-infected cells lacking the UL25 protein (pUL25), B-capsids were present 
and an accumulation of A-capsids were observed, which are the by-products of 
failed DNA packaging events (McNab et al., 1998).  In addition, considerably 
more genomic L termini were generated than S terminal sequences in KUL25NS-
infected cells.  Since the direction of packaging is generally regarded to be in 
the direction of the L to S termini, the results suggested that packaging was 
initiated but failed to go to completion and was aborted prior to the second 
cleavage event (Stow, 2001, Varmuza & Smiley, 1985).  Although, DNA-
containing capsids were not observed in KUL25NS-infected Vero cells 
characterised by McNab et al. (1998) packaged viral DNA, shorter than unit-
length, was subsequently detected in the mutant-infected cells by Stow (2001).  
This work led Stow (2001) to suggest that HSV-1 pUL25 is critical for the 
retention of full-length viral DNA in capsids.   
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When large amounts of DNA are tightly packaged into the confines of the capsid 
shell the packaging rate decreases as the immature capsid is filled, indicating 
that a large internal energy is generated that creates an increased potential 
force for DNA exit (Smith et al., 2001).  Stow (2001) proposed that by binding to 
capsids pUL25 could stabilise the capsid against the internal forces generated as 
increasing amounts of DNA are packaged.  However, alternative mechanisms 
have been suggested to explain the means that pUL25 uses to retain full-length 
viral genomes in C-capsids.  Ogasawara et al. (2001) carried out experiments 
which indicated that pUL25 bound to the a sequence of the HSV-1 genome.  They 
proposed that pUL25 functioned by physically plugging the portal, thereby 
retaining the packaged DNA in C-capsids.  However, to date no DNA binding 
activity has been confirmed for pUL25.  Indeed, experiments carried out within 
our lab failed to detect binding of purified pUL25 to DNA (Dr N. Stow, personal 
communication).  It has also been suggested that pUL25 enhances the activity of 
the packaging machinery by stabilising the terminase complex that drives the 
DNA into the capsid shell.  Nevertheless in support of Stow’s (2001) hypothesis, 
conformational changes do occur on the maturing capsids that create or expose 
new binding sites, such as the VP26 binding sites on hexons following procapsid 
maturation.  It is therefore conceivable that new pUL25 binding sites also 
become available during capsid maturation, which allows the protein to stabilise 
the structure thereby overcoming the expected tendency of the DNA to exit the 
shell.  Consistent with this idea is the observation that increasing concentrations 
of the protein are observed in the maturing capsid forms.  Very little pUL25 is 
detected on procapsids, greater amounts are observed on B-capsids and DNA-
containing C-capsids contain the highest levels (Ogasawara et al., 2001, Sheaffer 
et al., 2000, Sheaffer et al., 2001).  In the light of these results, Sheaffer et al. 
(2001) proposed that the recruitment of pUL25 was inversely related to level of 
scaffold protein present in the maturing capsid.  While procapsids contain a full 
complement of unprocessed scaffolding proteins, B-capsids have a cleaved 
scaffolding core and mature C-capsids contain no scaffold.  Thus, this latter 
model predicts that the sequential addition of pUL25 to the maturing capsid, 
with concomitant loss of the scaffolding proteins during DNA packaging, 
stabilises the structure enabling the mature C-capsid to retain its full DNA cargo.  
This system is not unprecedented and is analogous to the functions of the head 
stabilising proteins of bacteriophage λ, gpW and gpD (Maxwell et al., 2000, 
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Perucchetti et al., 1988).  During DNA packaging of phage λ the head expands by 
approximately 20%, exposing binding sites that gpD interacts with on the surface 
lattice of the icosahedral shell (Imber et al., 1980).  Once packaging is 
complete, gpW also interacts with the DNA-filled heads to stabilise them.  
Similar to pUL25, both gpD and gpW are dispensable for procapsid assembly but 
are essential for stable encapsidation of the viral genome and, like pUL25, the 
requirement for gpD is redundant if less than unit-length genomes are packaged 
(Perucchetti et al., 1988, Sternberg & Weisberg, 1977a, Sternberg & Weisberg, 
1977b).  Although there is no head expansion in HSV-1, like gpD and gpW, pUL25 
has been predicted to bind to different regions on the icosahedral capsid shell 
(Trus et al., 2007).  
 
The UL25 protein is not only involved in DNA packaging but is also important 
during DNA entry and has been implicated in egress (Coller et al., 2007, 
Pasdeloup et al., 2009, Preston et al., 2008).  The binding partners that interact 
with the multifunctional pUL25 together with crystallographic structure for the 
protein are discussed in Section 1.4.    
 
1.3.5.3 Packaged state of viral DNA    
In the HSV-1 virion the encapsidated DNA is so densely packed within the capsid 
shell that it exists in a liquid-crystalline state (Booy et al., 1991).  It is a 
remarkable achievement that viral DNA is packaged to a near-crystalline state, 
since entropic, electrostatic and bending energies of the DNA must be overcome.  
A study using optical tweezers to pull on single DNA molecules as they are 
packaged into the phage heads of Φ29 allowed a quantitative estimate of the 
build-up of the internal force that the prohead experiences as it is filled (Smith 
et al., 2001).  The force on the prohead starts to build only after approximately 
half of the Φ29 genome is already packaged.  However, the estimated pressure 
transmitted to the phage head on completion of the packaging of the viral 
genome suggests that the capsid must have a tensile strength that is similar to a 
typical aluminium alloy (Smith et al., 2001).   
Packaged DNA inside HSV-1 virions is organised into concentric layers (Figure 
1.16), a configuration that has been compared to the ‘spooling’ model of DNA 
Figure 1.16  Central cross-section of a cryo-EM reconstruction of HSV-1
The resolution of the virion reconstruction is 20 Å. The central cross-section 
(100 Å thick) through the structure is viewed along the two-fold axis, and is 
coloured radially as indicated on the colour bar below the virion.  The 
packaged viral DNA (red) is seen as concentric shells of density inside the 
capsid shell, with the spacing between the layers being 26 Å.  The capsid floor 
is shown in yellow and the triplexes and middle domains of the capsomers are 
indicated in green.  The outer domains of the capsomers together with the 
tegument densities associated with pentons are coloured blue and purple, 
respectively (adapted from Zhou et al., 1999). 
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packaging proposed for bacteriophage T7 where the strands are packaged in a 
hexagonal lattice (Cerritelli et al., 1997, Zhou et al., 1999).  This arrangement 
suggests that once the DNA has been inserted through the portal, it is packaged 
into the confines of the capsid cavity by wrapping around the inner surface of 
the shell and organising itself layer upon layer.  However, as the DNA is 
progressively packaged the layers become less ordered the further they are from 
the outer shell (Harrison, 1983).  Although the DNA appears to be closely 
associated with the inner shell, the structure of the packaged DNA shows no 
icosahedral symmetry that would indicate it specifically interacts with the 
capsid proteins (Zhou et al., 1999).  In the bacteriophage HK97 the inner floor of 
the capsid shell is highly charged (Wikoff et al., 2000).  Therefore, it has been 
suggested that in viral capsids the energy of the encapsidated negatively 
charged DNA may be lowered by its close association with the positively charged 
inner capsid floor (Tzlil et al., 2003).  However, to date there is no information 
on the charge present in the inner floor of the HSV-1 capsid.   
1.3.5.4 Model of HSV-1 DNA encapsidation  
Based on the current information outlined above, a model for HSV-1 packaging 
has been proposed and is illustrated in Figure 1.17 (Baines & Weller, 2005).  In 
addition to the concatemeric viral genomes generated following DNA replication, 
two other substrates, procapsids and the terminase are required for DNA 
encapsidation.  The procapsids, which contain the unprocessed scaffolding 
proteins preVP21 and preVP22a, are assembled within the nucleus close to or 
within replication compartments.  The putative terminase consists of pUL15, 
pUL28 and pUL33 and binds to the viral DNA concatemers via the pUL28 subunit.  
The terminase/DNA complex then binds to the capsid predominately through an 
interaction with the portal protein, pUL6.  The terminase scans the DNA for the 
appropriate Pac2 cleavage signal and at fixed distance from this site an initial 
cleavage event releases an L terminal genomic end.  The cleaved S terminal end 
that is not bound to the capsid is degraded.  The DNA cleavage and packaging 
reactions are initiated by protease activation and scaffold cleavage and the 
processed products VP21 and VP22a are released, while the protease (VP24) 
remains in the capsid.  Concurrently, the L-terminal viral DNA is inserted 
through the portal and translocation of the L/S junction followed by the S-
terminal end of the viral genome into the capsid is achieved by the energy 
Figure 1.17 HSV-1 DNA cleavage and packaging model
(1) The immature capsid is assembled in the nucleus.  (2) The procapsid is delivered to the 
replication compartment, the site of DNA encapsidation.  (3) The putative terminase, which consists 
of a heterotrimeric complex of the UL15, UL28 and UL33 gene products, binds the viral DNA 
concatemers via the UL28 protein subunit, and the DNA/terminase complex docks with the capsid 
at the portal.  The DNA is scanned by the terminase and the DNA concatemer is cleaved at the 
Pac2 signal.  A genomic L terminal end from the cleaved DNA concatemer is then inserted into the 
cavity of the capsid via the portal channel, and DNA packaging commences with the hydrolysis of 
ATP.  (4) Concomitantly as the DNA is packaged into the capsid, the cleaved scaffolding proteins, 
VP21 and VP22a, are released.  (5) The UL28 protein cleaves the DNA concatemer again, this 
time at the Pac1 motif, leaving a unpackaged L terminus and an encapsidated unit-length viral 
genome.  During the final stages of DNA encapsidation, the structure is stabilised by the 
association of the UL25 protein to the binding sites that are exposed during capsid maturation 
(adapted from Steven et al., 2005).  
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supplied through ATP hydrolysis, which is mediated by the terminase associated 
pUL15.  As the procapsid matures, pUL17 is added to prevent premature 
angularisation, which would inhibit DNA packaging.  In addition, pUL28 cleaves 
the viral DNA again, on this occasion using the Pac1 cleavage signal, generating 
the packaged S-terminus of the full-length viral genome.  At the same time the 
internal scaffold is lost and pUL25 is added to the outer shell through its 
interaction with pUL17, stabilising the structure and resulting in the production 
of the mature C-capsid.   
1.3.6 Egress 
Once DNA encapsidation is complete, unit length DNA-containing C-capsids must 
cross the nuclear membrane to complete the assembly of the infectious virus 
particle in the cytoplasm.  The nuclear envelope consists of an inner and an 
outer nuclear membrane (INM and ONM, respectively) that are traversed by 
multiple nuclear pore complexes (NPCs) and lined by a meshwork of 
intermediate filaments comprising the nuclear lamina.  Three proteins, encoded 
by US3, UL31 and UL34, allow the C-capsid to escape the egress barrier 
presented by the nuclear membrane.  Following the release of the naked C-
capsid into the cytoplasm, tegument proteins bind to the capsid and direct the 
transport of the particle to the site of secondary envelopment, where further 
tegument proteins are added prior to envelopment and the release of mature 
virions from the cell by exocytosis (reviewed in Mettenleiter, 2006, Roizman et 
al., 2007).   
1.3.6.1 Nuclear egress and primary envelopment       
Three different models have been proposed for nuclear egress of C-capsids, 
which have been designated the ‘envelopment/de-envelopment’, the ‘luminal’ 
and the ‘nuclear pore’ pathways, each of which are illustrated in Figure 1.18 
(Johnson & Spear, 1982, Roizman et al., 2007, Skepper et al., 2001, Wild et al., 
2005).  A prerequisite for capsid egress is the engagement of the C-capsid with 
INM.  Two of the proposed pathways, the envelopment/de-envelopment and the 
luminal model, involve budding of the capsid at the INM and result in enveloped 
capsids within the perinuclear space.  In the luminal or single envelopment 
model, the primary envelope retains its integrity and the enveloped virus 
Normal NPC
Double envelopment model
Single envelopment model
Nuclear pore model
Vesicles derived from the 
trans-Golgi network
fragmented by infection
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Plasma
membrane
Transport vehicle
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INM ONM
Cytoplasm
Figure 1.18 Models for egress of HSV-1 from the host cell
The proposed pathways for maturation of filled capsids from the nucleus to the exterior of the 
infected cell are illustrated.  In the double envelopment pathway, C-capsids undergo primary 
envelopment at the inner nuclear membrane (INM), then de-envelopment at the outer nuclear 
membrane (ONM), followed by secondary envelopment at cytoplasmic membranes.  The 
enveloped viral particles are then transported in vesicles to the plasma membrane. Fusion of 
the vesicle with the plasma membrane releases the virion into the extracellular space.  In the 
single envelopment model, the C-capsid is enveloped at the INM, enters a vesicle at the ONM 
and is then transported to the plasma membrane where the virion is released.  In the nuclear 
pore model, C-capsids exit the nucleus through enlarged nuclear pores and become envel-
oped by budding into cytoplasmic vesicles, which are transported to the plasma membrane 
where the virion is released (adapted from Roizman et al., 2007).   
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particle is transported via the secretory pathway to the extracellular space 
(Roizman et al., 2007).  In the envelopment/de-envelopment or double 
envelopment model the primary envelope is subsequently lost by fusion with the 
ONM, resulting in de-envelopment and release of ‘naked’ capsids into the 
cytosol, followed by subsequent secondary envelopement at the trans-Golgi 
network (Stackpole, 1969). 
A third pathway, the nuclear pore model, for nuclear capsid egress was 
suggested following analysis of bovine herpesvirus type 1-infected cells using 
high pressure freeze-fracturing (Wild et al., 2005).  In these studies the nuclear 
pores appeared enlarged, with nuclear material including capsids, protruding 
into the cytoplasm of the infected cells.  These observations led to the proposal 
that capsids escape the nucleus via dilated NPC (Figure 1.18).  Such a pathway 
suggests that the general integrity of the NPC is violated in order to 
accommodate this process (Leuzinger et al., 2005).  However, subsequent 
findings have indicated that NPC morphology is unaffected and that their gating 
function remained intact until late infection (Hofemeister & O'Hare, 2008, 
Mettenleiter et al., 2006).  In support for these studies, nuclear capsid egress 
does not appear to be conditional on the alterations to the NPC that occur late 
during infection (Nagel et al., 2008).  In the single envelopment pathway all the 
components of the primary enveloped particle must be part of the mature 
virion, equally, all the constituents of the mature particle would be expected to 
be components of the primary enveloped particle.  Inconsistent with this idea is 
the observation that neither of the two major components of primary enveloped 
capsids, pUL31 and pUL34, have been detected on mature virions (Fuchs et al., 
2002a, Klupp et al., 2000, Reynolds et al., 2002).  Conversely, other tegument 
and envelope proteins that are constituents of mature virions have not been 
detected on primary enveloped viral particles (Granzow et al., 2004).  Further 
support for a double envelopment mechanism of capsid egress is demonstrated 
not only by the difference in the protein composition between primary 
enveloped and mature virions but also in differences observed between their 
lipid envelope.  Unlike the nuclear membrane seen in perinuclear virions, in 
mature virions the lipid membrane resembles those observed in Golgi-derived 
vesicles (Van Genderen et al., 1994).     
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Translocation of naked or enveloped capsids into the cytoplasm requires at least 
three viral proteins encoded by UL34, UL31 and US3 (Poon et al., 2006, Reynolds 
et al., 2004, Reynolds et al., 2001, Reynolds et al., 2002).  The proteins encoded 
by UL31 (pUL31) and UL34 (pUL34) are essential for primary envelopment and in 
the absence of either, intranuclear capsids do not access the INM.  Both UL31 
and UL34 are structurally and functionally conserved throughout Herpesviridae, 
UL34 encodes a type II transmembrane protein that is present in nuclear 
membranes and in primary envelopes, and physically interacts with pUL31 (Fuchs 
et al., 2002a, Lake & Hutt-Fletcher, 2004, Reynolds et al., 2002, Sanchez & 
Spector, 2002).  Since the passage of C-capsids through the INM is obstructed by 
the nuclear lamina network, the pUL34/pUL31 complex is required for 
conformational alterations to the nuclear lamins (Mou et al., 2008, Reynolds et 
al., 2004, Simpson-Holley et al., 2005).  The network of nuclear lamins is 
loosened by phosphorylation, predominately by pUL31/pUL34 recruitment of the 
cellular protein kinase C and the HSV-1 kinase encoded by US3 (pUS3) (Mou et 
al., 2008, Muranyi et al., 2002, Park & Baines, 2006).  EM studies have shown 
that, in the absence of HSV-1 or PRV pUS3, enveloped particles accumulate in 
the perinuclear space, indicating that primary envelopment takes place but de-
envelopment is impaired (Reynolds et al., 2002, Wagenaar et al., 1995).  It 
appears that expression of pUS3 in infected cells promotes but is not essential 
for nuclear egress, since in cultured epithelial cells the absence of pUS3 only 
mildly reduces the titre of extracellular virions (Klupp et al., 2007).   
1.3.6.2 Tegumentation and secondary envelopment      
Following nuclear egress, the C-capsid acquires its full complement of tegument 
proteins and the final or secondary envelope.  By conventional EM analysis 
cytosolic capsids appear ‘naked’, however, immunolabelling studies have 
revealed that pUL36 and pUL37 are closely associated with cytoplasmic C-capsids 
(Fuchs et al., 2002a).  Whether these proteins are added during primary 
envelopment and remain associated with the translocated capsid, or whether 
they are recruited after nuclear egress remains unclear.  However, structural 
analysis of HSV-1 has indicated that there is a clear distinction between the 
envelope-associated amorphous outer tegument layer and the icosahedrally 
arranged capsid-associated inner tegument layer (Zhou et al., 1999).  In 
addition, the stoichiometric proportions of the inner tegument proteins are 
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relatively constant, whereas the outer tegument proteins can show considerable 
variation (Del Rio et al., 2005, Michael et al., 2006).   
Studies have indicated that in the absence of pUL36 in PrV, the movement of 
virus particles to the site of secondary envelopment is blocked during egress 
(Luxton et al., 2006).  Since PrV and HSV-1 pUL36 appear to be functionally 
conserved, the results suggest that pUL36 may be linked to cytoplasmic capsid 
transport, which is dependent on microtubules in virus-infected cells (Coller et 
al., 2007).  This possible role for pUL36 during exit is supported by observations 
that during entry a few tegument proteins, including pUL36 and pUL37, remain 
associated with incoming capsids during their transport along microtubules to 
the NPC (Antinone & Smith, 2006, Granzow et al., 2005, Luxton et al., 2005).  
While both pUL36 and pUL37 are essential for virion morphogenesis (Section 
1.2.3), pUL37 is dispensable during entry but may play an accessory role in 
pUL36 function, for example, by increasing the mobility of the capsid along the 
microtubule network (Krautwald et al., 2009, Leege et al., 2009, Roberts et al., 
2009).  Herpesvirus capsids are connected to the envelope via the outer 
tegument proteins.  The UL36 protein appears to play a pivotal role during viral 
assembly by acting as the link between the capsid and tegument components, 
since the capsid-tegument interaction is suggested to be mediated through an 
association between pUL36 and capsid-associated pUL25 (Section 1.2.3).   
Cytoplasmic structures termed ‘assembly compartments’ have been defined as 
the sites of secondary envelopment for several herpesviruses, in particular for 
HCMV (Das et al., 2007, Sanchez et al., 2000).  How partially tegumented 
capsids are directed to the assembly compartments for secondary envelopment 
is unclear.  It is apparent, however, that subsequent layers of outer tegument 
are added to the viral particle in an ordered manner not only during 
nucleocapsid transport through the cytoplasm but also at the site of secondary 
envelopment (reviewed in Mettenleiter, 2006).  Interestingly, the production of 
L-particles within infected cells where tegumentation of cytoplasmic C-capsids is 
impaired suggests that secondary envelopment is not dependent on the presence  
of nucleocapsids (McLauchlan & Rixon, 1992).  Whereas entry requires dynein-
mediated minus-end microtubule-directed transport, egress is dependent on 
kinesin-mediated plus-end directed movement (reviewed in Lyman & Enquist, 
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2009).  The difference in tegument composition between the incoming and 
outgoing viral particles has been suggested to influence the direction of capsid 
transport (Luxton et al., 2005).  
The final stage in viral assembly is the acquisition of the secondary envelope, 
followed by transport of vesicles containing the enveloped particle to the plasma 
membrane and the subsequent budding of these structures at the plasma 
membrane to release the virus to the extracellular matrix.  The tegumented 
capsids in the cytoplasm of the infected cell gain their final envelope from 
vesicles that are derived from the trans-Golgi network and where the viral 
glycoproteins are acquired (Harley et al., 2001, Mettenleiter, 2004).  A complex 
network of protein-protein interactions, which are summarised in Figure 1.19, 
drives primary envelopment, de-envelopment, tegumentation and secondary 
envelopment by budding at the trans-Golgi network.  The conservation of the 
complex interactions between tegument proteins across the alphaherpesviruses 
is highlighted by the observation that HSV-1 pUL11 interacts with HSV-1 and PrV 
UL16 encoded proteins (pUL16), and PrV pUL16 in turn complexes with PrV UL21 
encoded protein (pUL21), which suggests the formation of a tripartite complex 
(Klupp et al., 2005, Loomis et al., 2003, Yeh et al., 2008).  The HSV-1 UL11 
encoded tegument protein plays an important role during viral exit, since a 
deletion mutant of pUL11 has been shown to be deficient in egress (Baines & 
Roizman, 1992).  In addition, pUL11 has been suggested to direct tegument 
proteins to the secondary envelopment site (Baines & Roizman, 1992, Fulmer et 
al., 2007).  Indeed, the protein appears to show intrinsic targeting properties, 
since a fusion protein of HSV-1 pUL11 and HIV-1 gag was found to be directed to 
the Golgi apparatus instead of the plasma membrane, while the protein itself 
has been demonstrated to localise to a cytoplasmic site overlapping the ER-Golgi 
intermediate compartment (Bowzard et al., 2000, Sanchez et al., 2000).  It has 
been proposed that pUL11 binds to membranes via N-terminal myristoyl and 
palmitoyl lipid side chains attached to the protein at conserved sites, which are 
essential for efficient packaging of the protein into virions (Baird et al., 2008, 
Koshizuka et al., 2007, Loomis et al., 2006).   
As mentioned above, viral glycoproteins are present on trans-Golgi derived 
vesicles prior to secondary envelopment, since they are transported to this 
compartment to undergo post-translational modifications following translation 
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Figure 1.19 Molecular interactions during HSV-1 egress
The numbers indicate primary envelopment (1), de-envelopment (2), 
and secondary envelopment (3).  The rectangles represent the 
designated gene and solid lines or direct contacts between them 
denote physical interactions, whereas arrows indicate functional 
effects.  Dotted lines indicate suggested but not firmly established 
interactions.  In the case of glycoproteins only direct contacts 
resulting in complex formation are depicted.  Proteins that are 
conserved in all three herpesvirus subfamilies are marked in orange 
(adapted from Mettenleiter, 2006).
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on the ribosomes of the endoplasmic reticulum.  Nucleocapsids are connected to 
the envelope by the tegument through interactions between tegument proteins 
and the cytoplasmic tails of the envelope glycoproteins.  In PrV the UL49 
encoded outer tegument protein, pUL49, binds to the cytoplasmic domains of gE 
and gM.  Deletion of both these glycoproteins genes results in the accumulation 
of cytoplasmic C-capsids embedded in tegument and the inhibition of secondary 
envelopment (Brack et al., 1999, Fuchs et al., 2002a).  In addition, this 
interaction is required for the inclusion of pUL49 into mature virions.  In HSV-1, 
pUL49 also binds to gE and gM, although only the interaction with gE is essential 
during virion morphogenesis.  HSV-1 pUL49 also interacts with another tegument 
protein, VP16 expressed by UL48, which in turn binds to the cytoplasmic tail of 
gH and gD.  VP16 has been proposed as the protein that links the inner and outer 
layers of tegument during virion morphogenesis through its interaction with 
pUL36 (Fuchs et al., 2002b, Kamen et al., 2005, Mossman et al., 2000).  
Nevertheless, the link between inner and outer tegument proteins may involve 
multiple proteins, since there is a significant degree of redundancy found 
between the networks of interactions that occur among tegument proteins and 
between tegument and envelope proteins (reviewed in Mettenleiter, 2006).   
1.3.7 Latency 
One of the defining features of herpesviruses is their ability to establish a life-
long latent infection in the host.  Unlike the persistent lytic infection, no viral 
progeny are produced during latent infections and only very limited amounts of 
gene transcription can be detected in infected cells.  Latency can be divided 
into three stages; establishment, maintenance and reactivation (Rock, 1993).  
Following primary infection, HSV-1 enters sensory neurons in the dorsal root 
ganglia by fusion at the axonal termini and is transported via retrograde axonal 
transport to the nucleus of the neuronal cell body.  Once in the neuron, the viral 
DNA persists in the nucleus in a circular episomal form for the lifetime of the 
host.  Periodic reactivation of infectious virus can occur in the neurons 
harbouring latent HSV-1 in response to external stimuli.  The virus then passes 
down the axons by anterograde axonal transport to replicate near the site of the 
initial infection (reviewed by Roizman et al., 2007).   
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Although lytic gene expression has been detected at very low levels in latently 
infected cells, the only abundant viral mRNAs transcribed during latency are the 
latency associated transcripts (LATs) (Wagner et al., 1995).  Despite extensive 
research, the precise role of LATs during latency is controversial and remains 
unclear.  Expression of the LAT gene transcription unit (Figure 1.20) is controlled 
by a latency specific promoter (LAP) and splicing of its primary 8.3 kb transcript 
yields several RNA species.  The 8.3 kb transcript accumulates at low levels in 
latently infected neurons, while the 2.0 kb and 1.5 kb introns derived from the 
primary transcript are abundant and stable (Wagner et al., 1988).  However, 
since no LAT-encoded protein has been conclusively demonstrated to exist, one 
recent investigation has focused on the idea that the LAT might function as a 
primary microRNA (miRNA) transcript (Drolet et al., 1997, Umbach et al., 2008).  
These miRNA molecules are single-stranded non-coding RNA structures, which 
vary in length from between 21-23 nucleotides and are partially complementary 
to mRNA, while their main function is to regulate gene expression.  Umbach et 
al. (2008) demonstrated that the LAT transcript encodes four distinct miRNAs in 
HSV-1 infected cells, one of which is transcribed in an antisense orientation to 
ICP0, the virus IE transcriptional activator that is important for productive HSV-1 
replication and is thought to have a role in reactivation from latency (Everett, 
2000).  They found the miRNA associated with ICP0 was able to reduce the 
protein’s expression, thereby increasing the possibility that the virus in infected 
neurons entered and maintained latency.  In addition, they identified another 
HSV-1 encoded miRNA that showed partial complementarity to ICP4 mRNA and 
reduced the expression of the gene (Umbach et al., 2008).  Similar to ICP0, ICP4 
can also promote the reactivation of HSV-1 from latency, thus the presence of at 
least two primary HSV-1 miRNA may assist the establishment and maintenance of 
the latent state in infected neurons (Halford et al., 2001, Umbach et al., 2008).   
1.4 UL25 protein stucture  
HSV-1 pUL25 is a 580 residue, 62.7 KDa minor capsid protein, and the 
crystallographic structure of an N-terminally truncated form of the protein 
(UL25nt), corresponding to the residues 134-580, has been determined to 2.1 Å 
(Bowman et al., 2006).  Large quantities of soluble protein are required as a 
starting material for crystallographic studies.  However, initial attempts to 
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Figure 1.20 Map of the latency-associated transcript (LAT) gene
(A) The HSV-1 genome structure is shown.  The UL and US denote the unique sequences of the 
long (L) and short (S) components of the genome, respectively.  The unique regions are flanked 
by the inverted repeats (TRL/TRS and IRL/IRS).  The a sequences are highlighted in red.  (B) 
Expanded view of L and S junction showing the relative position of the LAT promoter (LAP).  (C)  
Locations and orientations of transcripts of the L-S junction region are denoted by arrows.  
These include the LAT primary transcript at 8.3 kb and the two transcripts, 2.0 kb and 1.5 kb, 
which are stable intron transcripts derived from the full-length 8.3 kb RNA.  The LATs are 
transcribed antisense and at least partially complementary to the gene encoding ICPO (adapted 
from Roizman et al., 2007).  
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express and purify the full-length pUL25 as a GST fusion protein in sufficient 
quantities necessary for crystallography were unsuccessful.  Secondary-structure 
analysis predicted the presence of a long unstructured loop in the N-terminal 
region of pUL25.  When sequences encoding this loop were removed from the 
construct, the resulting GST-fusion protein containing the pUL25 residues R45-
V580 was soluble and expressed to high levels in E. coli.  During the purification 
of this fusion protein, removal of the GST tag by protease digestion resulted in a 
secondary cleavage event that released a stable fragment of 48 KDa, referred to 
as UL25nt, which formed crystals that defracted.  To date, the structure of 
UL25nt is the only herpesvirus DNA packaging protein that has been solved.  It 
exists as a monomer in the crystal, and the first ordered N-terminal residue is 
A134.  UL25nt has a novel fold that consists of a box-shaped core comprised 
mostly of α-helices, with a few minor β-sheets, and a striking feature of the 
molecule is the presence of numerous loops that emanate from the core of the 
protein, some of which extend for some distance (Figure 1.21).     
Interestingly, five of the extended loops (L1-L5) in the UL25nt crystal contain 
disordered residues, with an additional unstructured region, containing three 
amino acids (L6) situated at carboxyl terminus of the protein (Figure 1.21).  
Regions that are referred to as disordered or unstructured are areas of the 
crystallised protein that are missing from the resulting electron density maps 
determined by X-ray crystallographic studies.  For successful crystallography 
experiments, the corresponding atoms in the different protein molecules must 
be uniformly spaced throughout the crystallised protein, which leads to a regular 
diffraction pattern from these atoms.  If a region is dynamically flexible or 
adopts different structures in different molecules in the crystal, then the atoms 
in the same region are not uniformly spaced and therefore fail to diffract.  The 
unstructured residues contained in the regions L1-L6 are shown in Table 1.4.  
The crystal structure of UL25nt does not include the N-terminal 133 residues of 
pUL25.  The secondary-structure prediction for this region suggests it is 
composed of a long α-helix (residues 48-110), preceded by a 45-residue 
unstructured N-terminal loop (Bowman et al., 2006).  Analysis of the 
electrostatic surface potential of UL25nt revealed an interesting distribution of 
surface charges, with one face of the protein being essentially electropositive 
while the opposing face is essentially electronegative (Figure 1.22).  The 
Figure 1.21 Ribbon diagram of UL25nt
The secondary structure elements are coloured red (α-helices), blue (β-
strands), green (extended loops) and grey (disordered loop regions).  N 
and C labels identify the amino- and carboxyl-terminal ends, respectively.  
The unstructured looped out regions, L1-L5, are indicated, and the L6 
unstructured residues located at the C-terminus are shown.  
L2
L4
L1
L3
L6
L5
C
N
A B
Figure 1.22 Electrostatic surface charge of UL25nt
(A) A space fil l ing model showing the electrostatic 
surface representation of the electronegative face of 
UL25nt.  (B) A 180o rotation of the view in panel A, 
showing the electropositive face of UL25nt (adapted 
from Bowman et al., 2006). 
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significance of the charged faces in UL25nt is unclear, but they may play a role 
in interactions of pUL25 with other proteins.  Since pUL25 has been reported to 
bind DNA, the basic face may mediate this association, perhaps at some point 
during DNA packaging or during entry and release of the viral genome from the 
capsid at the NPC (Ogasawara et al., 2001, Bowman et al., 2006).   
 
 
 
Loop Region Residues   Unstructured residues 
L1 H247 – T259 A249 – D254 
L2 V325 – A347 R335 – G345 
L3 A415– D437  P417 – A425 
L4 Q475 – S490 P479  – T483 
L5 R509 – P516 R511 – N513 
L6 L577 – V580 S578 – V580 
 
Table 1.4 Residues in the extended loops (L1-L5) and the unstructured L6 region of UL25nt. 
 
1.4.1 The predicted functional interfaces 
UL25 is one of approximately 40 core genes conserved among all members of the 
family of Herpesviridae (Davison, 2002).  The sequence alignment of the UL25 
protein homologues from the eight human herpesviruses revealed that the N-
terminal 133 residues, in particular residues 1-45 that were predicted to be 
unstructured, were the least conserved part of pUL25.  Within the UL25nt 
portion of the protein, 24 residues were identified that were completely 
conserved in the eight human herpesviruses.  However, subsequent mapping of 
these residues onto the known structure of UL25nt showed that they were 
mostly hydrophobic core residues situated in the interior of the protein.  
Therefore, these amino acids are more likely to be critical for maintaining the 
structural integrity of the protein.   
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To identify important functional interfaces on the surface of UL25nt, an 
evolutionary trace (ET) analysis was performed on a multiple-sequence 
alignment of UL25 and homologous protein sequences.  ET was developed by 
Lichtarge et al. (1996) and exploits the fact that residues important for the 
structure of a protein tend to be strongly conserved across species.  The ET 
algorithm uses phylogenetic information to identify conserved amino acids 
within a protein family and then maps this information in the context of an 
atomic structure (Lichtartge & Sowa, 2002).  The method has been successful in 
identifying functional sites in a wide range of proteins (Chakravarty et al., 2005, 
Mikalek et al., 2003, Sowa et al., 2001).  The phylogenetic tree for UL25nt is 
shown in Figure 1.23.  Partitioning of the tree divides the set of proteins into a 
number of classes; each containing related sequences derived from a node 
within that partition.  Residues that are important for the protein’s structural 
integrity usually are highly conserved and show the least variation in a family of 
related proteins, while residues that are functionally important are less well 
conserved but are invariant among a group of closely related proteins or 
subgroup.  Clustering of these specific residues onto the structure of the protein 
implies a functional interface, since evolutionary divergence and functional 
specificity is associated with changes in the amino acid composition.  By 
examining the pattern of conservation within a family of related proteins, ET 
analysis can reveal relationships that conventional sequence comparisons do not.  
At P07, there are nine protein classes defined that are distributed across the 
three herpesvirus subfamilies and contain more than a single member (Figure 
1.23).  Mapping of the class-specific residues at this level on the surface of 
UL25nt identified four clusters (C1-C4) of particular interest.  The class-specific 
surface residues and the cluster to which they were assigned to are listed in 
Table 1.5, and illustrations of the four clusters and their constituent amino acids 
on the surface of UL25nt are shown in Figure 1.24.  All four potential binding 
interfaces contain both charged and uncharged residues.  Three of the four 
clusters are located on or near areas where there are disordered flexible loops 
and it is conceivable that these unstructured loops become ordered upon binding 
to another protein partner.  C1 resides are on the same face as C2, which 
traverses the entire molecule and lies adjacent to L5.  C3 is situated at the 
opposite end of the molecule from C1, near L3, whereas C4 also lies next to L3 
but is located on the face 180º from C1 and C2.  The wide distribution of the 
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Figure 1.23 Evolutionary trace of herpesvirus UL25 homologues
P01 to P10 represent the different partitions of the ET phylogenetic 
tree.  The branches defining the three herpesvirus subfamilies are 
labelled α, β and γ.  The numbers 1-9, which are highlighted in red, 
denote the nine protein classes at P07 that contain more than a single 
member.  The virus species are listed next to the tree and the names 
in boldface are human viruses (adapted from Bowman et al., 2006).  
 
 
 
 
 
Cluster Cluster Residues 
C1 G225 R288 R305 P327 G331 H348 R362 G363 N365 
C2 R148 D150 N152 D156 L214 N508    
C3 G169 S170 G172 R180 G202 R203 K206 P413  
C4 R390 N396 Y398 D400 L402 R552    
 
Table 1.5 The residues within the four clusters (C1-C4) of pUL25 identified in the structural analysis 
Cluster 1
Arg 484
Cluster 2
Arg 484
Cluster 3
Arg 484
Cluster 4
Arg 484
Figure 1.24  UL25nt predicted functional amino acid clusters
Space-fi l l ing models of UL25nt, with the exterior residues 
identified by the evolutionary trace for each cluster highlighted in 
red.  The position of the residue argine 484 (Arg 484) in UL25nt is 
indicated as a reference point.
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predicted binding sites on UL25nt, its flexible architecture and distinctive 
electrostatic pattern, are consistent with an intrinsically plastic and dynamic 
protein that is capable of accommodating the multiple roles that pUL25 is 
implicated in.   
1.5 The binding partners of pUL25 
The HSV-1 UL25 gene product is a multifunctional capsid protein that is essential 
during viral DNA packaging (Section 1.3.5.2.5), is important for viral entry and 
has been implicated during viral egress.  In addition, it interacts with an 
assortment of virus and cellular encoded proteins that are required during these 
processes (Table 1.6).  The UL25 protein is located on the capsid surface and 
binds to the structure in increasing amounts as the capsid matures during DNA 
packaging, with the highest concentrations of pUL25 identified on C-capsids 
(Newcomb et al., 2006, Ogasawara et al., 2001, Sheaffer et al., 2001, Thurlow 
et al., 2006, Trus et al., 2007).  This observation led to the proposal that pUL25 
stabilises the C-capsid by attaching to binding sites that are exposed on the 
surface of the capsid as it matures during DNA packaging.  In support of this 
model was the finding that removal of viral DNA from C-capsids led to a 
reduction in the amount of pUL25 attached to the A-capsids that were generated 
(Trus et al., 2007).  The binding of pUL25 to capsids is also dependent on the 
presence of another essential DNA packaging protein, pUL17, since B-capsids 
lacking pUL17 contain low levels of pUL25 (Thurlow et al., 2006).   Similarly, 
reduced levels of pUL17 are found on capsids isolated from non-permissive cells 
infected with a UL25 null mutant.  These two observations led to the suggestion 
that pUL25 and pUL17 interact with each other (Thurlow et al., 2006).   
A subsequent study involving cryoelectron microscopy and image reconstruction 
provided further evidence that pUL25 binds to pUL17.  Extra mass was identified 
on the surface of the wt C-capsid, adjacent to the pentons at the capsid 
vertices, which was not seen on wt and UL25-null mutant A-capsids.  This extra 
mass, referred to as the C-capsid specific component (CCSC), was proposed to 
be a complex of pUL25 and pUL17 (Trus et al., 2007).  Additional contact points 
were also identified for pUL25 on the capsid that were calculated to be located 
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at the triplexes and peripentonal hexons surrounding the penton.  These findings 
are corroborated by observations that pUL25 interacts directly with the triplex 
protein VP19C and the major capsid protein, VP5 (Ogasawara et al., 2001).  Trus 
et al. (2007) proposed that the predicted triplex and hexon interaction sites for 
pUL25 are the binding sites, which are exposed as a consequence of the 
conformational changes induced in the capsid during DNA packaging.  In addition 
they suggested that, as a consequence of the pUL25 binding to pUL17, VP19C 
and VP5, during capsid maturation, the shell is stabilised during encapsidation of 
full-length viral genomes.   
UL25 protein partners  Reference 
pUL6 Pasdeloup et al., 2009 
pUL17 Thurlow et al., 2006; Trus et al., 2007 
pUL36 Coller et al., 2007; Pasdeloup et al., 2009 
VP5 Ogasawara et al., 2001 
VP19C Ogasawara et al., 2001 
Nucleoporin CAN/Nup214 Pasdeloup et al., 2009 
Nucleoporin hCG1 Pasdeloup et al., 2009 
   Table 1.6 UL25 protein binding partners 
 
Immunofluorescence studies have demonstrated that the capsid-binding domain 
(CBD) of the HSV-1 large tegument protein pUL36 requires the presence of pUL25 
for its recruitment onto capsids, indicating a role for pUL25 during 
tegumentation (Coller et al., 2007, Lee et al., 2006).  Co-immunoprecipitation 
experiments have confirmed that the CBD, which consists of the 62 amino acid 
carboxyl-terminal region of pUL36, interacts directly with pUL25 (Coller et al., 
2007).  Previous studies have shown that the CBD of PrV pUL36 localises to 
nuclear capsid assembly sites when transiently expressed as a GFP-fusion protein 
in virus-infected cells (Lee et al., 2006).  Although not addressing the site of 
tegumentation, Coller et al. (2007) proposed that the interaction between 
pUL25 and pUL36 is the initial step necessary for tegument acquisition during 
virus assembly.      
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1.6 The aims of the study 
Although the 3D crystal structure of the N-terminally truncated form of pUL25 
(UL25nt, residues 134-580) has been determined, the lack of structural similarity 
to a known protein has made it difficult to deduce the function of the protein 
with reference to the structural information alone (Bowman et al., 2006).  ET 
analysis had identified clusters of external residues, which are likely to be 
important during protein interactions, and flexible loops that may be essential in 
accommodating the conformational alterations necessary for these interactions.  
The UL25 encoded gene product is a multifunctional protein that is important at 
a number of stages during the virus life cycle and has several protein partners 
that are also involved at these points of the HSV-1 growth cycle.  The aim of the 
project was to exploit the 3D crystallographic information for HSV-1 pUL25 by 
engineering site-directed mutations into selected regions of the gene and 
characterising the resulting mutant proteins in order to relate the protein’s 
structure to its function.  It was anticipated that by determining the effect the 
mutations had on the function of pUL25 the project would lead to a better 
understanding of the protein’s role(s) during HSV-1 lytic infection.  
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2 Materials and methods 
2.1 Materials 
2.1.1 Chemicals and reagents 
The chemicals and reagents used for EM analysis were purchased from Agar Aids 
or TAAB laboratories.  All other chemicals and reagents were obtained from 
Sigma-Aldrich Co. Ltd, unless otherwise stated below or in subsequent sections. 
Chemical Supplier 
Acetic acid Rhone-Poulenc Ltd 
Acrylamide solution (40% w/v) Bio-Rad Laboratories 
Acrylamide: N, N’methylene-bis acrylamide Solution, 19:1 
(40% w/v) Bio-Rad Laboratories 
Ammonium persulphate Bio-Rad Laboratories 
BDMA  Bio-Rad laboratories 
Blotting paper Whatman International Ltd 
Butanol Prolabo 
Chloroform Prolabo 
Copper grids Agar Aids 
Dimethyl sulphoxide (DMSO)  BDH laboratory Supplies 
DNA (lambda) 1 Kb ladder New England Biolabs 
ECL reagent GE Healthcare 
EDTA (ethylenediaminetetraacetic acid disodium salt) BDH 
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Chemical Supplier 
Ethanol Prolabo 
Epon 812 Resin TAAB 
Glacial acetic acid Prolabo 
Glass fibre discs Whatman International Ltd 
Glutaraldehyde Agar Scientific 
Hydrochloric acid Rhone-Poulenc Ltd 
IPTG (Isopropyl β-D-1-thiogalactopyranoside) Gibco BRL 
Lipofectamine reagent Invitrogen 
Methanol Prolabo 
Optimem BDH 
Osmium tetroxide TAAB 
PCR tubes Applied Biosystems 
Plus reagent Invitrogen 
Mini protease inhibitor tablets Boehringer Mannheim 
Rainbow markers GE Healthcare 
Surfact-AmpsTM NP40 Pierce 
Uranyl acetate BDH 
X-omat film Kodak Ltd 
Chapter 2 69
2.1.2 Enzymes 
New England Biolabs, Sigma-Aldrich Co. Ltd, or Roche Diagnostics Ltd supplied 
the restriction enzymes and DNA modifying enzymes. 
2.1.3 Antibiotics  
The antibiotics used in this study together with their suppliers are listed below: 
 
Antibiotic Supplier 
Ampicillin Smithkline Beecham Research 
Chloramphenicol Sigma-Aldrich Co. Ltd 
Gentamicin Life Technologies 
Kanamycin Sigma-Aldrich Co. Ltd 
Penicillin Life Technologies  
Streptomycin Life Technologies  
Tetracycline Sigma-Aldrich Co. Ltd 
2.1.4 Tissue culture cell lines  
Vero cells (Rhim and Schell, 1967):  These African green monkey kidney cells 
were obtained from the American Type Culture Collection and supplied by Dr. V. 
Preston.  
8-1 cells (McNab et al., 1998):  This Vero cell line, which expressed the HSV-1 
packaging gene UL25 under the control of the HSV-1 ICP6 promoter, was 
obtained from Dr P. Desai and supplied by Dr V. Preston.  
Sf21 cells (Vaughn et al., 1977):  This insect cell line was derived from pupal 
ovarian tissue of the fall armyworm (species Spodoptera frugiperda) and 
obtained from the MRC Virology Unit’s Cytology Department. 
U2OS cells (Ponten and Saksela, 1967): This epithelial cell line was cultured 
from the cancerous bone tissue of a human female suffering from osteosarcoma.  
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It was obtained from the American Type Culture Collection and supplied by Dr V. 
Preston. 
2.1.5 Tissue culture medium and growth conditions  
Tissue culture media were obtained from Gibco BRL and media supplements 
were purchased from Life Technologies, except for human serum (HS), which 
was supplied by MP Biomedicals LLC.  The growth medium and supplement 
requirements for each of the cell lines used were as follows: 
Vero and 8-1 cells were grown at 37oC in atmosphere containing 5% CO2 in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 1X penicillin 
(pen)/streptomycin (stp) (100 units/ml pen and 100 μg/ml stp) plus 10% (v/v) 
foetal calf serum (FCS).  
U2OS cells were grown under the same conditions as Vero and 8-1 cells except 
that a concentration of 5% (v/v) FCS was used. 
Sf21 cells were cultured at 28oC in TC100 medium supplemented with 1X 
pen/stp and 5% (v/v) FCS. 
2.1.6 HSV-1 stocks 
Wild-type (wt) HSV-1 strain 17 syn+ (Brown et al., 1973): This virus was obtained 
from the MRC Virology Unit’s virus stocks. 
ΔUL25MO: This deletion mutant lacks the complete UL25 ORF (nucleotide 
sequences 48,813 to 50,555 in the HSV-1 strain 17 syn+ genome) and contains in 
its place the rpsL-neo antibiotic selection cassette (Chapter 3).  
KUL25NS (McNab et al., 1998): This UL25 null mutant was a gift from Dr P. Desai 
and was supplied by Dr V. Preston.  The virus has a 14bp SpeI linker containing 
stop codons in all 3 open reading frames inserted at codon 104 of the UL25 ORF. 
MRUL25MO: Marker rescuant of ΔUL25MO (Section 3.3.2).  
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2.1.7 Baculoviruses 
The 11 recombinant baculoviruses listed below were used in this study.  AcUL25-
Δ1-45, -Δ1-59, -Δ1-133 and AcUL17 were supplied by Dr V. Preston and the 
remaining viruses were constructed during this project using the procedure 
outlined in Section 2.2.12.  The inserted genes in each virus were under the 
control of the HCMV IE promoter.   
Baculovirus  Expressed HSV-1 Protein 
AcpCI None 
AcWTUL25 pUL25  
AcUL25-C3B pUL25-C3B 
AcUL25-C4A pUL25-C4A 
AcUL25-L3 pUL25-L3 
AcUL25-L5 pUL25-L5 
AcUL25-L6 pUL25-L6 
AcUL25Δ1-45 pUL25Δ1-45 
AcUL25Δ1-59 pUL25Δ1-59 
AcUL25Δ1-133 pUL25Δ1-133 
AcUL17 pUL17 
               
2.1.8 E. coli strains and culture medium 
DH5α (Life Technologies): This strain of E. coli contains the endA and recA 
mutations.  The endA mutation prevents the degradation of the plasmid DNA by 
eliminating endonuclease I activity in the bacterial cell, thereby improving the 
quality of the DNA preparations.  The recA mutation enhances the stability of 
the plasmid by reducing homologous recombination between plasmid DNAs 
within the bacterial cell.   
DH10Bac: This strain of E. coli contains the baculovirus shuttle vector (bacmid), 
bMON14272, and a helper plasmid, the mini-F replicon pMON7124.  
Electrocompetent DH10Bac cells (Section 2.2.5) were used to create the 
recombinant baculoviruses.  Bacteria were grown in the presence of 50 μg/ml 
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kanamycin (km) to maintain the bacmid and 10 μg/ml tetracycline (tet) to 
maintain the helper plasmid. 
DH10B: This is a transformation competent strain of E. coli used as the host 
bacteria for the mutation of a bacterial artificial chromosome (BAC) possessing a 
copy of a mutated HSV-1 strain 17 syn+ genome (fHSVΔpac) (Saeki et al., 1998) 
lacking the packaging signals.  The bacteria containing the BAC were maintained 
in the presence of 15 μg/ml of chloramphenicol (cm) and 50 μg/ml of stp.    
BL21: This strain was used for expression of the GST tagged fusion proteins and 
was purchased from Stratagene.   
E. coli culture medium 
E. coli strains were cultured in L-broth containing the appropriate antibiotic, if 
required, for selection of the desired plasmid, BAC or recombinant bacmid.   
2.1.9 Plasmids  
pGEM-T Easy: This plasmid was used as a vector for cloning PCR products.  The 
plasmid was obtained from Promega as a linearised DNA molecule with a 3’-
terminal thymidine residue added to both ends.  Since the Taq polymerase used 
in the PCR reactions described in this thesis adds a single deoxyadenosyl residue 
to the 3’ ends of the PCR products produced, the PCR fragments were directly 
cloned into pGEM-T Easy (Figure 4.4) without further enzymatic manipulation.   
pFBpCI: This plasmid was produced by Professor R. Everett from the MRC 
Virology Unit, Glasgow (Sourvinos & Everett, 2002)  and was made by inserting a 
BglII/EcoRI fragment, containing the promoter and enhancer sequences from 
pCI-neo (Promega), into BamHI/EcoRI digested pFastBac Hta (Life Technologies) 
(Figure 5.2).  The plasmid was used as a cloning plasmid for the UL25 ORF, as a 
mammalian expression vector and as a baculovirus transfer vector for the 
production of the recombinant baculovirus. 
pGX37: This plasmid contains the HSV-1 strain 17 syn+ BamHI G fragment, (HSV-1 
strain 17 syn+ nucleotides 52589-60363), inserted into the BamHI site of the 
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plasmid vector pAT153 (Abbotts et al., 2000)).  The BamHI G probe used in 
Southern blot hybridisation was purified from the BamHI-digested pGX37 vector. 
pGX2: This plasmid contains the HSV-1 strain 17 syn+ BamHI K fragment (HSV-1 
strain 17 nucleotides 123461-129403) inserted into the BamHI site of pAT153.  
The BamHI K fragment in this plasmid has a single a sequence. 
pGX292: This plasmid contains the HSV-1 strain 17 syn+ BamHI U fragment 
inserted into the BamHI site of pAT153.  BamHI U spans the HSV-1 strain 17 syn+ 
nucleotides 48635 – 50929, which contains the entire UL25 ORF.    
pBE1: This plasmid was derived from pGX2 and was constructed to detect the 
joint spanning region and the L terminus of the HSV-1 genome (Stow, 2001).  It 
contains sequences corresponding to HSV-1 strain 17 syn+ nucleotides 596 to 
2905 of TRL (Figure 5.1). 
pST17: This plasmid, like pBE1, was derived from pGX2 but was constructed to 
detect the joint spanning region and the S terminus of the HSV-1 genome (Stow, 
2001).  It contains sequences corresponding to HSV-1 strain 17 syn+ nucleotides 
148825 to 151857 of TRS (Figure 5.1). 
pGEX-2TNMCR: This plasmid was produced by Professor R. Everett from the MRC 
Virology Unit, Glasgow, and was derived from a commercially available plasmid, 
pGEX2T (Pharmacia).  The vector was designed for inducible, high-level bacterial 
expression of proteins or protein fragments as fusions with Schistosoma 
japonicum glutathione S-transferase (GST).  Expression of GST fusion proteins 
was under the control of the IPTG-inducible tac promoter.   
2.1.10 Antibodies 
Anti-pUL25 MAb166: The mouse monoclonal antibody (MAb) was raised against 
purified HSV-1 UL25-His tagged protein (Thurlow et al., 2005) and diluted 
1:1000. 
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Anti-pUL25 RAb335: The rabbit polyclonal antibody was raised against purified 
HSV-1 UL25 (residues 342 – 580) GST fusion protein (Thurlow et al., 2006) and 
diluted 1:1000.  
Anti-pUL17 MAb203: The MAb was raised against purified HSV-1 UL17-NusA 
tagged protein (residues 154-703) (Thurlow et al., 2005) and diluted 1:1000.  
Anti-GST antibody:  The goat polyclonal antibody was raised against purified 
GST (GE Healthcare) and diluted 1:2000. 
Anti-goat IgG hrp-conjugate:  The donkey polyclonal antibody was raised 
against purified goat IgG conjugated to horseradish peroxidase (Santa Cruz 
Biotechnology) and diluted 1:80000.      
Protein A hrp-conjugate: protein A-horseradish peroxidase (Sigma-Aldrich) was 
diluted 1:1000. 
Anti-mouse IgG hrp-conjugate: The goat polyclonal antibody was raised against 
mouse IgG and conjugated to horseradish peroxidase (Sigma-Aldrich) and diluted 
1: 1000.   
Anti-mouse IgG FITC-conjugate: The goat polyclonal antibody was raised against 
purified mouse IgG and conjugated to the fluorophore FITC (Sigma-Aldrich) and 
diluted 1:100.   
2.1.11 Buffers and solutions 
Common solutions Constituents 
Acid wash 0.14 M NaCl, 0.1M glycine pH 3.0 
Alkaline transfer solution 0.4 M NaOH, 0.6 M NaCl 
Antibody buffer A 5% (w/v) marvel, 0.05% (v/v) Tween-20 in PBS 
Antibody buffer B 2% (w/v) marvel, 0.05% (v/v) Tween-20 in PBS 
Boiling mix (3X) 6% (w/v) SDS, 30% (v/v) glycerol, 0.3% (w/v) bromophenol blue, 210 mM β-mercaptoethanol 
Buffer A  50 mM Tris HCl pH 7.5, 100 mM NaCl, 5% Glycerol, 0.1% Triton X100 
Chloroform:Isoamyl alcohol 24 parts choloroform:1 part isoamyl alcohol (v/v) 
Chapter 2 75
Common solutions Constituents 
CLB (Cell lysis buffer) (2X) 20 mM TrisHCl pH 7.5, 2 mM EDTA, 1.2% SDS 
DABCO soluition 25% DABCO in dH2O, stored at -20oC 
Denhardt’s solution 0.02% Ficoll 400, 0.02% polyvinylpyrrolidone, 0.02% bovine serum albumin 
DNA loading buffer (4X) 0.1 M EDTA, 0.25% (w/v) bromophenol blue, 50% (w/v) sucrose 
Elution buffer 500 mM NH4Acetate, 1 mM EDTA, 0.1% SDS  
Epon 812 resin mix 150 μl DBMA, 10 ml Epon 812 resin 
EZ lysis buffer 100 mM TrisHCl pH 8.0, 100 mM KCl, 10% glycerol, 1% NP40.  1 mini protease tablet per 10 ml buffer 
Hybridisation buffer  50% formamide, 10% dextran sulphate and 4X SSC (1X SSC is 0.15 M NaCl, 0.015 M sodium citrate) 
Loening’s buffer (1X) 40 mM NaH2PO4, 36 mM Tris, 1mM EDTA 
Lead citrate solution 1.33g Pb(NO3) 2, 1.76g Na3(C6H5O7).2H2O, 30 ml boiled and cooled dH20 
Membrane wash buffer 0.2X SSC, 0.1% SDS 
Mowiol mounting solution 2.4g Mowiol 4-88, 6g glycerol, 6 ml dH20, 12 ml 0.2 M Tris HCl pH 8.5, 10% DABCO solution 
Neutralising solution  0.5 M TrisHCl pH 7.0 
PBS (Phosphate-buffered 
saline) 
170 mM NaCl, 3.4 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 
7.2 
PBS-1% FCS PBS containing 1% Foetal calf serum 
10X Phosphate buffer 58 mM Na2HPO4, 17 mM NaH2PO4, 68 mM NaCl pH 7.5 
Protease 20 mg/ml grade XIV protease 
RGB (4X Resolving gel 
buffer) 1.5 M TrisHCl pH 8.8, 0.4% (w/v) SDS 
RNase mix (200X) 1 mg/ml RNaseA, 10000 u/ml RNase T1 in TE 
Sonication buffer 20 mM TrisHCl pH 7.5, 0.1% NP40,, 10% glycerol, 1 miniprotease tablet per 7 ml of buffer 
RSB (Reticulocyte 
standard buffer) 10 mM TrisHCl pH 7.5, 10 mM KCl, 1.5 mM MgCl2 
SGB (4X Stacking gel 
buffer) 488 mM TrisHCl pH 6.8, 0.4% (w/v) SDS 
Southern prehybridisation 
buffer 0.5 M sodium phosphate buffer pH 7.4, 7% SDS 
SSC (20X)  3 M NaCl, 0.3 M sodium citrate 
Tank buffer (1X)  52 mM Tris, 53 mM glycine, 0.1% SDS 
TBE (Tris-borate-EDTA) 90 mM Tris base, 89 mM boric acid, 1 mM EDTA 
TBS (Tris-buffered saline) 137 mM NaCl, 5 mM KCl, 0.7 mM NaH2PO4, 5.5 mM glucose, 25 mM TrisHCl pH 7.4 
Towbin buffer 25 mM Tris, 192 mM glycine, 20% (v/v) methanol 
Triton 1X buffer 0.1% Triton X100 diluted in PBS and 1 miniprotease tablet per 7 ml of solution 
Trypsin 0.25% (w/v) trypsin (Sigma-Aldrich) dissolved in TBS 
Versene 0.6 mM EDTA, 0.002% phenol red in PBS 
X-gal solution 20 mg/ml X-gal in dimethyl formamide 
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2.1.12 Oligonucleotides 
Oligonucleotides for PCR amplification and sequencing were synthesised and 
purified by either Sigma-Genosys or MWG Biotech.  
2.1.13 Radiochemicals 
5’ (α32P) dCTP and 5’ (α32P) dGTP, at 10 μCi/μl (3000 Ci/mMole), were 
purchased from GE Healthcare, UK.  
2.1.14 Commercial kits 
The commercial kits used in this study are listed in below or in the relevant 
sections. 
Commercial Kits Supplier 
AdvantageTM-GC 2 PCR Kit Clontech 
Counter-Selection BAC Modification Kit Version 2.4 (June 2005) Gene Bridges 
pGEM-T Easy Vector System Promega 
Qiagen Plasmid Purification – QIAGEN-tip 100 (3rd Edition June 2005) Qiagen 
QIAprep Spin Miniprep Kit Qiagen 
QIAQuick Gel Extraction Kit Qiagen 
 
 
2.1.15 Computer software 
Computer software used for analysis in this study and the manufacturer or web 
link is listed below:  
Computer Software Link/Manufacturer 
ET analysis http://www-cryst.bioc.cam.ac.uk/~jiye/evoltrace/evoltrace.html 
Protein Bank Database http://www.rcsb.org 
SIFT Analysis http://sift.jcvi.org 
Webcutter http://rna.lundberg.gu.se/cutter2/ 
Chimera  http://www.cgl.ucsf.edu/chimera 
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2.2 Methods 
2.2.1 DNA cloning and manipulation  
2.2.1.1 Restriction endonuclease digests 
Typically, 1 μg of plasmid DNA was digested with 10 units of the desired 
restriction endonuclease (REN) in a 20 μl reaction volume containing the 
appropriate restriction buffer and 2 μg BSA (if recommended) for 1-4 hours (h) at 
the recommended temperature.  For double digests both RENs were added to 
the same reaction provided the enzyme conditions were compatible, if not, two 
sequential reactions were carried out.  In this instance the DNA was digested 
with the first REN in a reaction volume of 20 μl at the recommended 
temperature for 1-2 h.  This was followed by the addition of the second REN and 
modification of the REN buffer in a final volume of 30 μl.  The incubation was 
continued for a further 1-2 h at the second enzyme’s recommended 
temperature.  All REN digests were confirmed by gel electrophoresis (Section 
2.2.3.1). 
2.2.1.2 Polymerase chain reaction (PCR) 
Each PCR was set up in thin-walled 0.2 ml PCR tube using the enzyme, buffer 
and dNTP mix from the Clontech AdvantageTM-GC 2 PCR kit.  A typical PCR 
reaction mix contained 50 ng of template DNA with the forward and reverse 
primers at a concentration of 100 pmoles/μl in a total volume of 50 μl.  The 
PCRs were performed using Applied Biosystems GeneAmp PCR System 9700 
thermocycler running the following programmes: 
PCR –cycle1 
Step 1: 1 cycle 95oC for 5 min 
Step 2: 35 cycles 95oC for 30 sec 
 58oC for 1 min 
 68oC for 2 min 
Step 3: 1 cycle 68oC for 7 min 
Step 4 Hold at 4oC 
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PCR-cycle2 
Step 1: 1 cycle 95oC for 5 min 
Step 2: 30 cycles 95oC for 30 sec 
 68oC for 3 min 
Step 3: 1 cycle 68oC for 7 min 
Step 4 Hold at 4oC 
 
2.2.1.3 Annealing overlapping oligonucleotides 
Each oligonucleotide was supplied as a lyophilised powder and resuspended in 
the appropriate amount of dH2O to give a final concentration of 100 pmoles/μl.  
The two oligonucleotides were mixed together and diluted to a final 
concentration of 10 pmoles/μl in 1X T4 ligase buffer (BRL) in a total volume of 
50 μl.  The reaction mix was heated to 100oC for 5 minutes (min) and allowed to 
cool slowly to room temperature (RT).  The sample was stored at –20oC until 
required. 
2.2.2 Ligation of DNA fragments 
2.2.2.1 Standard ligation 
Purified insert and vector DNA fragments were mixed at a 3:1 molar ratio in a 10 
μl reaction volume containing 1 unit of T4 DNA ligase and 1X T4 ligase buffer 
(BRL).  The reaction was incubated overnight at 16oC followed by storage at       
-20oC until required. 
2.2.2.2 Ligation of PCR products 
Typically, a molar ratio of 3:1 of gel-purified PCR product to pGEM-T Easy vector 
was used for the ligation reactions.  The identity of the cloned PCR product was 
confirmed by analytical REN digestion and DNA sequencing. 
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2.2.2.3 Ligation of overlapping oligonucleotides 
Annealed overlapping oligonucleotides, which were prepared as outlined in 
Section 2.2.1.3, were routinely diluted 1:3 or 1:10 in dH20 and 1 μl was used in 
the ligation reaction.  
2.2.3 DNA analysis and purification 
2.2.3.1 Separation and purification of restriction endonuclease (REN) 
fragments on agarose gels 
Routine analysis of DNA REN digests was carried out on 1% agarose gels in 1X 
TAE.  The gels were prepared by heating the agarose mixture in a microwave 
oven until the agarose was dissolved.  After the solution had cooled to 55-60oC, 5 
μl ethidium bromide (10 mg/ml) was added and the solution, which was then 
poured into a horizontal gel kit containing a 14-well comb.  When the gel had set 
it was submerged in 1X TAE buffer, the comb was removed and the samples, 
containing 4X DNA loading buffer (1:4 loading buffer:sample), and the 
appropriate size markers were added to the wells.  The gel was electrophoresed 
in a BRL horizontal electrophoresis apparatus at 100 V for 30-40 min.  The DNA 
fragments were visualised under long-wave UV light and excised from the gel 
using a sterile scalpel.  DNA fragments were purified from agarose gel slices 
using the Qiagen Qiaquick Gel Extraction kit in accordance with the standard 
protocol supplied. 
2.2.3.2 Separation and purification of REN fragments on polyacrylamide gels 
Separation 
DNA fragments of less than 500 bp were resolved on 5% polyacrylamide gels.  
The gels were prepared by mixing 8.3 ml 40% acrylamide bis-acrylamide (19:1) 
(Bio-Rad), 4.2 ml 40% acrylamide, 5 ml 10X TBE, 100 μl TEMED, 700 μl 10% 
ammonium persulphate in a final volume of 100 ml.  The mixture was 
immediately poured between glass plates and a 12-well comb inserted.  Once 
the gel had set the samples to be analysed were mixed with 4X DNA loading 
buffer and loaded onto the gel.  The samples were run alongside a 100 bp ladder 
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and electrophoresed in 1X TBE at 100 V for 30-40 min, before the bromophenol 
blue dye front reached the bottom of the gel.  The DNA fragments were stained 
by submersing the gel for 30 min in a 100ml solution of 1X TBE containing 5 μl of 
ethidium bromide (10 mg/ml).  The DNA was visualised under long-wave UV light 
and the DNA fragment was excised from the gel using a sterile scalpel. 
Purification 
The excised fragment was transferred to a 0.5 ml reaction tube, containing a 
small aperture in the bottom, and the tube placed inside a 1.5 ml reaction tube.  
After the sample had been centrifuged at 13000 rpm for 5 min in a 
microcentrifuge, 400 μl of elution buffer (Section 2.1.11) was added to the 
pulverised gel in the 1.5 ml reaction tube, and the mixture incubated overnight 
at 42oC.  The polyacrylamide gel was removed from the mixture by filtering the 
sample through a glass fibre disc, pre-soaked briefly in elution buffer and placed 
in a 2 ml syringe.  Two volumes of ethanol (200 μl) were added to the filtered 
sample and the tube was placed on dry ice.  After 1 h incubation the sample was 
centrifuged at 13000 rpm in a bench-top microcentrifuge for 10 min and the 
supernatant discarded.  The DNA pellet was dissolved in 300 μl of sodium 
acetate pH 5.5 and 600 μl of ethanol was added to the solution to precipitate 
the DNA.  The mixture was chilled on dry ice for 30 min prior to centrifugation at 
13000 rpm for 10 min.  The supernatant was removed and the DNA pellet was 
washed in 70% ethanol.  The centrifugation step repeated and the supernatant 
was removed and discarded.  The DNA pellet was left to air dry for 5 to 10 min 
at RT and then dissolved in 30 μl 10mM TrisHCl pH 8.0.  Typically, 3 μl of the 
sample was analysed on an agarose gel (Section 2.2.3.1) to determine the yield 
and purity of the eluted DNA fragment, while the remainder of the sample was 
stored at -20oC until required.  
2.2.3.3 Plasmid DNA preparation 
Plasmid DNA was routinely isolated from bacterial clones using 1.5 ml of a 5 ml 
overnight bacterial culture (Section 2.2.4).  The culture was transferred into a 
1.5 ml reaction tube and the bacteria centrifuged for 1 min at 13000 rpm in a 
bench-top microcentrifuge.  The supernatant was discarded and the pelleted 
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bacteria were processed using the QIAprep Spin Miniprep Kit (Section 2.1.14) 
according to the manufacturer’s instructions.  The final concentration of the 
plasmid DNA was determined by measuring the absorbance at 260 nm (A260), 
based upon an A260 value of 1.0 corresponding to a dsDNA concentration of 50 
μg/ml.  The identity of the plasmid DNA was confirmed by an analytical REN 
digest (Section 2.2.1.1) and DNA sequencing (Section 2.2.3.4).  The plasmid 
stocks were stored at -20oC until required. 
2.2.3.4 DNA sequencing  
All DNA sequencing was carried out commercially by Geneservices Ltd. 
2.2.4 Growth and maintenance of E. coli bacteria 
2.2.4.1 Culture of E. coli 
For the production of small-scale E. coli cultures a tube containing 5 ml of L-
broth supplemented with the appropriate antibiotic was inoculated with a single 
isolated bacterial colony and the culture grown overnight at 37oC in the orbital 
shaker at 225 rpm.  These cultures were used in the preparation of small 
amounts of plasmid DNA (Section 2.2.3.3).  The small-scale bacterial culture was 
also used as a starter culture for large-scale plasmid DNA production.  A volume 
of 2.5 ml of the overnight culture was added to 250 ml of L-broth, containing the 
appropriate antibiotics, and the sample incubated as before at 37oC overnight. 
2.2.4.2 Storage of E. coli 
A small-scale culture of E. coli was grown as outlined above (Section 2.2.4.1).  
After overnight incubation 900 μl of the cell suspension was transferred to a 1.5 
ml cryotube and mixed with 100 μl DMSO, frozen on dry ice and stored at -70oC.  
2.2.5 Preparation and transformation of electrocompetent E. coli 
Prior to preparation each of the E. coli stocks was thawed from long-term 
storage at -70oC.  The bacterial suspension was streaked onto L-broth agar plates 
containing the appropriate antibiotics.  Following overnight incubation at 37oC a 
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single colony was selected from each strain and used to produce the following 
electrocompetent bacteria.  
2.2.5.1 E. coli DH5α  
A single colony of E. coli DH5α was inoculated into a 50 ml starter culture of L-
broth and incubated at 37oC in the oribital shaker at 225 rpm.  The following day 
20 ml of the starter culture were added to 1 litre of pre-warmed L-broth and the 
culture incubated as before until an OD600 of 0.5 to 0.6 was reached.  The 
contents were then transferred to six pre-chilled 250 ml Falcon tubes and 
incubated on ice for 30 min, followed by centrifugation at 3000 rpm for 25 min 
in a Sorvall SLA-1500 rotor.  The bacterial pellets were vigorously resuspended in 
200 ml of ice-cold sterile dH20.  The bacterial suspensions were centrifuged 
again at 3000 rpm and the supernatants were subsequently discarded.  The dH2O 
wash was repeated twice more.  After the final wash the combined cell pellet 
was vigorously resuspended in 20 ml of sterile dH20 containing 10% glycerol 
(v/v).  The cell suspension was transferred to a pre-chilled 50 ml SS34 tube and 
centrifuged at 5800 rpm in a Sorvall SS34 rotor for 15 min at 0oC.  After 
centrifugation the supernatant was discarded and the cell pellet was 
resuspended in 2 ml ice-cold sterile 10% glycerol.  Aliquots (80 μl) of the 
competent bacteria were stored at -70oC until required. 
Aliquots of electrocompetent E. coli DH5α were removed from -70oC storage and 
thawed slowly on ice immediately prior to electroporation using a Hybaid Cell 
Shock Electroporator.  A 1 μl volume of the appropriate ligation reaction was 
added to each aliquot of DH5α.  The mixture was transferred into a pre-chilled 
Gene Pulser cuvette (Bio-Rad), placed into the Hybaid Cell Shock CS 100 system 
set at 1.8 kV and the machine activated.  The bacteria were subsequently 
resuspended in 1 ml of unsupplemented L-broth, transferred to a 25 ml universal 
and incubated in the orbital shaker at 37oC for 1 h.  The bacterial suspension 
was diluted 1:10 in unsupplemented L-broth and a 100 μl aliquot was plated onto 
an L-broth agar plate containing the appropriate antibiotic, followed by 
incubation overnight at 37oC.  Plasmid DNA was prepared from the recombinant 
bacteria obtained as outlined in Section 2.2.3.3. 
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2.2.5.2 E. coli DH10Bac  
Electrocompetent DH10Bac cells were prepared and transformed essentially as 
described for DH5α (Section 2.2.5.1), except DH10Bac were grown in the 
presence of 50 μg/ml km and 10 μg/ml tet and following electroporation they 
were incubated for 4 h at 37oC.  Serial dilutions of 10-1 to 10-3 of the bacterial 
suspension were prepared.  A 100 μl sample of each dilution was plated onto L-
broth agar plates containing 50 μg/ml km, 7 μg/ml gentamicin (gm), 10 μg/ml 
tet, 100 μg/ml X-gal and 40 μg/ml IPTG and the plates incubated at 37oC for 48 
h.  White bacterial colonies, unable to express functional β-galatosidase, were 
streaked onto fresh supplemented agar plates and incubated at 37oC overnight.  
Bacmid DNA was prepared from the recombinant bacteria obtained as outlined in 
Section 2.2.12.1. 
2.2.5.3 E. coli DH10B 
A single colony of E. coli DH10B carrying fHSVΔpac was inoculated into 50 ml of 
L-broth, supplemented with 15 μg cm and 50 μg of stp, and grown overnight at 
37oC.  A 30 μl aliquot of the bacterial suspension was inoculated into a universal 
containing 1.4 ml of L-broth and the antibiotics described above.  After 
incubation at 37oC for 2 h on a platform shaker at 1000 rpm the bacterial 
suspension was transferred to a pre-chilled reaction tube and centrifuged at 
11000 rpm for 30 sec at 4oC.  The bacterial pellet was resuspended in 1 ml of 
ice-cold dH2O and centrifuged as before.  The electrocompetent bacteria were 
resuspended in a residual volume of the supernatant (30 μl) and stored on ice 
prior to transformation as outlined in section 2.2.8. 
2.2.5.4 E. coli BL21  
A single colony of E. coli BL21 was inoculated into 5 ml L-broth and incubated at 
37oC in the orbital shaker at 225 rpm overnight.  A 30 μl aliquot of the overnight 
culture was inoculated into 1.4 ml of L-broth in a universal and the culture 
incubated as before.  After 2-3 h incubation the culture was transferred to a 
pre-chilled reaction tube and the bacteria pelleted by centrifugation at 13000 
rpm for 30 sec in a microcentrifuge located in the 4oC cold room.  The 
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supernatant was discarded and the pellet was resuspended in ice-cold dH2O, 
followed by centrifugation at 13000 rpm for 30 sec.  The wash was repeated 
twice more.  After the final wash the bacterial pellet was resuspended in a 
volume of 30 μl of the residual supernatant and the remaining supernatant was 
discarded. The bacterial suspension was stored on ice prior to transformation as 
outlined in Section 2.2.5.1.   
2.2.6  Maintenance and passage of tissue culture cells 
2.2.6.1 Mammalian cell lines 
Cells were grown overnight in in a 175 cm2 tissue culture dish and the confluent 
cell monolayer was rinsed with 20 ml of versene, followed by a brief wash in 20 
ml of 1X trypsin (diluted in versene) at RT.  The trypsinised cells were detached 
from the culture vessel by gentle agitation and resuspended in 10 ml of fresh 
medium.  Typically, 1/5th of the total volume of resuspended Vero or 8-1 cells 
and 1/3rd of the total volume of resuspended U2OS cells was seeded into a new 
flask.  The cells were passaged every 3-4 days.   
2.2.6.2 Insect cell line 
Cells were grown overnight in a 175 cm2 tissue culture dish. Confluent Sf21 
monolayers were detached from the flask by agitation alone and resuspended in 
10 ml of fresh medium.  Generally, 2 ml of the cell suspension was seeded into a 
fresh flask and the cells passaged every 3-4 days. 
2.2.6.3 Counting cells    
Tissue culture cells were diluted 1:10 in cell culture medium and counted in a 
haemocytometer (Neubauer) under an inverted light microscope (Olympus). 
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2.2.7 Complementation analysis 
2.2.7.1 Transfection of mammalian cells 
Duplicate transfections were prepared for each DNA sample that was analysed.  
Vero cells were seeded at a density 1 x 105 cells/well in 24-well tissue culture 
dishes and incubated at 37oC.  The following day 0.5 μg of the appropriate 
recombinant plasmid DNA was diluted in Optimem to a final volume of 21 μl in a 
0.5 ml reaction tube and mixed with 4 μl of Plus reagent.    After 15 min at RT 
25 μl of diluted Lipofectamine (1 μl Lipofectamine + 24 μl Optimem) was added 
to each sample and the mixture was incubated for a further 15 min at RT.  
During the incubation the Vero cell monolayers were washed twice with 
unsupplemented growth medium and then overlaid with 200 μl of the same 
medium.  The transfection mix (50 μl) was added to each cell monolayer and the 
cells incubated at 37oC for 3 h.  The transfection mix was removed from the 
transfected cells and 1 ml of supplemented growth medium was added to each 
monolayer.  One set of transfected cells was incubated overnight at 37oC and 
crude mammalian protein extracts were prepared (Section 2.2.7.2).  The other 
set of transfected cells was incubated at 37oC for a further 2 h prior to virus 
infection and subsequent analysis using the complementation yield assay 
described in Section 2.2.7.3.  
2.2.7.2 Production of crude mammalian protein extract  
The transfected cell monolayer (Section 2.2.7.1) in each well of the 24-well 
tissue culture dish was washed in 1 ml of PBS followed by the addition of 500 μl 
of fresh PBS.  Each cell monolayer was scraped into PBS and the suspension was 
transferred to a reaction tube.  After the sample had been centrifuged at 6000 
rpm for 30 sec in a bench top microcentrifuge, the cell pellet was resuspended 
in 20 μl dH2O and the cells lysed by the addition of 10 μl of 3X boiling mix.  The 
cell lysate was then stored at –20oC, if necessary.  To determine the level of the 
recombinant proteins produced, a 15 μl sample of the cell lysate was analysed 
by Western blotting (Section 2.2.18.2).   
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2.2.7.3 Complementation yield assay 
The transfection mix was removed from each sample prepared in Section 2.2.7.1 
and the transfected cells were washed once with 1ml of growth medium.  Each 
monolayer was infected with 100 μl HSV-1 UL25 null virus (ΔUL25MO) at a 
concentration of 2 PFU/cell and incubated at 37oC for 1 h.  To ensure that the 
virus was equally absorbed over the cell monolayer and that the cells did not dry 
out, the tissue culture dishes were gently rocked every 15 min throughout the 
incubation.  After viral absorption, the cells were treated with acid as described 
in Section 2.2.7.4, followed by incubation in 1 ml of growth medium at 37oC.  
The next day each cell monolayer was scraped into the medium and transferred 
to a 15 ml Falcon tube prior to sonication at 4oC.  The yield of the progeny virus 
produced was determined by titrating the virus on 8-1 cells (Section 2.2.10).    
2.2.7.4 Acid wash of cell monolayers 
The acid wash was carried out in order to eliminate residual viral particles from 
the cell surface after viral absorption.  The viral inoculum was removed from 
each monolayer, the cells were washed twice with 1 ml 0.14 M NaCl and then 
overlaid with 1 ml acid wash (Section 2.1.11) for 1 min at RT.  The acid wash 
was promptly removed after incubation.  The cells were washed with 1 ml of 
growth medium, then overlaid with 1 ml of fresh medium and incubated at 37oC.  
2.2.8 Generation of HSV-1 UL25 null mutant (ΔUL25MO) 
To generate the new HSV-1 UL25 null virus the commercially supplied Counter-
Selection BAC Modification Kit (Gene Bridges version 2.4, 2005) was utilised.  
The manufacturer’s recommended controls were included throughout the 
procedure to ensure that the techniques were correctly applied. A synopsis of 
the methodology and theory behind the strategy is outlined in Section 3.2.  A 
revised and amended version of the manual used in the procedure can be seen at 
the link below:   
http://www.genebridges.com/gb/pdf/K001%20Q%20E%20BAC%20Modification%20
Kit-version2.6-2007-  
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2.2.8.1 Transformation of DH10B carrying fHSVΔpac with the Red/ET 
plasmid (pRed/ET) and expression of recombination enzymes   
A 1 μl (20 ng) aliquot of the Red/ET plasmid (pRed/ET) (Gene Bridges) was 
electroporated into 30 μl of freshly prepared electrocompetent DH10B cells 
(Section 2.2.5.3) containing the HSV-1 strain 17 syn+ BAC (fHSVΔpac).  After 
electroporation the bacteria were resuspended in 1 ml of L-broth and incubated 
at 30oC for 70 min in a platform shaker at 1000 rpm.  The transformed DH10B 
culture was plated onto L-broth agar plates, supplemented with 15 μg/ml of cm 
and 3 μg/ml of tet, and incubated at 30oC for 18-24 h.  Since tet is light sensitive 
the agar plates containing this antibiotic were wrapped in tin foil during 
incubations.  Following incubation a well-isolated single colony was selected and 
inoculated into 50 ml of L-broth containing cm/tet and the culture was 
incubated at 30oC for 18-24 h on the platform shaker at 1000 rpm.  The next day 
duplicate samples (one set for the induced cultures and one set for the 
uninduced cultures), were prepared by adding 30 μl of the overnight culture to 
1.4 ml of L-broth supplemented with cm/tet.  The duplicate bacterial 
suspensions were incubated at 30oC for 2 h on a platform shaker at 1000 rpm 
until the OD600 reached 0.3.  The expression of the genes mediating Red/ET 
homologous recombination was induced by adding 50 μl of 10% L-arabinose to 
one set of samples (induced) and shifting the temperature from 30oC to 37oC.  
Both the induced and uninduced cultures were incubated at 37oC for 45-60 min 
on a platform shaker at 1000 rpm.  After incubation the induced and uninduced 
bacterial suspensions were prepared for electroporation as described in section 
2.2.5.3.  The competent bacteria were subsequently transformed with the PCR 
product, rps-L neo-PCR1, as described below.  
2.2.8.2 Step 1 of the Counter-Selection BAC Modification procedure:- 
insertion of rpsL-neo-PCR1 selection cassette into the HSV-1 BAC 
(fHSVΔpac )  
A 2 μl (200 ng) aliquot of the rpsL-neo-PCR1 product (Section 3.2.2) was 
electroporated into the induced and uninduced bacteria as described in Section 
2.2.5.3.  After electroporation 1 ml of L-broth was added to each cuvette and 
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the bacterial suspension was divided between two universals, representing the 
recombinant and non-recombinant samples.  The non-recombinant samples for 
the induced and uninduced suspensions were retained on ice.  The recombinant 
samples from the induced and uninduced cultures were incubated at 37oC for 70 
min on the platform shaker at 1000 rpm to allow recombination between the 
PCR product and fHSVΔpac to take place.  After incubation each of the four 
cultures was streaked onto an L-broth agar plate supplemented with 15 μg/ml 
cm, 3 μg/ml tet and 15 μg/ml km and incubated at 30oC for 36-48 h.  Bacterial 
colonies from the recombinant induced samples were each inoculated into 100 μl 
of L-broth, supplemented with cm/tet/km, and incubated for 1-2 h at 30oC on a 
platform shaker at 1000 rpm.  After incubation four aliquots of each overnight 
culture were used as follows: an aliquot was prepared for storage (Section 
2.2.4.2) and the other aliquots were used for the functional analysis of the rpsL-
neo-PCR1 cassette (Section 2.2.8.3), preparation of recombinant BAC DNA 
(Section 2.2.8.4) and step 2 of the Counter-Selection BAC Modification procedure 
(Section 2.2.8.5). 
2.2.8.3 Functional analysis of the rpsL-neo-PCR1 selection cassette 
To verify the km resistance (kmR) of selected colonies from the induced 
recombinant plates (Section 2.2.8.2) each colony was replica plated onto L-broth 
agar plates containing either cm/tet and 50 μg/ml stp or cm/tet/km and 
incubated at 37oC for 2 days.  Bacteria containing an inserted and functional 
rpsL-neo-PCR1 cassette within the BAC should display kmR and sensitivity to stp 
(stpS). 
2.2.8.4 Preparation of BAC DNA and confirmation of correct insertion of the 
rpsL-neo-PCR1 selection cassette 
BAC DNA was prepared from bacterial cultures that were kmR and stpS.  A 30 μl 
aliquot of bacterial culture from the 30oC incubation described in Section 2.2.8.2 
was transferred into 2 ml of L-broth supplemented with cm/km and the sample 
incubated at 37oC on the platform shaker at 1000 rpm.  After an overnight 
incubation the culture was inoculated into 100 ml of L-broth containing cm/km 
and incubated again at 37oC in the orbital shaker at 225 rpm overnight.  A 
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modified version of the QIAGEN-tip 100 protocol (Section 2.1.14), designed for 
the production of very low-copy number plasmids, was utilised for the 
preparation of the BAC DNA.  Following the manufacturer’s instructions, 100 ml 
of the bacterial culture was used, along with proportional amounts of the 
reagents supplied with the QIAGEN-tip 100 kit for the preparation of DNA.  Each 
purified BAC DNA sample was resuspended in a final volume of 50 μl 10 mm 
TrisHCl pH 8.0 and stored at 4oC until required. 
2.2.8.5 Step 2 of the Counter-Selection BAC Modification procedure:- 
replacment of the rpsL-neo-PCR1 selection cassette with the non-
selectable PCR product (non-sm) 
An aliquot of each of the 100 μl kmR/stpS cultures from the 1-2 h 30oC incubation 
described in Section 2.2.8.2 was used for Step 2 of the BAC counter-selection 
procedure (Section 3.2.6).  A 300 μl aliquot of L-broth, supplemented with 
cm/tet/km, was added to each sample and the cultures were incubated at 30oC 
overnight on a platform shaker at 1000 rpm.  A 30 μl aliquot of each of the cell 
cultures was transferred to a tube containing 1.4 ml of L-broth, supplemented 
with the same antibiotics as before, and the incubation continued at 30oC until 
the OD600 was 0.3.  The bacterial culture was divided into the uninduced control 
and the induced samples.  A volume of 50 μl of 10% L-arabinose was added to 
each of the induced samples, to initiate the expression of the genes mediating 
Red/ET recombination, and Step 2 of the procedure was started by shifting the 
temperature from 30oC to 37oC.  Both the induced and uninduced cultures were 
incubated at 37oC for 45-60 min on a platform shaker at 1000 rpm and 
subsequently prepared for electroporation (Section 2.2.5.3).  A 2 μl aliquot of a 
1:2 dilution of the overlapping nucleotide non-sm (Section 3.2.5) was added to 
each sample and the DNA electroporated.  Following electroporation 1 ml of L-
broth was added to each cuvette and each culture was divided into two, one 
representing the recombinant sample and the other representing the non-
recombinant sample.  The induced and uninduced non-recombinant samples 
were retained on ice as controls.  The induced and uninduced recombinant 
cultures were incubated at 37oC for 70 min on the platform shaker at 1000 rpm 
to allow recombination between non-sm and the inserted rpsL-neo-PCR1 product 
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contained in fHSVΔpac.  After incubation each culture was replica plated onto L-
broth agar plates containing cm/tet/stp or cm/tet/km. 
2.2.8.6  Transfection of 8-1 cells with HSV-1 BAC DNA containing the rpsL-
neo-PCR1 cassette   
UL25 expressing (8-1) cells were seeded at a density of 5 x 105 cells/dish on 35 
mm dishes and incubated at 37oC.  The following day 5 μl of HSV-1 BAC DNA and      
0.5 μg of the BamHI K fragment, purified from plasmid pGX2, were diluted in 
100 μl Optimem prior to the addition of 3 μl of Plus reagent.  The solution was 
mixed and incubated at RT for 15 min.  A 3 μl aliquot of Lipofectamine mix, 
diluted in 100 μl of Optimem, was added to each sample and the transfection 
mix was incubated for a further 15 min at RT.  During the incubation the medium 
was removed from the monolayers and the cells were washed with 1 ml of 
Optimem.  The transfection mix was added to each dish containing 800 μl 
Optimem and the cells were incubated at 37oC.  After 4.5 h the medium was 
removed and the cells were washed with 1 ml of fresh medium prior to being 
overlaid with 2 ml of growth medium and incubated at 37oC.  After 2-3 days 
incubation the monolayer was scraped into the growth medium, and the viral 
particles were released by sonication.  The virus was plaque-purified (Section 
2.2.9) and a large-scale virus stock prepared.   
2.2.9 Virus plaque purification  
Eighty percent sub-confluent cell monolayers, seeded in 35 mm tissue culture 
dishes, were overlaid with 100 μl of the sonicated viral preparation (Section 
2.2.8.6).  The dishes were incubated at 37oC for 1 h and the dishes were gently 
rocked every 15 min to stop the cells drying out.  After viral absorption the cells 
were overlaid with 2 ml of methyl cellulose medium, to reduce the spread of the 
resulting plaques, and incubated as before for another 2-3 days.  Well-isolated 
plaques were picked from the virus-infected monolayers and transferred into 1 
ml of growth medium, then frozen on dry ice before being stored at –70oC.  The 
titres of the plaque-purified stocks were determined as described in Section 
2.2.10 prior to large-scale viral production (Section 2.2.11).   
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2.2.10 Titration of HSV-1 stocks (plaque assay) 
Serial tenfold dilutions of the virus sample were prepared and 100 μl aliquots 
from each dilution were added to 80% sub-confluent cell monolayers.  After 
incubation at 37oC for 1 h with intermittent rocking, the cells were overlaid with 
2 ml of DMEM supplemented with 2% FCS, 3% human serum and 1X pen/stp.  
Human serum was added to the growth medium during the viral titrations to 
neutralise any unabsorbed virus and to prevent secondary plaque formation.  
Following incubation at 37oC for 2-3 days the medium was removed from the 
cells and replaced with 1 ml of Giemsa stain per dish.  After 20 min at RT the 
stain was washed off the cells under gently running water and the plaques 
counted using a dissecting microscope.  The virus titre was determined by the 
following calculation: 
Titre = number of plaques on 10-n dilution x 10n+1 x 10n+1 PFU/ml.  
2.2.11 Large scale production of HSV-1 stocks 
Four 850 cm2 roller bottles, containing 80% sub-confluent monolayers, were each 
infected with virus at a concentration of 0.01 PFU/cell in a 40 ml volume of 
medium and incubated at 37oC.  After 3-4 days the virus-infected cells were 
harvested into the medium by agitation and pelleted by centrifugation at 1,500 
rpm in a Sorval RT7 centrifuge for 10 min at 4oC.  The supernatant was 
centrifuged at 12000 rpm in a Sorval RC 5B Plus centrifuge for 2 h at 4oC to 
concentrate the cell-released virus.  The resulting pellets of cell-released virus 
were combined in a total volume of 5 ml of medium, dispersed in a bath 
sonicator and divided into aliquots, which were subsequently frozen on dry ice 
and stored at -70oC.  The virus-infected cell pellet was resuspended in 5 ml of 
medium, disrupted by bath sonication and the cell debris removed by 
centrifugation at 3000 rpm in a Sorval RT7 centrifuge for 10 min at 4oC.  The 
supernatant, containing the cell-associated virus, was divided into aliquots and 
frozen on dry ice prior to storage at -70oC.      
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2.2.12 Generation of recombinant baculoviruses 
The recombinant baculoviruses were generated using the Bac-to-Bac system 
from Life Technologies and a synopsis of the procedure used is described in 
Section 5.2. 
2.2.12.1 Preparation of recombinant bacmid DNA 
Recombinant bacmid DNA was isolated from transformed DH10Bac using a 
modified version of the Qiagen Plasmid Purification QIAGEN-tip 100 procedure 
(Section 2.1.14).  A single white colony was inoculated into 5 ml of L-broth 
containing 50 μg/ml km, 7 μg/ml gm and 10 μg/ml tet and incubated at 37oC.  
The following day 1.5 ml of the bacterial suspension was transferred to a 
reaction tube and the cells were pelleted by centrifugation at 13000 rpm for 1 
min.  The cell pellet was resuspended in 300 μl of ice-cold solution P1 (Qiagen), 
gently mixed in 300 μl of solution P2 (Qiagen) and the lysate was incubated at 
RT for 5 min.  Subsequently, 300 μl of P3 (Qiagen) solution was slowly added to 
the sample, producing a white precipitate that contained both protein and E. 
coli genomic DNA.  The sample was incubated at 4oC for 5-10 min prior to 
centrifugation at 13000 rpm for 10 min.  The supernatant was transferred to a 
fresh reaction tube and 800 μl of isopropanol was added.  The samples was 
mixed and placed on ice for 5-10 min prior to centrifugation for 15 min at 13000 
rpm.  The residual salt was washed off the pelleted DNA by the addition of 500 
μl of 70% ethanol.  The sample was centrifuged for 5 min at 13000 rpm and the 
supernatant discarded.  The bacmid DNA pellet was air dried for 5 min, then 
resuspended in 40 μl 10 mM TrisHCl and stored at 4oC until required. 
2.2.12.2 Transfection of Sf21 cells with the modified BAC DNA 
Sf21 cells were seeded onto 35 mm dishes at a concentration of 1 x 106 cells per 
dish and incubated at 28oC overnight.  A 10 μl aliquot of the prepared 
recombinant bacmid DNA (Section 2.2.12.1) was added to 6 μl of Lipofectamine 
diluted in 100 μl of Optimem and incubated at RT for 15 min.  This was followed 
by the addition of 4 μl of Plus diluted in 100 μl of Optimem.  The transfection 
mix was then incubated for a further 15 min at RT.  During the incubation the 
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Sf21 monolayers were washed twice with Optimem and overlayed with 300 μl 
Optimem.  The transfection mix was added to the cell monolayers and the dishes 
placed inside a sealed sandwich box containing a small amount of dry ice.  After 
incubation at 28oC for 5 h the transfection mix was replaced with growth 
medium and the incubation continued for a further 3 days.  The medium was 
then transferred to a 15 ml Falcon tube and the residual Sf21 cells were 
removed by centrifugation at 1,500 rpm for 5 min at 4oC in a bench top 
centrifuge.  The supernatant containing the cell-released virus was retained and 
stored at -70oC. 
2.2.12.3 Production of high-titre baculovirus stocks 
Four 850 cm2 roller bottles of Sf21 cells were each seeded at a density of 2 x 105 
cells/ml in a total volume of 300 ml of growth medium and incubated at 28oC.  
After two days, when the cells had reached a density of 5 x 105 cells/ml, they 
were infected with the recombinant baculovirus at a multiplicity of infection 
(MOI) of 0.1 PFU/cell (1.5 x 107 PFU) and the incubation was continued for a 
further 6 days.  The virus-infected cells were removed from the medium by 
centrifugation at 3000 rpm in a Sorval RT7 centrifuge for 10 min at 4oC.  The 
clarified supernatant was centrifuged at 12000 rpm in a Sorval RC 5B Plus 
centrifuge for 2 h at 4oC.  The resulting viral pellet was resuspended in 2-3 ml of 
growth medium, sonicated, divided into aliquots and fast-frozen on dry ice prior 
to storage at -70oC. 
2.2.12.4 Titration of baculovirus stocks  
Sf21 cells were seeded onto 35 mm dishes at a density of 1 x 106 per plate in 2 
ml of growth medium and incubated overnight at 28oC.  The next day the 
medium was removed and 100 μl of serial tenfold dilutions of the viral sample 
was added to the cells.  The dishes were incubated at RT for 1 h with periodic 
rocking.  The cells were then overlaid with 1.5 ml of TC100 growth medium 
containing 1.5% (w/v) LGT agarose, prewarmed to 45 oC.  When the agarose had 
set 1.5 ml of TC100 growth medium was added to each dish and the incubation 
continued at 28oC.  At 4-5 days post-infection the liquid overlay was removed 
and the cell monolayers were overlaid with 1 ml TC100 medium containing 2% 
neutral red and incubated for 3-4 h at 28oC.  After the stain was removed, the 
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dishes were inverted overnight at 28oC.  The following day the plaques were 
counted using the dissecting microscope. 
2.2.12.5 Preparation of baculovirus protein extract from insect cells 
Sf21 cells were seeded into a 175cm2 flask at a density of 3 x 107 cells in 40 ml of 
growth medium and incubated at 28oC.  The following day the cells were 
infected with the appropriate recombinant baculovirus at a MOI of 5 PFU/cell.   
After incubation at 28oC for 2 days the cells were detached from the flask into 
the medium by gentle agitation and pelleted by centrifugation at 3000 rpm in a 
Sorval RT7 centrifuge for 10 min at 4oC.  The supernatant was discarded and the 
cells were washed twice in PBS, before being resuspended in 1 ml of sterile 1X 
phosphate buffer (Section 2.1.11) containing protease inhibitors (Boehringer 
Mannheim).  The cell suspension was sonicated and then centrifuged at 35000 
rpm for 30 min in a TLA 100.2 rotor using a BECKMAN TL-100 centrifuge.  The 
supernatant, containing the protein extract, was retained and divided into 
aliquots prior to fast-freezing on dry ice and storage at –70oC.   
2.2.12.6 Baculovirus infection of mammalian cells 
U2OS cells were seeded onto 35 mm dishes at a density of 8 x 105 cells per dish 
and incubated at 37oC.  After incubation overnight the cell density was assumed 
to be 1.6 x 106.  The medium was removed from the monolayers and the cells 
were singly infected with baculovirus at an MOI of 50 PFU/cell in a final volume 
of 100 μl or infected with two viruses, each at an MOI of 25 PFU/cell/ in a final 
volume of 50 ul.  After absorption of the virus at RT for 1 h the inocula were 
removed and the cells were washed twice with fresh growth medium.  The cells 
were then infected with ΔUL25MO at an MOI of 2 PFU/cell in a final volume of 
100 μl.  After virus absorption at 37oC for 1 h the inocula were removed and the 
cells were washed twice with fresh medium.  The cells were overlaid with 2 ml 
of growth medium and incubated at 37oC for 18-24 h.  If the cells were to be 
analysed using immunofluorescence (Section 2.2.12.8 and 2.2.17.2) they were 
seeded at a density of 1 x 105 cells onto 13 mm glass coverslips placed at the 
bottom of a 24-well dish and overlaid with 1 ml of growth medium.  After 
overnight incubation at 37oC, viral infection of the cells was carried out as 
described above.  
Chapter 2 95
2.2.12.7 Preparation of baculovirus protein extract from mammalian     
cells  
U2OS cells were grown on 35 mm tissue culture dishes and infected with the 
appropriate baculovirus stock as described in Section 2.2.12.6.  At 24 hpi the cell 
monolayers were scraped into the growth medium, and each transferred to a 1.5 
ml reaction tube.   The cells were pelleted, by centrifugation at 2000 rpm for 1 
min, resuspended in TBS containing protease inhibitor tablets and the 
centrifugation step was repeated.  The cell pellet was mixed with 500 μl ice-
cold EZ lysis buffer and placed on ice for 20 min, with periodic vortexing.  A 20 
μl aliquot, referred to as the total protein sample (TP), was transferred to a 
reaction tube containing 10 μl 3X boiling mix and stored at -20oC until required.  
The remaining lysed cells were clarified by pelleting the cell debris at 35000 rpm 
for 20 min at 4oC in a TLA 100.2 rotor, using a BECKMAN TL-100 ultra centrifuge.  
After centrifugation another 20 μl sample, referred to as the soluble protein 
extract (SP), was transferred to a reaction tube containing 10 μl of 3X boiling 
mix and stored at -20oC until required.    
2.2.12.8 Assessment of the efficiency of baculovirus infection using an 
immunofluoresence assay 
Baculovirus-infected U2OS cell monolayers were prepared as described in 
Section 2.2.12.6.  The monolayers, grown on the coverslips placed in 24-well 
plates, were washed twice with PBS and then carefully overlaid with 1 ml PBS 
containing 5% (v/v) formaldehyde, 2% (w/v) sucrose in a fume hood at RT.  After 
10 min the monolayers were washed three times with PBS prior to 
permeabilisation of the cells with 1 ml PBS containing 0.5% NP40 10% sucrose.  
Following incubation for 5 min at RT the cells were washed three times with 
PBS-1% FCS (Section 2.1.11).  With the cell monolayer facing down, the 
coverslips were each transferred on to a 20 μl droplet of the UL25 monoclonal 
antibody MAb166, diluted 1:500 in PBS-1% FCS, placed in the well of the lid from 
a 24-well dish.  The coverslips on the lid were put inside a sealed box to reduce 
evaporation and incubated for 1 h at RT.  Unbound antibody was subsequently 
removed by immersing each coverslip three times in PBS-1% FCS for 5 min at RT.  
Each coverslip was then transferred to a 20 μl droplet of the secondary antibody 
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anti-mouse IgG conjugated to FITC, diluted 1:100 in PBS-1% FCS, and incubated 
for 1 h as before.  Unbound antibody was removed by washing each coverslip 
three times in PBS-1% FCS.  The cell nuclei were stained with 20 μl propidium 
iodide solution (20 μl propidium iodide in 20 ml PBS) for 2 min at RT and the 
coverslips were again washed three times in PBS-1% FCS, followed by two rinses 
in dH2O to remove any residual salt remaining from the PBS washes.  With the 
cell monolayer facing up, the coverslips were transferred onto Whatman’s 
number 1 blotting paper and allowed to dry.  Each coverslip was subsequently 
transferred, with the cell monolayer facing down, onto a 5 μl droplet of Mowiol 
(Harco) mounting fluid on a glass slide.  The cells were examined using the Zeiss 
Axioplan 2 confocal microscope and the images were obtained using the 
associated LSM 510 software.    
2.2.13 Sterility of viral stocks 
The sterility of the viral stocks was checked by streaking a small sample onto a 
blood agar plate.  The plate was sealed with ParafilmTM and incubated at 37oC 
for up to 5 days.  Contaminated viral stocks were discarded. 
2.2.14 Detection of full length packaged viral DNA  
2.2.14.1 Preparation of total and DNase I resistant viral DNA  
DNA preparation for Southern blots 
 
U2OS cells, seeded onto 35 mm dishes, were grown and infected with the 
appropriate baculovirus, as described in Section 2.2.12.6.  Following incubation 
at 37oC for 24 h the medium was removed and 2.3 ml of ice-cold TBS was added 
to each monolayer.  The cells were scraped into the TBS,  placed in a 15 ml 
Falcon tube and dispersed by vortexing.  Each cell suspension was divided into 
two 1 ml aliquots and transferred to reaction tubes labelled (A) and (B), with 
sample (A) representing the total viral DNA content of the cells and sample (B) 
representing the DNase I resistant (packaged) DNA fraction of the cells.  Both 
aliquots were centrifuged at 13000 rpm in a bench top microfuge for 12 sec and 
the supernatant discarded.  A 184 μl aliquot of RSB containing 0.5% NP40 was 
added to sample (A) and the mixture vortexed.  This was immediately followed 
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by the addition of 184 μl of 2X CLB containing 1 mg/ml of protease.  The sample 
was mixed by gentle inversion of the reaction tube and incubated at 37oC for     
1 h.  A 184 μl aliquot of RSB containing 0.5% NP40 and 200 μg/ml DNase I was 
added to sample (B), followed by incubation at 37oC for 20 min, with occasional 
vortexing.  Subsequently, 184 μl of 2X CLB containing 1 mg/ml of protease was 
added to (B) and the incubation continued for 1 h. 
Following incubation, 32 μl of 4 M NaCl, 50 mM EDTA solution was added to (A) 
and (B) samples and the DNA was sequentially extracted with phenol and 
chloroform:isoamyl alcohol.  After the addition of phenol the sample was mixed 
by rotation for 15 min.  The organic and aqueous phases were subsequently 
separated by centrifugation at 13000 rpm for 1 min and the DNA-containing top 
phase was transferred to a fresh reaction tube.  A 400 μl aliquot of 
chrolofrom:isoamyl alcohol (24:1) was added to the DNA solution and the sample 
mixed by rotation for 15 min.  The DNA-containing top phase was removed and 
the DNA was precipitated from the solution by adding 1 ml of ethanol to each 
sample, mixing and then placing them overnight at –20oC.  The following day the 
samples were centrifuged at 13000 rpm for 10 min, after which the DNA pellet 
was allowed to air dry for 5-10 min.  A 160 μl and 80 μl aliquot of 10 mM TrisHCl 
pH8.0 containing 1X RNase was added to each of the (A) and (B) samples, 
respectively.  After the DNA was dissolved thoroughly by incubating the samples 
for 6 h at 37oC, the samples were stored at 4oC until required. 
DNA preparation for pulse field gels 
 
U2OS cells were grown on 35 mm dishes as outlined in Section 2.2.12.6, except 
that after virus-absorption the residual virus was removed from the cells by an 
acid wash (Section 2.2.7.4).  DNA was prepared from infected U2OS cells in 
essentially the same manner as for Southern blots except for the following 
modifications.  The amount of RSB containing 0.5% NP40 and the amount of 2X 
CLB containing 1 mg/ml of protease added to samples (A) were reduced to 100 
μl.  Similarly, the amount of RSB containing 0.5% NP40, plus 200 μg/ml DNase I, 
and the amount of 2X CLB containing 1 mg/ml of protease added to sample (B) 
were reduced to 100 μl.  The samples were carefully mixed throughout, and 
both phenol extraction and ethanol precipitation of the DNA were omitted to 
minimise shearing of the high molecular weight DNA.  The DNA molecules 
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obtained were separated using pulse field gel electrophoresis as described in 
Section 2.2.16. 
2.2.14.2 Preparation of a 32P-labelled DNA probe 
DNA was labelled with 32P using Roche’s Random Primed DNA Labelling kit.  
Briefly, 500 ng of plasmid DNA in a total volume of 9 μl was boiled for 10 min 
and chilled on ice before the addition of 20 μCi of α-32P dCTP, 20 μCi of α-32P 
dGTP, 3 μl dNTP mix, 2 μl 10X reaction mix containing random primers and 1 
unit of Klenow in a final volume of 20 μl.  After incubation at 37oC for 1 h the 
reaction was stopped by the addition of 5 μl 0.2 M EDTA pH 8.0 and diluted to a 
final volume of 50 μl with 25 μl 10 mM TrisHCl pH 8.0.  Unincorporated 32P-
labelled nucleotides were removed from the sample using a Microspin Sephadex 
G-50 spin column, following the manufacturer’s instructions.  The probe was 
diluted by the addition of 40 μl 10 mM Tris pH 8.0 and subsequently denatured 
by the addition of 20 μl 1 M NaOH.  After incubation at RT for 5 min the reaction 
was neutralised by the addition of 20 μl 1 M HCl.   
2.2.15 Southern blots 
2.2.15.1 DNA digestion and electrophoresis 
Following digestion of a 36 μl aliquot of DNA with BamHI the reaction was 
stopped by the addition of 10 μl of DNA loading buffer.  Subsequently, the 
sample was loaded onto a 0.8% agarose gel in 1X Loening’s buffer (Section 
2.1.11) and the DNA separated by electrophoresis at 15-20 V overnight in a BRL 
horizontal electrophoresis apparatus.  To confirm that the DNA was both 
completely digested and that equal amounts had been loaded into each well, the 
gel was examined under short wave UV light the following day and the ethidium 
bromide-stained DNA photographed using a gel documentation system (Bio-Rad) 
prior to Southern blot transfer (Section 2.2.15.2).  
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2.2.15.2 Southern blot transfer 
DNA was denatured by immersing the gel in 400 ml of alkaline transfer solution 
for 15-30 min and then transferred to a Hybond-XL membrane (Amersham) by 
capillary transfer in alkaline transfer solution overnight at RT.  The following day 
the membrane was removed from the gel and soaked in 100 ml of neutralising 
solution for 15 min with occasional agitation.  The membrane-bound DNA was 
cross-linked by exposure to 120 mJ/cm2 UV light in a Stratalinker (Stratagene).  
The membrane was then placed in a Hybaid bottle containing 50 ml of Southern 
blot prehybridisation buffer.  After incubation in the Hybaid oven at 68oC for 1-2 
h the solution was replaced with 20 ml Southern blot prehybridisation buffer 
containing 0.01 mg/ml of denatured sheared calf thymus DNA and the incubation 
continued for a further 3-5 h.  The purified denatured 32P-labelled probe 
(Section 2.2.14.2) was added to the solution and the hybridisation carried out at 
68oC for a further 16-24 h.  The radioactive solution was removed and the 
membrane was washed with 50 ml Southern blot prehybridisation buffer at 68oC 
for 45 min.  This was followed by two 30 min washes with membrane wash 
buffer (Section 2.1.11) at 68oC and final rinse of the membrane with dH2O.  The 
Hybond-XL membrane was exposed to a phosphorimager screen and the screen 
was analysed on a Bio-Rad Personal Molecular Imager FX using Quantity One 
software.    
2.2.16 Pulse field gels  
DNA was prepared and treated with DNase as described in Section 2.2.14.1.  A 25 
μl aliquot of each DNA sample was analysed on the Bio-Rad DR-II apparatus as 
recommended by the manufacturer.  Using a wide-bored tip, DNA samples were 
loaded onto a 1% agarose (Bio-Rad: pulse field gel electrophoresis [PFGE] 
certified) gel in 0.5X TBE buffer.  The DNA was resolved with a voltage gradient 
of 6 volts/cm for 18 h at 14oC, with a linear time switch gradient from 1 to 15 
sec.  After electrophoresis the gel was stained with ethidium bromide and 
photographed.  The DNA fragments were transferred onto a Hybond-XL 
membrane by Southern blotting (Section 2.2.15.2).     
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2.2.17 Analysis of viral assembly in infected cells 
2.2.17.1 Electron microscopy   
Cells were grown on 35 mm dishes and infected at 37oC with the appropriate 
baculovirus as outlined in Section 2.2.12.6.  At 24 hpi the medium was removed, 
the cells were washed twice with 1 ml of PBS and then fixed by the addition of 
500 μl of 2.5% glutaraldehyde in PBS overnight at 4oC.  The following day the 
cells were rinsed twice with 1 ml of PBS and incubated at RT in 200 μl of osmium 
tetroxide, with occasional rocking of the dishes.  After 1 h the monolayers were 
washed twice with PBS, scraped into 0.5 ml of PBS and each transferred to a 1.5 
ml reaction tube.  The cells were pelleted by centrifugation at 3000 rpm for 5 
min and then each sample was resuspended in 0.5 ml of 1% SeaPlaque agar 
(Lonza) pre-warmed to 50oC.  The samples were spun at 5000 rpm for 5 min in a 
swing-out rotor in a Beckman Microfuge 12 to ensure the pellet formed at the 
bottom of the reaction tube.  Following centrifugation the samples were left at 
4oC for 1-2 h to allow the agar to set.  The bottom of the tube was then cut off 
to release the agar embedded cell pellet and the cell/agar plugs were trimmed 
to approximately 2 mm3.  Each agar plug was transferred to a beem capsule and 
the pellets were dehydrated by sequential 1 h incubations at RT in increasing 
concentrations (30, 50, 70, 90, 100%) of ethanol, with a final incubation at RT 
overnight in 100% ethanol.  The following day the ethanol was carefully removed 
from each sample and replaced with freshly prepared Epon 812 resin mix 
(Section 2.1.11).  The samples were incubated overnight at RT, with the lids of 
the beem capsules left open to allow residual ethanol to evaporate from the 
mix.  The next day the cell pellets were drained and fresh Epon 812 resin mix 
added.  The samples were incubated overnight at RT before being labelled and 
placed in an embedding oven at 65oC for 2 days to allow the resin to harden.       
The embedded samples were sectioned using an ultra-microtome (Leica Ultracut 
E) and the thin sections mounted onto 400 mesh uncoated copper grids by Dr F. 
Rixon or Mr J. Aitken at the MRC Virology Unit.  The sections were each 
subsequently stained in 100 μl of a saturated solution of uranyl acetate in 90% 
ethanol for 1 h, and washed twice by immersion in 300 μl of sterile dH2O for 5 
min.  The excess water was drained off each grid, by carefully blotting the grid 
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onto Whatman’s no. 1 filter paper.  Each grid was subsequently transferred into 
100 μl lead citrate solution (Section 2.1.11) and stained for 1 min, followed by 
three 10 min washes in sterile dH2O and then dried.  The grids were examined at 
80 KV using a JEOL 100S electron microscope.           
2.2.17.2 Fluorescent in-situ hybridisation (FISH) 
To determine the location of viral DNA within the cell, the U2OS cells on 
coverslips were infected with the appropriate baculovirus and prepared as 
outlined in Section 2.2.12.6.  Following overnight incubation at 37oC the cells 
were washed twice with 1 ml of PBS-1% FCS and then fixed in 1 ml of pre-chilled 
95% ethanol containing 5% acetic acid at –20oC for 5 min.  After fixation the cells 
were carefully rinsed three times with 1 ml of PBS-1% FCS and stored at 4oC until 
required.  Preparation of the Cy3-labelled cos56 probe, containing HSV-1 strain 
17 syn+ nucleotide sequences 79,442-115,152, and FISH were carried out by Mrs 
J.  Murray from the MRC Virology Unit (Cunningham & Davison, 1993, Everett et 
al., 2007).  The probe was labelled by nick translation using Cy3-dCTP 
(Amersham), following the manufacturer’s protocol.  After DNase I treatment 
the cells were incubated for 30 min at 37°C in 20 µl hybridisation buffer (Section 
2.1.11) per coverslip in a humidified microarray hybridisation chamber (Camlab).  
The coverslips were removed from the chamber, drained and incubated in 20 μl 
hybridisation buffer containing the probe at a concentration of 1 ng/µl for 2 min 
at 95°C to denature the probe.  The coverslips containing the probe were then 
placed in the humidified chamber and the hybridisation was continued overnight 
at 37°C.  The cells were washed at 60°C for 5 min with 2x SSC and once with 2x 
SSC at RT.  After two washes with PBS-1% FCS, the coverslips were incubated in 
PBS-1% FCS containing 1 μg/ml DAPI for 2.5 min.  The cells were then washed 
three times with PBS-1% FCS, air dried, and mounted in Citifluor AF1 (Citifluor 
Ltd) on glass slides.  The prepared slides were examined using a Zeiss LSM 510 
confocal microscope with 405 and 543-nm laser lines, scanning each channel 
separately under image capture conditions that eliminated channel overlap.  The 
images were exported for analysis as tagged-image format files and then 
processed using Adobe Photoshop.   
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2.2.18 Protein analysis  
2.2.18.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were resolved by electrophoresis on 10% SDS-polyacrylamide gels in 1X 
RGB (Section 2.1.11) prepared from a stock solution of 30% w/w acrylamide:0.8% 
bisacrylamide (37.5:1) (Protogel, National Diagnostics).  The resolving gel layer 
was polymerised by the addition of 200 μl of 10% ammonium persulphate and 20 
μl TEMED and cast into the Mini Protean II gel sandwich (Bio-Rad) to 
approximately 5 mm below the gel comb slot.  The gel solution was overlaid with 
1X RGB.  After the gel had polymerised, the 1X RGB solution was removed and 
the resolving gel was overlaid with 5% polyacrylamide in 1X SGB (Section 2.1.11) 
containing the polymerisation reagents.  The comb was inserted into the solution 
and gel was allowed to polymerise at RT.  Boiling mix (3X) (Section 2.1.11) was 
added to the protein samples at a final concentration of 1X, and the samples 
were heated to 100oC in a boiling water bath for 3 min shortly before they were 
loaded onto the gel.  The molecular weight markers used were either Rainbow 
Markers (Amersham Pharmacia) or MagicMark (Life Technologies).  The proteins 
were separated by electrophoresis in 1X Tank buffer (Section 2.1.11) at 200 V 
until the tracking dye had reached the bottom of the resolving gel.  The gels 
were then prepared for Western blotting (Section 2.2.18.2).  
2.2.18.2 Western blotting  
Protein transfer and detection 
 
Proteins separated by SDS-PAGE (Section 2.2.18.1) were transferred onto a 
Hybond-ECL membrane using a Mini Protean II blotting apparatus (Bio-Rad), 
according to the manufacturer’s instructions.  Transfer of the protein to the 
Hybond-ECL membrane was carried out in 1X Towbin buffer (Section 2.1.11) at 
100 V for 1-2 h.  To block non-specific protein-binding sites, the Western blot 
was transferred into blocking buffer (5% (w/v) dried skimmed milk powder, 
0.05% (v/v) Tween-20 in PBS) and incubated overnight at 4oC with gentle 
shaking.  The following day the blot was placed in fresh blocking buffer, 
containing the appropriately diluted primary antibody (Section 2.1.10), and 
incubated for 1-4 h at RT with gentle shaking.  Unbound primary antibody was 
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removed by rinsing the blot twice in wash buffer (0.05% (v/v) Tween-20 in PBS), 
followed by incubation in fresh wash buffer for 15 min at RT with gentle shaking.  
The blot was washed twice more in wash buffer for 5 min at RT and subsequently 
placed in the appropriate secondary antibody solution (Section 2.1.10) diluted in 
2% (w/v) dried skimmed milk powder, 0.05% (v/v) Tween-20 in PBS and 
incubated for 1 h at RT with gentle shaking.  Unbound secondary antibody was 
washed off the blot as outlined for the unbound primary antibody.  Bound 
antibody was detected using an ECL chemiluminescence kit (Amersham) with 
Kodak X-OMAT autoradiograph film.   
Stripping antibodies from Hybond-ECL membranes 
   
After Western blotting the Hybond-ECL membrane was stored in PBS 
supplemented with 0.05% (v/v) Tween-20 at 4oC.  To remove the antibodies the 
Western blot was immersed in a solution containing 100 mM β-mercaptoethanol, 
2% SDS and 2.5 mM Tris HCl pH 6.0 and incubated at 55oC for 1 h with gentle 
shaking.  The membrane was then washed extensively in wash buffer at RT.  
2.2.19 GST-fusion protein expression and GST pull-down assay  
2.2.19.1 Induction of GST-UL36CBD and GST proteins expressed in E. 
coli BL21  
E. coli BL21 cells were transformed (Section 2.2.5.4) with either the GST 
expression plasmid, pGEX-2TNMCR (Section 2.1.9), or the recombinant pGEX-
2TNMCR plasmid containing the pUL36 capsid binding domain (UL36cbd), pGEX-
UL36cbd (Section 7.1.1).  Single colonies were selected from the recombinants 
obtained and inoculated into 10 ml of L-broth, supplemented with 100 μg/ml 
amp.  After the samples had been incubated overnight at 37oC, a 2.5 ml aliquot 
from each culture was inoculated into 250 ml of amp containing L-broth and the 
bacterial suspensions were incubated at 37oC in the oribital shaker at 225 rpm 
until the OD600 reached 0.4-0.6.  At this point 1ml of each culture, representing 
the uninduced sample, was removed and stored at 4oC for further analysis by 
SDS-PAGE.  Expression of the GST-fusion proteins was induced in the remainder 
of each culture by the addition of IPTG to a final concentration of 0.2 mM.  After 
the induced cultures had been incubated for 3 h at 37oC, a 1 ml aliquot was 
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removed from each sample and stored at 4oC for further analysis.  The 
remainder of each culture was used for protein purification (Section 2.2.19.2).  
The 1 ml uninduced and induced samples were removed from 4oC storage and 
centrifuged at 13000 rpm for 5 min at RT.  The bacterial pellets were 
resuspended in 100μl of 10mM TrisHCl pH8.0 and 5μl of each sample was 
resolved by SDS-PAGE (Section 2.2.18.1).    
2.2.19.2 Purification of GST-UL36CBD and GST proteins from E. coli 
BL21  
The induced bacterial culture retained for protein purification (Section 2.2.19.1) 
was centrifuged at 5000 rpm in a SORVAL RC 5B Plus for 10 min at 4oC.  After 
centrifugation the bacterial pellet was resuspended in 2.5 ml of sonication 
buffer (Section 2.1.11) and placed on ice.  Subsequently, the bacterial cells 
were lysed by sonication using a Branson sonifier 450 soni-probe, with the 
machine giving five 15 sec bursts set at 90% intensity.  Following sonication the 
sample was centrifuged in a SORVAL RC 5B Plus at 6000 rpm for 30 min at 4oC, 
and the supernatant was retained for analysis.  The pellet was resuspended in 
sonication buffer and the sample was resonicated for two 15 sec bursts at the 
same intensity as before.  The cell debris was subsequently removed by 
repeating the previous centrifugation step.  The supernatants obtained were 
pooled and were clarified further by centrifugation at 30000 rpm for 30 min at 
4oC in TLA 100.2 rotor using a BECKMAN TL-100 ultra centrifuge.  The 
supernatants containing the soluble GST-UL36CBD or GST protein extracts were 
divided into 500μl aliquots, frozen on dry ice and stored at –70oC until required.      
2.2.19.3 GST pull-down assay 
Aliquots of 200 μl of either the GST or GST-UL36cbd protein extracts (bait 
proteins) or the target protein extracts expressing the wt pUL25 or mutant UL25 
proteins, which were prepared as described in Section 2.2.12.5, were mixed 
with 400 μl of Triton 1X buffer (Section 2.1.11).  Gluthathione-Sepharose 4B 
beads were rehydrated in PBS-A to make a 1:1 (v/v) slurry according to the 
manufacturer’s instructions (GE Healthcare) and 50 μl of the suspension was 
added to each sample and mixed by rotation for 1.5 h at 4oC.  The samples were 
then centrifuged at 13000 rpm for 30 sec at 4oC.  The beads that had been 
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incubated with the bait protein extracts were retained and washed three times 
with 100 μl of Triton 1X buffer.  After each wash the beads were concentrated 
by centrifugation as described above.   The washed beads were resuspended in 
100 μl of Triton 1X buffer and each sample transferred to a fresh 1.5 ml reaction 
tube.  The beads were again concentrated by centrifugation and the supernatant 
discarded.  Beads that had been incubated with the target protein extracts were 
discarded but the supernatants were retained.  This procedure was used to pre-
clear the target protein lysates of any aggregated or insoluble proteins that 
could bind non-specifically to the bait-bound beads.  A 300 μl volume of the pre-
cleared target protein extract was added to the tubes containing the bait-bound 
beads, and the samples were mixed by rotation at 4oC for 1.5 h.  The beads were 
pelleted by centrifugation at 13000 rpm for 30 sec at 4oC, washed three times in 
750 μl of Buffer A (Section 2.1.11).  The beads were concentrated by 
centrifugation and the supernatant discarded.  A volume of 40 μl of Triton 1X 
buffer was added to each sample together with 10 μl of 3X boiling mix prior to 
storage of the samples at –20oC.  Before the samples were loaded onto an SDS-
polyacrylamide gel they were heated to 100oC for 3 min to elute the bound 
proteins, and the beads were removed by centrifugation at 13000 rpm for 1 min 
at RT.  A 25 μl aliquot of each supernatant was loaded onto an SDS-
polyacrylamide gel and the presence of a particular protein was detected by 
Western blot analysis (Section 2.2.18.2).     
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3 Generation of the HSV-1 UL25 deletion mutant 
ΔUL25MO 
3.1 Introduction 
An existing HSV-1 UL25 null virus, KUL25NS (McNab et al., 1998), which was 
constructed by the insertion of an in-frame stop codon in the UL25 open reading 
frame, was available at the beginning of this study (Figure 3.1).  However, the 
problem with KUL25NS is that during complementation assays recombination can 
occur between the UL25 sequences in KUL25NS and the UL25 sequences present 
in the expression plasmid, resulting in the production of wt progeny.  The 
presence of wt virus among the progeny makes it difficult to distinguish between 
non-functional mutant constructs and those that have a low level of activity.  To 
increase the sensitivity of the functional assay, an HSV-1 UL25 deletion mutant 
was generated using the Counter-Selection BAC Modification kit, supplied by 
Gene Bridges (Section 3.2).  This kit utilises homologous recombination in vivo in 
E. coli to introduce mutations into BACs, which are large stable genetic 
elements that are replicated in E. coli vectors and can harbour foreign DNA 
sequences of up to 300 kb.  The BAC used in this study (fHSVΔpac) has the cm 
resistance gene, ensuring the BAC is maintained in the E. coli host strain DH10B 
in the presence of chloramphenicol, and contains a mutant HSV-1 strain 17 syn+ 
genome lacking the packaging signals.  The mutated HSV-1 containing BAC was 
transfected into UL25-expressing 8-1 cells together with the a sequence to 
generate the HSV-1 UL25 deletion virus ΔUL25MO.     
3.2 The Counter-Selection BAC Modification technique  
3.2.1 Red/ET recombination 
Conventional methods of DNA cloning and manipulation rely on the use of 
restriction enzymes and DNA ligases to construct novel combinations of DNA 
molecules in vitro.  Restriction enzymes generally cut on average about every 
250-4000 bp, limiting manipulations to only short segments of DNA.  Rare cutting 
enzymes are available which can produce fragments of up to approximately 50 
CTAGACTAGTCTAG
UL US48
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3
50
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5
UL25
E S
UL25 ORF
N
SpeI linker
Figure 3.1 Strategy used by McNab et al. (1998) to create a UL25 null mutant
The HSV-1 genome is shown at the top with long and short unique region 
sequences labelled as UL and US, respectively.  Below, the 6,282 bp EcoRI (E) - 
SnaBI (S) fragment is expanded, which contains the UL25 ORF specified by 
sequences 48,813 to 50,555.  This fragment was cloned into a vector and the single 
NotI (N) site present was converted to a SpeI site by insertion of a 14 bp linker.  The 
linker contained stop codons in all three reading frames.  The NotI site is located at 
codon 104 of the UL25 ORF,  therefore insertion of the SpeI linker would terminate 
translation of UL25 at this point (adapted from McNab et al., 1998).
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kb, but ligating these in vitro is difficult.  The advent of PCR reduced the 
reliance on restriction enzymes but amplifying pieces of DNA larger than 10 kb is 
difficult, and the technique also suffers from poor fidelity that becomes more 
significant the larger the sequence being amplified.  The Counter-Selection BAC 
Modification procedure was designed to address some of the limitations by using 
the Red/ET recombination system, which is also referred to as lambda-mediated 
recombination.  Red/ET recombination relies on homologous recombination in 
vivo in E.coli strains that express the phage-derived protein pair, Redα and 
Redβ, an exonuclease and DNA annealing protein, respectively.  A functional 
interaction between Redα and Redβ is necessary for the proteins to catalyse the 
homologous recombination event, which is illustrated in Figure 3.2.  This process 
is assisted further by the lambda encoded Gam protein that inhibits the RecBCD 
exonuclease activity of E.coli.  The advantage of this approach is that a range of 
modifications, such as insertions, deletions or substitutions, can be precisely 
introduced at any target site as the regions of homology can be chosen freely in 
DNA molecules of any size.  Since the recombination event is carried out in vivo, 
it is considered inherently more accurate than PCR, because the endogenous 
proofreading and repair machinery of E. coli are constantly monitoring the 
process.   
3.2.2 RpsL-neo counter-selection system 
The technique relies on the rpsL gene, which encodes the S12 ribosomal protein, 
and stp selection.  Bacterial resistance to high concentrations of stp is the result 
of recessive mutations in the rpsL gene.  However, if both the wt and mutant 
alleles of rpsL are expressed in the same strain of E. coli, the strain is sensitive 
to stp (stpS).  The rpsL-neo counter-selection cassette (Figure 3.3) used in the 
BAC modification procedure exploits this feature by introducing the wt rpsL gene 
and hence conferring stpS to the host bacteria that were previously stpR.  An 
additional antibiotic marker, km, is also carried on the rpsL-neo cassette and 
consequently both positive and negative drug selection markers are introduced 
into the host. 
Double-stranded break
Redα = 5'        3'
'                    exonuclease
Redβ =  Single stranded 
              binding protein
Joint molecule formation
DNA replication
Figure 3.2  Red/ET recombination
A functional interaction between Redα and Redβ is required to catalyse 
the homologous recombination event.  The double-stranded break (DSB) 
is initiated by the protein pair.  First, Redα digests one strand of the DNA 
from the DSB, leaving the other strand as a 3' ended single-stranded 
DNA overhang.  Redβ then binds to and coats the single-stranded DNA 
and then aligns with homologous DNA.  Once the protein-nucleic acid 
f i lament is  a l igned i t  acts as a pr imer for  DNA repl icat ion.   The 
recombination enzymes can be expressed from the plasmid pRed/ET and 
are therefore transferrable to any E.coli strain (adapted from the Counter-
Selection BAC Modification manual, version 2.4, June 2005). 
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Figure 3.3 A schematic representation of the rpsL-neo counter-selection cassette 
 
Counter-Selection BAC Modification is essentially a two-step approach.  In the 
first step the rpsL-neo cassette (rpsL-neo) flanked by homology arms is inserted 
by a Red/ET mediated recombination event into the target DNA, conferring 
kmR/stpS onto the host bacteria.  In the second step the counter-selection 
cassette is replaced with markerless (non-selectable) DNA using Red/ET 
recombination, and the host bacteria containing the markerless DNA are 
identified by their kmS/stpR.  The recombination events are initiated in the host 
bacteria after transformation with the Red/ET expression plasmid, pRed/ET, 
which is shown in Figure 3.4.  This plasmid carries the genes specifying the 
recombination proteins Redα and Redβ that are under the control of the 
arabinose-inducible pBAD promoter and also contains the tet resistance marker, 
conferring tet resistance (tetR) to the host cell.  The experimental approach 
used is summarised in Figure 3.5 and the methods employed are described in 
detail in Section 2.2.8.   
For the counter-selection technique to work it is important that the E.coli strain 
used in the procedure carries a mutated rpsL gene and consequently is stpR.  
Prior to using the Counter-Selection BAC Modification kit, DH10B bacteria 
carrying the HSV-1 BAC were plated onto L-broth agar supplemented with stp, 
cm, km or tet to verify they were indeed stpR, cmR, kmS and tetS.  Subsequently, 
the DH10B bacteria were transformed with pRed/ET and grown at 30oC in order 
to maintain the temperature sensitive plasmid within the host cells.  To induce 
expression of the Redα and Redβ genes from the pRed/ET plasmid in DH10B cells 
L-arabinose was added to the bacterial culture and the incubation temperature 
was shifted from 30oC to 37oC.    
Figure 3.4 Map of Red/ET expression plasmid pRed/ET  
The plasmid carries the lambda red alpha and beta genes that 
express the Red/ET recombination proteins, which together with 
the gam and recA genes are located in a polycistronic operon 
under the control of the inducible promoter pBAD.  Expression of 
the Red/ET recombination proteins is induced by L-arabinose 
activation of pBAD at 37oC.  The pBAD promoter is both positively 
and negatively regulated by the product of the araC gene.  AraC is 
a transcriptional regulator that forms a complex with L-arabinose 
and allows transcription to begin.  In the presence of glucose, or 
the absence of arabinose, transcription is blocked by the AraC 
dimer.
Figure 3.5 Flow diagram of the experimental outline for the generation of the UL25 null   
HSV-1 BAC 
(A) The E. coli strain DH10B carrying the HSV-1 BAC (fHSVDpac) was transformed with the 
expression plasmid pRed/ET.  The chloramphenicol marker (cm) highlighted in brown is 
shown on the HSV-1 BAC together with the homology regions (hm) highlighted in blue.   The 
expression of genes mediating Red/ET recombination was induced by the addition of L-
arabinose and a temperature shift from 30oC to 37oC.  
(B) Following induction of the Red/ET recombination enzymes, step 1 of the Counter-
selection BAC Modification technique was carried out.  The bacteria were prepared for 
electroporation and the linear rpsL-neo counter-selection/selection cassette (rpsL-neo-PCR1 
PCR product) flanked by HSV-1 homology arms (shown in blue) was electroporated into the 
bacteria.  Red/ET recombination inserts the functional cassette into the target locus in the 
fHSVDpac BAC.  Only colonies carrying the modified BAC will survive km selection and will 
also become stpS.
(C) Following selection of kmR/stpS colonies and verification that they contained a modified 
BAC, step 2 of the Counter-selection BAC Modification technique was performed.  The 
expression of genes mediating Red/ET was induced by the addition of L-arabinose and a 
temperature shift from 30oC to 37oC, after which the bacterial cells were prepared for 
electroporation.  The non-selectable DNA fragment (Non-sm) consisting of sequences from 
the right and left homology arms of the selection cassette was electroporated.  Red/ET 
recombination should replace the rpsL-neo-PCR1 selection/counter-selection cassette with 
the markerless Non-sm fragment.  Only colonies that have lost the cassette will grow on stp 
containing plates and will also be kmS.  
L-arabinose
30oC to 37oC
PCR product
rpsL-neo-PCR1
non-selectable overlapping 
oligonuleotide (Non-sm)
L-arabinose
30oC to 37oC
+
+
A
B
C
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3.2.3 Generation of the rpsL-neo counter selection cassette 
flanked by homology arms (rpsL-neo-PCR1) 
To target the UL25 gene of fHSVΔpac, a PCR product (rpsL-neo-PCR1) that 
contained the rpsL-neo counter-selection cassette flanked by sequences 
homologous to 50 bp immediately upstream and downstream of the UL25 ORF 
was generated.  The 1.4 kb rpsL-neo-PCR-1 fragment was produced using the 
forward primer PRC1-For and the reverse primer PRC1-Rev (Table 3.1) and 
amplified from the rpsL-neo DNA template supplied by the manufacturer using 
the PCR-cycle1 conditions described in Section 2.2.1.2.  The purified 1.4 kb rpsL-
neo-PCR-1 PCR product obtained is shown in Figure 3.6.   
3.2.4 Step 1 - insertion of rpsL-neo-PCR1 into fHSVΔpac  
Following incubation at 30oC overnight, DH10B bacteria containing fHSVΔpac 
that had been transformed with the pRed/ET expression plasmid (Section 
2.2.8.1), and control cells consisting of E.coli strain HS996 that contained a 
control BAC (pBeloBAC11) and pRed/ET, were divided into two aliquots. One 
bacterial suspension from each E. coli strain was induced by the addition of 
arabinose to express the genes mediating Red/ET recombination, while the other 
bacterial suspension acted as a control and remained uninduced.  To allow 
expression of the genes mediating the Red/ET recombination enzymes, the 
induced and uninduced samples were incubated at 37oC for 45-60 min (Section 
2.2.8.1).  Step 1 of the BAC modification procedure was initiated by 
electroporating the purified 1.4 kb rpsL-neo-PCR-1 PCR product into the induced 
and uninduced DH10B cells.  In addition, the induced and uninduced aliquots of 
HS996 cells were transformed with an rpsL-neo PCR product that had 
complementary sequences to pBeloBAC11 and was supplied by Gene Bridges.  
Following transformation of DH10B and HS996 with their respective rpsL-neo PCR 
products the induced and uninduced bacterial suspensions were subsequently 
divided into two further aliquots, representing the recombinant and non-
recombinant samples.  To allow recombination of the rpsL-neo PCR product into 
the BAC DNA contained in the host cell, the recombinant samples from each 
bacterial strain were incubated at 37oC for 70 min, while the non-recombinant 
control samples were stored on ice.  A summary of the experimental outline and 
 
 
 
 
Primer ID Primer Sequence 
PCR1-For 5’-GACAACGACCGCAGTTCTCGTGTGTTATTTTCGCTCTCCGCCTCTCGCAGGGCCTGGTGATGATGGCGGGATCG-3’ 
PCR1-Rev 5’-TCTTGTTTTTTCTCCCTAATGCCCCCTCCCCCCTCGCCCACCACCCACTATCAGAAGAACTCGTCAAGAAGGCG-3’ 
Non-smF 5’-GCAGTTCTCGTGTGTTATTTTCGCTCTCCGCCTCTCGCAGΔTAGTGGGTGGTGGGCGAGGGGGGAGGGGGCATTAGGGAGA-3’ 
Non-smR 5’-TCTCCCTAATGCCCCCTCCCCCCTCGCCCACCACCCACTAΔCTGCGAGAGGCGGAGAGCGAAAATAACACACGAGAACTGC-3’ 
 
 
Table 3.1 Oligonucleotides used to generate the DNA fragments required for the Counter-Selection BAC Modification procedure  
The PCR primers, PCR1-For and PCR1-Rev, were used to generate rpsL-neo-PCR1 and contained 50 bp of HSV-1 homology directly upstream and downstream of the 
UL25 ORF and 24 bp of homology to the rpsL-neo cassette template (highlighted in red).  The complementary oligonucleotides Non-smF and Non-smR were annealed to 
produce the non-selectable overlapping oligonucleotide, Non-sm.  The symbol Δ represents the deleted UL25 ORF sequences.   
 
0.5 kb
1.0 kb
1.5 kb
2.0 kb
3.0 kb
0.5
  µ
l
1  
µl
2  
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rpsL-neo-PCR1 fragment
Figure 3.6  Gel photograph showing the purified rps-neo-PCR1 PCR 
product
0.5, 1 and 2 µl aliquots of the purified 1.4 kb rpsL-neo-PCR1 product were 
run on a 1% TAE gel to determine the purity and concentration of the 
fragment obtained.  Band sizes were estimated using a 1 kb DNA ladder 
(New England Biolabs), the sizes of the bands upto 3.0 kb are shown on the 
left of the diagram. 
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the bacterial samples generated are illustrated in Figure 3.7.  Following 
incubation, the DH10B and HS996 induced and uninduced recombinant and non-
recombinant samples were plated onto L-broth agar containing tet/cm/km.  As 
expected, the uninduced recombinant and non-recombinant bacterial samples 
remained kmS, reflecting the presence of an unmodified BAC in DH10B and HS966 
cells.  The efficiency of Red/ET recombination in the procedure is determined 
by the ratio of recombinant to non-recombinant kmR colonies produced by the 
induced bacterial suspensions during the experiment.  The observed frequency 
was close to the expected frequency of 100 recombinant: 1 non-recombinant 
colony per plate, signifying that the majority of induced recombinant E.coli 
isolates had successfully undergone Red/ET recombination.  To verify the 
fidelity of the amplified rpsL-neo-PCR1 product present in the induced 
recombinant bacteria and to confirm that the bacteria were kmR/stpS, fifteen 
kmR DH10B colonies were selected for replica plating onto L-broth agar plates 
containing either tet/cm/km or tet/cm/stp.  Included in the screen were five 
colonies of the kmR HS996 bacteria that were predicted to contain a modified 
BAC, and two kmS DH10B bacteria containing unmodified BACs.  The results, 
shown in Table 3.2, revealed that only one of the kmS DH10B colonies was also 
stpR and therefore contained an unmodified BAC.  However, the results 
confirmed that nine of the recombinant DH10B and three of the recombinant 
HS996 colonies selected were kmR/stpS and therefore contained fully functional 
rpsL-neo cassettes.   
3.2.5 Verification of the modified HSV-1 BAC by Southern blot 
analysis 
To confirm that the rpsL-neo-PCR1 product was inserted at the correct location 
within the modified fHSVΔpac BACs, DNA was prepared from each of the nine 
kmR/stpS DH10B clones and digested with BamHI.  The BamHI fragments were 
separated on an agarose gel and analysed by Southern blotting.  The DNA bound 
to nylon membrane was probed with the 32P-radiolabelled rpsL-neo-PCR1 
fragment to detect any rpsL-neo-PCR1 sequences present in the modified BAC 
DNAs.  The expected BamHI restriction digest patterns of the modified and 
unmodified HSV-1 BACs were obtained using Vector NTi software (Invitrogen).  
The digested wt HSV-1 or HSV-1 BAC DNA contains the 2,294 bp BamHI U 
      E. coli
DH10B/HS996
Induced uninduced 
recombinant recombinantnon-recombinant non-recombinant
Red/ET expression
A
B
C
37oC 37oC4oC 4oC
L-broth agar containing
tet/cm/km
incubated for 
70 mins
D
+ 
rpsL-neo product
+ 
rpsL-neo product
Figure 3.7 DH10B and HS966 samples generated during Step 1 of the 
Counter-Selection BAC Modification procedure
(A) Bacterial cultures of E. col i  strains DH10B and HS966, each 
containing their respective BACs and pRed/ET, were grown at 30oC 
overnight and then divided into two aliquots.  (B) Expression of the genes 
mediating Red/ET expression were ‘induced’ in one of the bacterial 
suspensions by the addition of arabinose, while the control cells remained 
‘uninduced’.  Both bacterial suspensions were then incubated at 37oC for 
45-60 min to allow expression of the Red/ET recombination enzymes and 
then electroporated with their respective rpsL-neo PCR products as 
indicated.  (C) The induced and uninduced bacter ia l  cel ls were 
subsequently divided into two further al iquots, representing the 
recombinant and non-recombinant samples for each strain.  The 
recombinant samples for induced and unin-duced DH10B and HS966 
were incubated at 37oC for 70 min, while the non-recombinant bacterial 
suspensions for the induced and uninduced samples were stored on ice 
for 70 min.  (D) After incubation each bacterial culture was plated onto L-
broth agar containing tet/cm/km.
Step 1 Results Modified BAC 
Colony stpR kmR kmR/ stpS  
Recombinant DH10B Colonies 
1 + +  
2 - + Positive  
3 - -  
4 + +  
5 - + Positive 
6 - + Positive 
7 - -  
8 - + Positive 
9 - -  
10 - + Positive 
11 - + Positive 
12 - + Positive 
13 + +  
14 - + Positive 
15 - + Positive 
Recombinant HS996 Colonies 
1 - + Positive 
2 - + Positive 
3 - -  
4 - -  
5 - + Positive 
Non-recombinant DH10B Colonies 
1 + -  
2 - -  
 
 
Table 3.2 Counter-Selection BAC Modification Step 1 results for DH10B and HS996 cells 
with modified BACs 
  
The table shows DH10B and HS996 clones obtained after replica plating them onto L-broth agar 
containing either kanamycin or streptomycin after Step 1 of the BAC Modification Counter-
Selection procedure.  The bacterial colonies that screened positive for kanamycin resitance (kmR) 
and streptomycin sensitivity (stpS) are ones that contained a modified BAC with the functional rpsL-
neo-PCR1 product. 
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fragment (nucleotide sequences 48,635-50,929) spanning the UL25 gene of the 
HSV-1 strain 17 syn+ genome  (McGeoch et al., 1988).  When the rpsL-neo-PCR1 
product is recombined in this region of the HSV-1 genome, two BamHI 
fragments, 1,873 bp and 863 bp, are obtained instead of the wt BamHI 2,294 bp 
fragment.  A representative phosphorimage of a Southern blot is shown in Figure 
3.8.  Lanes 1-3 of the image, containing the BamHI-digested unmodified BAC 
DNA control (kmS/stpR DH10B) samples, show the expected 2,294 bp BamHI U 
fragment, whereas the remaining lanes (4-13) display the profiles of BamHI-
digested modified BAC DNAs.  Lane 4 of the Southern blot contains the positive 
control consisting of digested kmR/stpS HS996 modified BAC DNA, which shows 
the expected BamHI fragment of 8,907 bp generated by the insertion of the 
rpsL-neo PCR product. Lanes 5-13 of the Southern blot contain digested BAC DNA 
preparations from the nine recombinant kmR/stpS DH10B clones.  Although the 
BamHI 1,873 bp fragment was present in all nine kmR/stpS DH10B samples, it was 
most clearly visible in lanes 6 (clone 14), and 9-13 (clones 10, 8, 6, 5 and 2, 
respectively).  Lane 9, 10 and 13 also contained a BamHI U fragment, which is 
most clearly visible in lane 13, indicating that these samples had a mixture of 
both modified and unmodified BAC DNAs.  However, the presence of the BamHI 
1,873 bp fragment and the absence of the BamHI U fragment in the remaining 
samples suggest that these BACs contain the inserted rpsL-neo-PCR1 cassette 
with the concomitant deletion of the UL25 ORF.  
3.2.6 Generation of the non-selectable DNA product (Non-sm) 
In the second stage of the Counter-Selection procedure the rpsL-neo cassette in 
the BAC is replaced with the non-selectable DNA.  Two complementary 
oligonucleotides, Non-smF and Non-smR (Table 3.1), were annealed (Section 
2.2.1.3) to produce the non-selectable, or markerless, product Non-sm.  The 80 
bp Non-sm fragment contains HSV-1 sequences present in the right and left HSV-
1 homology arms of the rpsL-neo-PCR1 product to allow insertion by homologous 
recombination of the annealed overlapping oligonucleotide into fHSVΔpac, with 
the concomitant excision of the rpsL-neo-PCR1 cassette, to produce an HSV-1 
BAC lacking the UL25 ORF.  
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Figure 3.8  Southern blot of BamHI digested BAC DNAs from Step 1
The phosphorimage shows the BamHI digested BAC DNA samples from 
Step 1 of the Counter-Selection BAC Modification procedure.  Lane 1 is 
a negative control of an unmodified HSV-1 BAC from a DH10B clone.  
Lanes 2 and 3 are negative controls of an unmodified HSV-1 BAC from 
kmS/stpR DH10B clones.  Lane 4 is a positive control of a modified BAC 
containing a rpsL-neo cassette from the kmR/stpS HS996 colony 1 
(Table 3.2).  Lanes 5-13 are the recombinant kmR/stpS DH10B clones 
listed in Table 3.2, with the colony numbers for each clone indicated 
above the lanes.  The position of the 2,294 bp BamHI U fragment is 
indicated.
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3.2.7 Step 2 - replacing the rpsL-neo-PCR1 cassette with the non-
selectable (Non-sm) DNA in fHSVΔpac  
The second stage of the procedure was initiated by the addition of L-arabinose 
and induction of the Red/ET proteins in kmR/stpS modified BAC containing DH10B 
samples 11 and 12 and the control kmR/stpS HS996 samples 1 and 5 (Table 3.2).  
Subsequently, electrocompetent DH10B were transformed with the annealed 
overlapping oligonucleotide Non-sm (Section 2.2.1.3), and the electrocompetent 
HS996 were transformed with a BAC-repair oligonucleotide (Gene Bridges) 
designed to replace the rpsL-neo product inserted in the modified pBeloBAC11.  
Each transformed E. coli strain was divided into two aliquots with one 
representing the recombinant sample, which was incubated at 37oC to allow 
Red/ET recombination to proceed, and the other representing the non-
recombinant sample, which was retained on ice.  Following incubation for 70 
minutes the recombinant and non-recombinant samples from each bacterial 
strain were plated onto L-broth agar containing tet/cm/stp and the results are 
shown in Table 3.3.   
 
Bacterial colonies per plate  
Step 2  
Recombinant (StpR)  Non-recombinant  (StpR) 
Ratio 
(Rec:Non) 
DH10B  
11 1.5 x 105 9.0 x 103 16:1 
12 1.6 x 104 1.5 x 103 10:1 
HS996  
1 9.2 x 103 8.0 x 102  11:1 
5 1.0 x 104 9.0 x 102 11:1 
Table 3.3 The ratio of DH10B and HS996 recombinant:non-recombinants colonies obtained 
in step 2 of the Counter-Selection BAC Modification procedure  
 
As in step 1 of the technique, a high ratio of about 100 recombinant: 1 non-
recombinant colonies is indicative of efficient Red/ET recombination.  The 
frequency of recombination observed was lower than expected for both the 
experimental and control samples tested.  At this stage of the procedure 
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successful Red/ET recombination should result in the removal of the inserted 
rpsL-neo PCR product present in the host’s modified BAC and its replacement 
with the non-selectable DNA fragment.  Positive bacterial recombinants are 
selected on the basis of being kmS/stpR.  The antibiotic integrity of two of the 
stpR DH10B and two of the HS966 recombinants obtained in step 2 (Table 3.3) 
was tested by replica plating them onto to L-broth agar containing either 
tet/cm/km or tet/cm/stp.  Unexpectedly, the stpR DH10B and HS996 colonies 
tested had acquired dual drug resistance and were both kmR and stpR.  Additional 
attempts to obtain the desired recombinants at this stage produced the same 
results.  
3.3 Construction of ΔUL25MO and its marker rescuant 
MRUL25MO  
3.3.1 ΔUL25MO 
Results from the Southern blot analysis of the modified fHSVΔpac DNA (Section 
3.2.5) revealed that the rpsL-neo-PCR1 cassette was present, replacing the UL25 
ORF, and confirming that an HSV-1 UL25-deleted BAC had been created.  
Column-purified BAC DNA was prepared from E. coli carrying one of the modified 
BACs analysed by Southern blotting (lanes 6 in Figure 3.8, colony 14 from Table 
3.2) and transfected together with the HSV-1 BamHI K fragment, which was 
added to repair the deleted a sequences encoding the Pac signals in the 
modified fHSVΔpac, into UL25 expressing 8-1 cells.  Three of the viral plaques 
that formed were plaque-purified and each of their viral titres was determined 
as outlined in Section 2.2.4.  The stock with the highest titre was selected and 
subsequently referred to as ΔUL25MO.  The yield of ΔUL25MO was compared to 
KUL25NS, the original HSV-1 UL25 null mutant, by infecting 8-1 cells with virus 
at MOI of 5 PFU/cell.  After incubation for 24 hrs at 37oC the cells were 
harvested and the progeny virus was titrated on complementing (8-1) and non-
complementing (Vero) cells.  As expected, ΔUL25MO and KUL25NS both failed to 
form plaques on Vero cells.  In the complementing cells, although the size of the 
plaques obtained for both HSV-1 UL25 mutants were similar, ΔUL25MO produced 
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a yield that was approximately ten-fold lower than KUL25NS (Table 3.4).  The 
experiment was repeated twice more and the results produced were similar.   
 
Yield of virus from 8-1 cells (PFU/ml) 
Virus  
Non-complementing cells (Vero) Complementing cells (8-1) 
ΔUL25MO  <102 5.0 x 107 
KUL25NS  <102  5.1 x 108 
 
Table 3.4 Growth of HSV-1 UL25 null viruses on non-complementing and complementing 
cells 
A complementation assay (Section 2.2.7) was carried out to determine how well 
transiently expressed wt UL25 protein (pUL25) complemented the growth of 
ΔUL25MO and KUL25NS.  Vero cells were transfected with either the wt UL25 
expressing recombinant plasmid (pFB-UL25) or the empty vector control (pFBpCI) 
and subsequently infected with ΔUL25MO or KUL25NS at an MOI of 5 PFU/cell.  
At 24 hpi the cells were harvested and the progeny viruses were titrated on Vero 
and 8-1 cells.  The results obtained are shown in Table 3.5 and are the average 
of three independent experiments.  The progeny virus from ΔUL25MO-infected 
Vero cells expressing wt pUL25 did not form plaques on Vero cells, whereas some 
of the progeny from KUL25NS-infected Vero cells expressing wt pUL25 produced 
plaques on the non-complementing cells.  Furthermore, the total yield of virus 
from ΔUL25MO-infected Vero cells expressing wt pUL25 on 8-1 cells was 
approximately ten-fold higher than that obtained from KUL25NS-infected Vero 
cells expressing pUL25.   
Yield of virus (PFU/ml) 
Virus Plasmid 
Vero cells 8-1 cells 
pFBpCI < 101 (+/- 0.6) < 101  (+ /- 1.0) 
KUL25NS 
pFB-UL25 2.6 x 101 (+ /- 0.3) 4.6 x 105 (+/- 1.1) 
pFBpCI < 101  (+ /- 0) < 101  (+ /- 0) 
ΔUL25MO 
pFB-UL25 < 101  (+ /- 0) 3.3 x 106 (+/- 1.3) 
 
 
Table 3.5 Complementation efficiencies of HSV-1 UL25 null viruses 
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3.3.2 MRUL25MO 
To confirm that there were no secondary mutations in the ΔUL25MO genome 
that affected its viability, a marker rescuant of the virus was generated.  The 
plasmid pGX292 was digested with BamHI to release the HSV-1 strain 17 syn+ 
BamHI U fragment (nucleotide sequences 48,635-50,929), which contains the 
entire UL25 ORF (McGeoch et al., 1988).  Marker rescue of the deleted UL25 
sequences in ΔUL25MO is obtained by homologous recombination between the 
complementary sequences of the HSV-1 BamHI U fragment and the ΔUL25MO 
genome.  Vero cells were seeded into a well of a 24-well dish (Section 2.2.7.1) 
and transfected with BamHI-digested pGX292 and subsequently infected with 5 
PFU/cell of ΔUL25MO (Section 2.2.7.3).  After 24 h at 37oC the cells were 
harvested and the ability of the progeny virus to grow on Vero cells was 
determined.  A single well-isolated plaque was picked and the virus was plaque 
purified (Section 2.2.9) twice on Vero cells prior to the production of a high titre 
stock of the marker rescuant virus, which was referred to as MRUL25MO.  To 
compare the growth characteristics and phenotypes of ΔUL25MO, MRUL25MO and 
wt HSV-1, the yield of the viruses were compared in duplicate on complementing 
and non-complementing cells grown on 35 mm tissue culture dishes.  Each of the 
cell monolayers were infected with 10 PFU/cell of wt HSV-1, ΔUL25MO or 
MRUL25MO virus and incubated at 37oC.  After 1 h, the cells were treated with 
acid to remove residual input virus (Section 2.2.7.4) and then overlaid with 
supplemented DMEM and incubated at 37oC.  At 24 hpi the cells were harvested 
and the progeny viruses were titrated onto 8-1 cells (Table 3.6).  HSV-1 and 
MRUL25MO grew to comparable levels on permissive and non-permissive cells, 
confirming that the marker rescuant contained no deleterious secondary 
mutations.  As expected, ΔUL25MO grew on 8-1 cells but failed to grow on Vero 
cells, confirming that the mutation is lethal for growth.   
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Yield of virus on 8-1 cells (PFU/ml) 
 
Virus  
Growth in Vero cells Growth in 8-1 cells 
wt HSV-1  5.7 x 108 4.9 x 108 
MRUL25MO 3.3 x 108  2.25 x 108 
ΔUL25MO <101 4.0 x 108 
 
Table 3.6 Yield of HSV-1 viruses from non-complementing and complementing cells 
 
 
3.3.3 Single-step virus growth of HSV-1 viral stocks 
Replicate 35 mm tissue culture dishes of complementing cells were infected with 
10 PFU/cell of wt HSV-1, ΔUL25MO or MRUL25MO virus.  After 1 h at 37oC the 
cells were treated with acid wash and then overlaid with supplemented DMEM 
and incubated at 37oC.  At 3, 6, 12 and 24 hpi the cells were harvested and the 
progeny virus was titrated onto 8-1 cells.  The single-step growth analysis was 
performed only once, but demonstrated that ΔUL25MO and MRUL25MO exhibited 
similar growth patterns and grew to titres comparable to wt HSV-1 (Figure 3.9), 
indicating that no secondary mutations were contributing to the growth defect 
of ΔUL25MO.      
3.4 Discussion 
During the first step of the Counter-Selection BAC Modification technique no 
problems were encountered and the rpsL-neo selection/counter-selection 
cassette was readily inserted at the correct position in the HSV-1 fHSVΔpac 
genome.  Despite several attempts, I was unsuccessful in completing the second 
step of the procedure in which the inserted cassette is replaced with non-
selectable DNA that should result in the seamless deletion of the UL25 ORF in 
HSV-1 fHSVΔpac.  The inserted rpsL-neo cassette in the modified BACs of the 
host cells allows both positive and negative antibiotic selection of the 
recombinants obtained.  The cassettes are then replaced with the desired 
markerless DNA by a second recombination event and subsequent antibiotic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 Comparison of the growth of wt HSV-1, ΔUL25MO and MRUL25MO in 8-1 cells 
 
Single-step virus growth.  Replicate 35 mm dishes of complementing cells were infected with 10 
pfu/cell of HSV-1 strain 17 syn+, ΔUL25MO or MRUL25MO.  After 1 h at 37oC the cells were 
treated with acid to remove residual input virus and overlaid with supplemented DMEM and the 
incubation was continued at 37oC.  At 3, 6, 12 and 24 hpi the cells were harvested and the progeny 
virus were titrated onto 8-1 cells. 
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counter-selection to obtain stpR/kmS bacteria.  An inherent problem with the 
system used here appears to be the potential for spurious recombination events.  
Viral genomes contain a high number of repeated sequences and intramolecular 
recombination between them could result in the loss of the markers used in the 
system’s selection process (Tischer et al., 2006).  To ensure that the techniques 
for the system were being applied correctly, the manufacturer’s additional 
controls were included throughout the procedure.  However, the stpR 
recombinant colonies obtained in step 2 for both the DH10B and the control 
HS996 bacterial cells were shown to be stpR and kmR.  Subsequently, several 
colleagues using the same method encountered similar problems and also 
detected only stpR/kmR colonies at the second stage.  They also confirmed that 
non-specific recombination events were occurring in fHSVΔpac DNA.  Recent 
improvements to the technology by Tischer et al. (2006), in which the 
recombination event is targeted to specific sequences, has resulted in the 
successful production of mutated HSV-1 virus.  The difficulties encountered using 
the Counter-Selection BAC Modification system led to baculovirus vectors being 
used for subsequent functional analysis of the HSV-1 UL25 mutants generated.   
The ability of the UL25 expressing 8-1 cell line to complement the growth of 
ΔUL25MO suggested that no secondary mutations were contributing to growth 
defects of the mutant virus.  This was confirmed by single-step growth analysis 
on complementing cells, which showed that ΔUL25MO, MRUL25MO and wt HSV-1 
grew to comparable levels (Figure 3.8).  However, a ten-fold reduction in the 
yield of ΔUL25MO in comparison to the original HSV-1 UL25 null mutant KUL25NS 
was observed in 8-1 cells when the viral stocks were titrated on to 
complementing cells (Section 3.3).  The replication efficiency of ΔUL25MO might 
be compromised, since the virus was obtained from the HSV-1 BAC fHSVΔpac 
(Saeki et al., 1998) that lacks oriL.  In addition, the presence of the rpsL-neo 
cassette that replaces the UL25 ORF in the viral genome may also affect the 
viability of ΔUL25MO.  UL25 lies in a nested transcription region with UL26, a 
capsid maturation protease, and the transcription levels of UL26 may be 
affected as both UL25 and UL26 share 3’ co-terminal transcripts.  However, none 
of these possibilities seems likely, since the yield of ΔUL25MO from 
complementing cells was comparable to the yields observed for its marker 
rescuant, MRUL25MO, which were in turn similar to the yields obtained for wt 
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HSV-1 strain 17 syn+ (Table 3.6).  Alternatively, the disparity in yields observed 
between the two HSV-1 UL25 null mutants might be due to strain variations 
between the HSV-1 KOS derived KUL25NS and the HSV-1 strain 17 syn+ derived 
ΔUL25MO virus.  Although ΔUL25MO gave lower yields of virus in 8-1 cells in 
comparison to KUL25NS, it performed better in transient complementation 
assays than KUL25NS.  Since KUL25NS can produce a low level of wt virus as a 
consequence of recombination during complementation experiments, using 
ΔUL25MO increased the sensitivity of the assay making it easier to distinguish 
between non-functional and poorly complementing UL25 mutants.  
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4 Generation and complementation analysis of the 
mutant pUL25s  
4.1 Introduction 
As discussed previously (Section 1.4.1), Bowman et al. (2006) used both the 3D 
structural information and ET analysis of the N-terminally truncated version of 
pUL25 (residues 134-580) to identify four clusters of amino acids (C1-C4) on the 
surface of pUL25 that were predicted to be involved in protein-protein 
interactions.  Their study also revealed five looped out regions (L1-L5) 
containing unstructured residues, and three residues at the carboxyl terminus of 
pUL25 that were also disordered (L6).  The aim of the work described in this 
chapter was to relate the structure of pUL25 to its function by constructing a 
series of mutant UL25 genes and to characterise the expressed proteins.  
Specifically, amino acids within C1, C2, C3 and C4, were targeted as well as the 
unstructured residues in L1-L6.  Initially, residues mutated in C1, C2, C3 and C4 
were substituted with alanine. Since alanine is the smallest chiral amino acid, 
substitution with this residue will remove side-chain atoms that are present on 
the wt residue.  The observed effect of this removal during analysis is typically 
interpreted to indicate the contribution of the deleted side chain to the stability 
of any protein-protein interactions.  Alanine substitution is also considered to be 
a relatively conservative change due to the ambivalent nature of the amino acid.  
Since it is only slightly hydrophobic it can reside both inside and outside a 
protein molecule.  The codons of several residues within a cluster were mutated 
simultaneously to increase the probability of creating a functionally impaired 
pUL25.   
Although the amino acid sequence normally codes for the 3D structure of a 
protein, it may code for an entirely unfolded protein, or protein region, as 
indicated by the unstructured residues identified in the L1-L6 regions of pUL25.  
These disordered portions of a protein molecule are often highly flexible areas 
that are involved in molecular recognition.  To examine the functional roles of 
the unstructured portions of the molecule, a panel of deletion mutant proteins, 
pUL25-L1 – pUL25-L6, were generated that lacked the unstructured amino acids 
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of their particular regions.  Deletion mutants were created in preference to 
those with substitutions or insertions of additional amino acids at the disordered 
regions in order to increase the possibility of observing a phenotypic affect.  The 
absence of unstructured residues in a looped out region of the protein may 
compromise its flexibility and, as a consequence, affect the ability of pUL25 to 
interact with other proteins.  As well as an L6 mutant protein lacking the 
unstructured residues, an additional L6 mutant was constructed by substituting 
two of the three unstructured amino acids (S578 and V580) with alanine, since 
the wt residue at position 579 was alanine.    
To assess the functional impact of each of the mutant UL25 proteins generated, 
their ability to complement the growth of the HSV-1 UL25 null virus, ΔUL25MO, 
in non-permissive cells was examined.  Three deletion mutant proteins, 
pUL25Δ1-45, pUL25Δ1-59 and pUL25Δ1-133 were also included in the study to 
establish the significance of the uncrystallised portion of UL25 (residues 1-133).  
The plasmid constructs expressing these proteins were supplied by Dr V. Preston.   
4.2 Methods used for site-directed mutagenesis  
To create the mutated UL25 fragments, which were used to construct the 
mutant UL25 genes, either annealed complementary oligonucleotides were 
prepared or PCR was performed.  Convenient REN cloning sites, located 
upstream and downstream from the target residues, were included in the 
mutated fragments generated and used to transfer the sequences into the UL25 
gene.  If possible, additional REN sites were introduced by silent mutagenesis 
into the nucleotide sequence of the PCR primers or the complementary 
oligonucleotides.  These sites were useful for detecting plasmid constructs 
containing the mutated UL25 fragment.  The additional REN sites, which did not 
alter the protein sequence of the gene, were identified in the UL25 ORF using 
the Webcutter bioinformatics program (http://rna.lundberg.gu.se/cutter2/).  
When the distance between the cloning sites was less than 90 bp, overlapping 
oligonucleotides were prepared.  When the distance between the cloning sites 
was greater than 90 bp and the mutated residues were not sufficiently close to 
one of the cloning sites to amplify the required UL25 fragment in a single PCR, a 
two-step approach, referred to as overlap extension PCR (Ho, 1989), was used.  
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Summaries of the single-step and overlap extension PCR procedures are 
illustrated in Figure 4.1 and Figure 4.2, respectively. 
Dr. V. Preston had previously cloned the wt HSV-1 strain 17 syn+ UL25 ORF into 
pFBpCI to produce the recombinant plasmid, pFB-UL25 (Figure 4.3).  The pFB-
UL25 construct was used as the template DNA to generate and amplify the 
mutated UL25 fragments during PCR.  Each purified PCR product was subcloned 
into the pGEM-T Easy vector (Figure 4.4) and plasmid DNA was prepared from 
each of the isolates obtained.  The DNA samples containing UL25 inserts were 
identified with the appropriate REN digestion, and DNA sequencing with the M13 
DNA sequencing primers (Table 4.1) verified that the recombinant pGEM-T Easy 
DNAs contained the desired UL25 mutations.  To generate the recombinant 
plasmids, the purified PCR REN fragment from recombinant pGEM-T Easy plasmid 
or the annealed overlapping oligonucleotide was ligated to REN fragments from 
pFB-UL25.  The recombinant constructs produced, together with the mutated 
residues present in the UL25 gene, are listed in Table 4.2.  Prior to further 
analysis the entire UL25 mutant gene in each of the recombinant pFBpCI 
constructs was sequenced, using the DNA sequencing primers pFB-Forward and 
Reverse (Table 4.1), to confirm that each construct contained the expected 
UL25 nucleotide sequence with the desired alterations.  A summary of the 
cloning procedures used is illustrated in Figure 4.5.  In addition to containing the 
HCMV IE promoter that allows the expression of foreign proteins in mammalian 
cells, pFBpCI is also a baculovirus transfer vector.  This plasmid was selected on 
the basis that recombinant baculoviruses were required for subsequent 
experiments to investigate the DNA packaging and capsid assembly functions of 
the encoded mutant UL25 proteins (Section 5.2).   
4.3 Cluster mutants  
4.3.1 C1 mutant construct (pFB-UL25-C1) 
The nucleotide sequence that specifies three (R362, G363 and N365) of the nine 
residues in C1 is located between the REN sites DdeI (1100 bp) and NruI (1199 
bp) of pFB-UL25 (Figure 4.6).  A fragment was generated using the PCR primers 
C1-F that encoded the mutations R363A, G363A and N365A and the cloning site 
Figure 4.1  Site-directed mutagenesis by PCR
PCR is a cyclic process of double-stranded separation of the target DNA by heat denaturation, 
specific hybridisation or annealing of short oligonucleotide primers to the single-stranded DNA, and 
synthesis of double-stranded DNA by DNA polymerase (Saiki et al., 1985).  This process is 
illustrated in the boxed area of the diagram.  The full-length mutated DNA is amplified during 
subsequent amplification cycles to produce multiple copies of the fragment.  In site-directed 
mutagensis using PCR, the target gene is amplified using a flanking primer (Primer A) and a  
primer (Primer B), which overlaps the target area and contains the required mutation.  The primer 
pair are designed such that the amplified product can be REN digested and the full-length UL25 
gene reconstructed in a ligation reaction with vector and wt UL25 REN fragments.   
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Figure 4.2  Site-directed mutagenesis by overlap extension PCR
Two fragments of the target gene are amplified in two separate PCRs (PCR 1 and 2).  Both PCRs 
use a set of flanking (F1 and R2) and mutagenic primers (F2 and R1), with PCR 1 using the primer 
pair, F1 and R1, and PCR 2 using the F2 and R2 primers.  The fragments produced from each 
reaction contain a region of overlap where, in both products, the desired mutations are located.  
During PCR 3 the fragments from PCR 1 and 2 are mixed, denatured and annealed at the regions 
of overlap to form heteroduplexes that are extended, as indicated by the dashed lines, to form 
full-length double-stranded mutant DNA .  The full-length DNA is subsequently amplified during 
PCR 3 using the flanking primers, F1 and R2. 
mutated PCR product
PCR 3
F1
R2
amplifed
5'
5'3'
3'
F2
R2
5'
3' 5'
3'
pFB-UL25
8046 bp
HSV-1 sequences
pFBpCI
UL25 ORF
EcoRI (8)
Xba I (2147)
 
 
 
Figure 4.3 Plasmid map of pFB-UL25 
The green-hatched arrow represents the HSV-1 sequences inserted in the pFBpCI backbone, with 
the UL25 ORF denoted by the block green arrow.  The position of the unique REN sites, EcoRI and 
XbaI, are highlighted in red.  
 
 
 
 
 
Figure 4.4 pGEM-T Easy vector map
The position of the REN sites and the location of the ampicillin (Amp) gene, f1 origin of 
replication (f1 ori) and origin of replication (ori) are shown.  The broken arrow 
represents the site where the vector has been linearised with EcoRI and a T has been 
added to both 3’ ends (position 60 bp on the map) (adapted from Promega Technical 
Manual).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DNA Sequencing Primers 
pGEM-T Easy primers 
M13 Forward 5’-TCACACAGGAAACAGCTATGAC-3’ 
M13 Reverse 5’-CGCCAGGGTTTTCCCAGTCACGAC-3’  
pFB-UL25 primers 
pFB-Forward 
 
5’-TCTCCACAGGTGTCCACTCC-3’  
 
pFB-Reverse 5’-TTCTCGACAAGCTTGGTACC-3’ 
 
 
Table 4.1 DNA sequencing primers 
 
 
Plasmids Expressed protein Substituted residues in UL25 
pFB-UL25 pUL25       
pFB-UL25-C1 pUL25-C1 R362A G363A N365A    
pFB-UL25-C2 pUL25-C2 R148A D150A N152A D156A   
pFB-UL25-C3A pUL25-C3A G169A S170A G172A    
pFB-UL25-C3B pUL25-C3B G169A S170A G172A G202V R203A K206A 
pFB-UL25-C4A pUL25-C4A N396A Y398A D400A L402A   
pFB-UL25-C4B pUL25-C4B R390A N396A Y398A D400A L402A  
pFB-UL25-L6sub pUL25-L6sub S578A V580A     
Plasmids Expressed protein Deleted residues in UL25 
  From To Number of deleted residues   
pFB-UL25-L1 pUL25-L1 A249 D254 6   
pFB-UL25-L2 pUL25-L2 R335 G345 11   
pFB-UL25-L3 pUL25-L3 P417 A425 9   
pFB-UL25-L4 pUL25-L4 P479 T483 5   
pFB-UL25-L5 pUL25-L5 R511  N513 3   
pFB-UL25-L6 pUL25-L6 S578 V580 3   
pFB-UL25Δ1-45 * pUL25Δ1-45 M1 R45 45   
pFB-UL25Δ1-59 * pUL25Δ1-59 M1 R59 59   
pFB-UL25Δ1-133 * pUL25Δ1-133 M1 V133 133   
Plasmids Expressed protein Combination mutant  
pFB-UL25-C1L2 pUL25-C1L2 C1 mutations R362A, G363A and N365A and L2 deleted residues A249-D254 
 
 
Table 4.2  List of the pFB-UL25 constructs generated and their mutated residues 
(constructs marked * were supplied by Dr V. Preston)                                                                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Summary of the cloning strategies and methods used to generate the mutant 
UL25 constructs 
 
The mutated UL25 sequences were generated either by using primers containing the required 
nucleotide changes in a PCR reaction (Section 2.2.1.2) with pFB-UL25 as a template (1) or by 
annealing complementary (overlapping) oligonucleotides (Section 2.2.1.3) containing the desired 
mutations (2).  The PCR products were resolved on 5% polyacrylamide gels and the purified 
fragments (Section 2.2.3.2) were sub-cloned into the pGEM-T Easy vector (Section 2.1.9).  The 
ligated DNA (Section 2.2.2) was electroporated into DH5α (Section 2.2.5) and DNA samples were 
prepared from the ampicillin resistant colonies using the QIAprep spin miniprep protocol (Section 
2.1.14).  Each plasmid isolate was screened for the presence of the desired UL25 insert using REN 
analysis (Section 2.2.1.1) and by DNA sequencing (Section 2.2.3.4) with the primers M13 forward 
and reverse (Table 4.1).  PCR products with the correct UL25 insert were released from pGEM-T 
Easy recombinants using the appropriate REN digests and purified.  Mutant pFB-UL25 plasmids 
were generated by ligating the appropriate gel purified pFB-UL25 fragments to the mutated UL25 
fragments and electroporating the DNA into DH5α.  DNA was prepared from the recombinant pFB-
UL25 clones using the QIAprep spin miniprep protocol and recombinants containing the correct 
UL25 sequences were identified using REN analysis and by DNA sequencing with the pFB-UL25 
sequencing primers, pFB-Forward and pFB-Reverse, shown in Table 4.1.   
PCR Reaction
mutated UL25 
pGEM-T Easy
REN 1 REN 2
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pFB-UL25
REN 1 REN 2
complementation analysis
Subclone into pGEM-T Easy
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1
ligated to pFB-UL25 
digested with RENs
complementary (overlapping) 
oligonucleotides 
REN 1 REN 2
pFB-UL25
 Purified mutated UL25 PCR 
REN 1 REN 2
Annealed
UL25 ORF
pFB-UL25
Template DNA
annealed overlapping oligos
Digest with RENs 
and
 ligate to pFB-UL25 
digested with RENs
2
REN 2
REN 1
REN 2
REN 1
pFB-UL25-C1
8046 bp
UL25 ORF DdeI (1100)
EcoRI (8)
Xba I (2147)
Nru I (1199)
 
 
 
pFB-UL25-C2
8046 bp
UL25 ORF
EcoRI (8)
Xba I (2147)
Not I (336)
Kpn I (559)
Kpn I (2178)
 
 
 
Figure 4.6 Plasmid maps of pFB-UL25-C1 and pFB-UL25-C2 
   
The REN sites used in the construction and analysis of each plasmid are shown.  The green-
hatched arrow represents the HSV-1 sequences inserted in the pFBpCI backbone, with the UL25 
ORF denoted by the block green arrow.  Multiple cutting REN sites are coloured black and unique 
REN sites are highlighted in red.  
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DdeI, and C1-R that contained the NruI site (Table 4.3A).  The purified PCR 
product was cloned into pGEM-T Easy and plasmid DNA was prepared from the 
isolates obtained.  The recombinant pGEM-T Easy DNA was identified by the 
presence of a single NruI site located in the UL25 gene.  DNA samples from these 
plasmids were sequenced using the M13 sequencing primers, which revealed that 
one contained the desired mutations.  The 99 bp UL25 insert was released from 
the pGEM-T Easy recombinant by digestion with DdeI plus NruI.  The purified 
fragment was ligated to the pFB-UL25 EcoRI-DdeI 1092 bp and NruI-EcoRI 6855 bp 
fragments and then electroporated into DH5α.  Plasmid DNA samples, prepared 
from five recombinant bacterial clones, were digested with EcoRI plus NruI, and 
EcoRI alone.  Three of the plasmids produced the expected 1191 bp EcoRI-NruI 
and 8046 bp EcoRI fragments.  One of the plasmids was selected and renamed 
pFB-UL25-C1. 
4.3.2 C2 mutant construct (pFB-UL25-C2) 
The nearest convenient cloning sites flanking the codons specifying four (R148, 
D150, N152 and D156) of the six residues in the C2 region were NotI (336 bp) and 
KpnI (559 bp), which are shown in Figure 4.6.  Since the distance between the 
two REN sites and the desired mutations was too great to use either annealed 
overlapping oligonucleotides or to amplify the mutated sequences in a single 
PCR, overlap extension PCR (Ho, 1989) was utilised (Figure 4.2).  Unlike the 
single-step PCR procedure used previously, where two primers and one PCR 
reaction are required, overlap extension PCR uses four primers and three 
separate PCR reactions to introduce the desired site-specific mutations.  In the 
first PCR, one pair of primers amplifies the DNA that includes the mutations 
together with the upstream sequences.  The forward, or flanking, primer in this 
PCR contains the wt sequences and an appropriate REN cloning site, while the 
reverse primer contains the desired mutations.  In the second PCR, the primer 
pair amplifies the DNA that includes the mutations and the downstream 
sequences, with the forward primer in this pair containing the required 
mutations and the reverse, or flanking, primer containing the wt sequences and 
an appropriate REN cloning site.  The products generated during these initial two 
PCRs contain a region of overlap located at the site of the mutations.  These two 
fragments are mixed during a third PCR cycle and denatured and annealed at the 
 
Table 4.3A – The primers used to generate the UL25 mutant constructs listed 
 
Bases highlighted in red are the base pair changes resulting in substitutions of amino acids within the UL25 protein.  The bases highlighted in green are nucleotide 
changes used to adjust the percentage of G + C bases in a primer so that a pair of primers had an equal percentage.  The REN sites included in the primers are underlined 
and their respective names are shown underneath.   
UL25 Mutant Primer ID C1 – C2 Primers  
C1-F 
 
5’-TTCCTCAGCGCTGCACATGCCCTATTCCTGTGGGAGGACCAGACTCTGC-3’ 
            DdeI 
pFB-UL25-C1 
C1-R 
 
5’-ACGTTACCGTTCGCGAGAAGACGCTGGATAACGCCCAGGGCCGTTATGG-3’     
                                 NruI 
C2-F1 
 
5’-CGAAACGTACATGAAATTGCAGGTGCTCTAGAAGCACTAGAAACAGCAGCGGCCGCCGCCGAAGAGGCGGATGC-3’ 
                                                                                                                                                 NotI 
C2-R1 
 
5’-CGTACACCATGTGTAGCAGAGCTACAGGAAGTGCAGTAGCATATGCTAGCGGCGGGTCGTTGCGCACGATCTGG-3’      
 
C2-F2 
 
5’-CAGATCGTGCGCAACGACCCGCCGCTAGCATATGCTACTGCACTTCCTGTAGCTCTGCTACACATGGTGTACGC-3’  
 
pFB-UL25-C2 
C2-R2 
 
5’-GGTCAGGGGAAAATCTGTAATAGTACGATCCTGGATAGTGCGGTACCAGGTCCCGAACACCACCCCCGACGAGC-3’ 
                                                                                                               KpnI 
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region of overlap to generate heteroduplexes, which are subsequently extended 
to form full-length double-stranded mutant DNA.  The full-length DNA is 
amplified during the third PCR cycle, using the two flanking primers from PCR 
reaction one and two that contain the REN cloning sites. 
To mutate the four C2 codons using overlap extension PCR, the flanking primers 
C2-F1 and C2-R2 (Table 4.3A), containing the cloning sites NotI (336 bp) and KpnI 
(559 bp) respectively, and the mutagenic primers C2-F2 and C2-R1 (Table 4.3A), 
containing the desired mutations and including overlapping sequences at their 
3’-ends, were constructed.  Two initial PCR reactions, PCR1 and PCR2, were 
performed using the primers C2-F1 and C2-R1, and C2-F2 and C2-R2, 
respectively.  The purified 165 bp PCR1 fragment and 223 bp PCR2 fragment 
were denatured and annealed during the third PCR cycle (PCR3) and extended, 
using the flanking primers C2-F1 and C2-R2 from PCR1 and PCR2, respectively, to 
form the full-length double-stranded mutant DNA.  The purified PCR3 315 bp 
product was subsequently ligated to pGEM-T Easy and electroporated into DH5α.  
Recombinant plasmids, prepared from pGEM-T Easy isolates, were identified by 
the presence of a single SmaI site that was located in the UL25 sequences.  
Three recombinant plasmids, which contained a single SmaI site, were digested 
with KpnI plus NotI.  One of the plasmids produced the expected 223 bp 
fragment, indicating that it contained the UL25 insert.  DNA sequencing of this 
plasmid verified that the UL25 insert encoded the mutated residues R148A, 
D150A, N152A and D156A.  The purified 223 bp fragment was subsequently 
ligated to the pFB-UL25 KpnI- XbaI 1588 bp and XbaI-NotI 6235 bp fragments to 
produce pFB-UL25-C2.                                            
4.3.3 C3 mutant constructs (pFB-UL25-C3A and pFB-UL25-C3B) 
Two C3 mutant constructs were generated.  The first construct, pFB-UL25-C3A, 
encoded three mutated residues and the second, pFB-UL25-C3B, encoded six 
mutated residues of the eight amino acids assigned to the cluster.   
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4.3.3.1 pFB-UL25-C3A              
The KpnI (559 bp) and NotI (336 bp) sites in the UL25 gene flanked the 
nucleotide sequences specifying three of the six residues in C3 (Figure 4.7).  
These two REN sites were incorporated in the PCR primers used to create the 
fragment encoding the three missense mutations G169, S170 and G172.  The 
primer C3A-F (Table 4.3B) contained the wt sequences upstream from the 
mutated codons and included the unique NotI (336 bp) site.  The reverse primer 
C3A-R (Table 4.3B) encoded the mutated residues G169A, S170A and G172A and 
wt sequences downstream of these mutations that encompassed a KpnI (559 bp) 
site.  Initial attempts using these primers and the PCR-cycle1 cycle (Section 
2.2.1.2) to obtain the required PCR product produced various sized fragments, 
none of which corresponded to the size of the predicted 284 bp PCR product.  To 
increase the specificity of the reaction a new PCR programme, PCR-cycle2 
(Section 2.2.1.2), was used that had a higher annealing temperature than PCR-
cycle1.  A PCR product of the correct size was identified and the purified 
fragment was cloned into pGEM-T Easy.  DNA was prepared from the 
recombinant bacterial clones and those containing UL25 inserts were identified 
by the presence of a single SmaI in the UL25 gene.  The recombinant plasmids 
containing a single SmaI site were digested with KpnI plus NotI and several 
produced a 223 bp fragment, confirming the presence of the PCR fragment.  DNA 
sequencing verified that one of the recombinant plasmids encoded a UL25 insert 
with the desired mutations.  The purified KpnI-NotI 223 bp insert from this 
bacterial clone was ligated to the pFB-UL25 KpnI-XbaI 1588 bp and XbaI-NotI 
6235 bp fragments and the ligated DNA was electroporated into DH5α.  Plasmid 
DNA samples, prepared from the recombinant bacterial clones and the control 
plasmid (pFB-UL25), were digested with KpnI plus NotI and EcoRI plus XbaI.  A 
recombinant plasmid contained the expected KpnI-NotI fragments of 223 bp, 
1619 bp and 6204 bp and the EcoRI-XbaI fragments of 2139 bp and 5907 bp and 
was named pFB-UL25-C3A.   
4.3.3.2 pFB-UL25-C3B              
Preliminary complementation experiments indicated that pUL25-C3A supported 
viral growth in non-permissive cells infected with ΔUL25MO.  A new construct 
pFB-UL25-C3A
8046 bp
UL25 ORF
EcoRI (8)
Xba I (2147)
Not I (336)
Kpn I (559)
Kpn I (2178)
 
 
pFB-UL25-C3B
8046 bp
UL25 ORF
BtsI (613)
BspHI (645)
EcoRI (8)
Xba I (2147)
 
 
 
Figure 4.7 Plasmid maps of pFB-UL25-C3A and pFB-UL25-C3B 
 
The REN sites used in the construction and analysis of each plasmid are shown.  The green-
hatched arrow represents the HSV-1 sequences inserted in the pFBpCI backbone, with the UL25 
ORF denoted by the block green arrow.  Multiple cutting REN sites are coloured black and unique 
REN sites are highlighted in red.  
   
  
 
 
 
                 
 
UL25 Mutant Primer ID C3 – C4 Overlapping Oligonucleotides and Primers  
C3A-F 
 
5’-GAAACGTACATGAAATTGCAGGTGCTCTAGAAGCACTAGAAACAGCAGCGGCCGCCGCCGAAGAGGCGGATGC-3’                    
                                                                                                                                 NotI 
pFB-UL25-C3A 
C3A-R 
 
5’-AGTCTTGAATAGTACGGTACCAAGTTCCAAATACTACTGCTGAAGCTGCGGTCGCCCCCGGCCCGCGTACACC-3’ 
                                            KpnI 
C3B-F 
 
5’-GACTTTCGGGACGTCGCTATGTCCGCGACCTT-3’ 
   BtsI                                                                       BspHI 
pFB-UL25-C3B 
C3B-R 
 
5’-CATGAAGGTCGCGGACATAGCGACGTCCCGAAAGTCGG  -3’ 
     BspHI                                                                               BtsI 
 
C4A-F 
 
          
5’-CGAACGGCGCAGTGGCGGCCGCACGCGCTAACAACCGCCTGCA-3’ 
     NruI                                     NotI                                                   PstI 
pFB-UL25-C4A 
C4A-R 
 
5’-GGCGGTTGTTAGCGCGTGCGGCCGCCACTGCGCCGTTCG-3’ 
    PstI                                           NotI                                      NruI 
 
C4B-F 
 
          
5’-TCTGTTCCTCAGCCGGGGCCACAACCTATTCCTGTGGGAGGACC-3’ 
                       DdeI 
pFB-UL25-C4B 
C4B-R 
 
5’-ACAGTTCGCGAGGAGTGCCTGGATAACGCCCAGGGCCGTTATGG-3’ 
                     NruI 
Table 4.3B – The overlapping oligonucleotides and primers used to generate the UL25 mutant constructs listed 
  
Bases highlighted in red are base pair changes resulting in substitutions of amino acids in the UL25 protein.  The bases highlighted in green are nucleotide changes used 
to adjust the percentage of G + C bases in a primer so that a pair of primers had an equal percentage.  The REN sites included in the primers are underlined and their 
respective names are shown underneath.   
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pFB-UL25-C3B was therefore created, containing the mutations in pFB-UL25-C3A 
(G169A, S170A and G172A) together with additional mutations, specifying 
substitutions at residues G202, R203 and K206 (Figure 4.7).  Substituting alanine 
at the mutated sites in pUL25-C3A resulted in a minimal reduction in the 
observed function of the protein.  As discussed earlier (Section 3.1), due its size 
and neutral nature, alanine is generally regarded as the preferred choice of 
amino acid when performing mutational analysis by substitution of any particular 
residue in a protein.  The problem with this general mutational approach is that 
it does not incorporate information specific to the protein of interest.  To help 
address this problem a bioinformatics program, SIFT (http://sift.jcvi.org), which 
had been brought to my attention at this time, was used.   Given a particular 
protein sequence, SIFT analysis will predict a list of residues that are considered 
tolerant or intolerant at each position along a protein sequence, hence the name 
SIFT, sorting intolerant from tolerant.  SIFT is a multi-step procedure that 
searches for and chooses similar sequences, makes an alignment of these 
sequences and then calculates scores based on the amino acids appearing at 
each position in the alignment.  The analysis of any particular residue is based 
on the conservation of each amino acid along the protein sequence and the 
physical properties of the residue at that position.  Tolerated amino acids, which 
included the wt residue, are predicted not to alter the protein’s function.  
Conversely, intolerant residues are predicted to affect the protein’s function if 
the amino acid is positioned at a functional interface.   
Prior to creating pFB-UL25-C3B, SIFT analysis was used to determine the 
predicted tolerant and intolerant residues at positions G202, R203 and K206.   
Although SIFT predicted that two of the residues, R203 and K206, would be 
intolerant to alanine substitution, the program calculated that the substitution 
of G202 with alanine would be tolerated and, therefore, would be expected not 
to alter the protein’s function.  From the list of intolerant residues that were 
suggested at position G202, valine was chosen as the amino acid substitute since 
its physical properties were the most closely related to alanine.  Consequently, 
two overlapping oligonucleotides, C3B-F and C3B-R (Table 4.3B), containing the 
necessary nucleotide changes for the substitutions G202V, R203A and K206A and 
the complementary ends of the REN cloning sites BtsI (613 pb) and BspHI (645 
bp) were constructed.  The annealed BtsI-BspHI 32 bp fragment was ligated to 
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the pFB-UL25-C3A EcoRI-BtsI 605 bp fragment, which encoded the G169A, S170A 
and G172A mutated residues, the pFB-UL25 BspHI-XbaI 1502 bp fragment and the 
XbaI-EcoRI 5907 bp fragment.  The ligated DNA was electroporated into DH5α 
and plasmid DNA samples were prepared from the recombinant bacterial clones.  
Double digestion of two recombinant plasmids with EcoRI and XbaI produced two 
fragments, one of 2139 bp in size and the other of 5907 bp.  These fragments co-
migrated on an agarose gel with the two fragments from pFB-UL25 digested with 
the same enzymes, indicating that the complete UL25 gene was present in each 
of the mutant constructs.  One of these plasmids was selected for further 
analysis and referred to a pFB-UL25-C3B.   
4.3.4 C4 mutant constructs (pFB-UL25-C4A and pFB-UL25-C4B)  
Two mutant constructs were generated for C4.  The plasmid pFB-UL25-C4A 
encoded four mutated residues and pFB-UL25-C4B specified five mutated 
residues of the six amino acids assigned to the region (Table 4.2).  These two 
constructs were created at the same time and it was only evident during 
subsequent complementation analysis that the four mutated residues encoded in 
pFB-UL25-C4A were sufficient to alter the function of pUL25.    
4.3.4.1 pFB-UL25-C4A 
This plasmid encoded four mutated amino acids N396A, Y398A, D400A and   
L402A from the C4 region of the protein.  The annealed complementary 
oligonucleotides, C4A-F and C4A-R (Table 4.3B), included the nucleotide changes 
for the desired amino acid substitutions, an additional NotI (1213 bp) site and 
the complementary ends of the cloning sites NruI (1199 bp) and PstI (1242 bp) 
(Figure 4.8).  The annealed 43 bp oligonucleotide was ligated to the purified 
pFB-UL25 XbaI-NruI 7098 bp and XbaI-PstI 905 bp fragments.  To obtain the XbaI-
PstI 905 bp fragment, pFB-UL25 was digested with EcoRI in addition to XbaI and 
PstI, in order to remove a 929 bp PstI-PstI fragment that was difficult to 
separate from the 905 bp XbaI-PstI fragment on a 1% TAE gel.  EcoRI cut the 
unwanted PstI-PstI 929 bp fragment into two products (265 bp and 664 bp) that 
were easily resolved from the required XbaI-PstI 905 bp fragment after 
electrophoresis on an agarose gel.  The ligation mixture was electroporated into 
DH5α and plasmid DNA was prepared from the recombinant bacteria.  The DNA 
pFB-UL25-C4A
8046 bp
UL25 ORF
NotI (1213)
EcoRI (8)
Xba I (2147)
Not I (336)
Nru I (1199)
Pst I (672)
Pst I (1242)
Pst I (2159)
Pst I (7789)
 
pFB-UL25-C4B
8046 bp
UL25 ORF
DdeI (1100)
NotI (1213)
Eco RI (8)
Xba I (2147)
Not I (336)
Nru I (1199)
 
 
Figure 4.8 Plasmid maps of pFB-UL25-C4A and pFB-UL25-C4B.   
The REN sites used in the construction and analysis of each plasmid are shown.  The green-
hatched arrow represents the HSV-1 sequences inserted in the pFBpCI backbone, with the UL25 
ORF denoted by the block green arrow.  Multiple cutting REN sites are coloured black and unique 
REN sites are highlighted in red.  
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samples and the control plasmid (pFB-UL25) DNA were digested with NotI to 
confirm that the DNA fragment with the mutations and the NotI site was 
present.  One of the recombinant DNAs produced the two expected fragments, 
877 bp and 7169 bp, which verified that it contained the additional NotI site 
together with the mutated UL25 sequences and this plasmid was renamed pFB-
UL25-C4A (Figure 4.8). 
4.3.4.2 pFB-UL25-C4B 
The pFB-UL25-C4B construct contained the mutations in pFB-UL25-C4A, encoding 
N396A, Y398A, D400A, L402A substitutions and specified an additional alanine 
substitution at R390 in the UL25 protein.  The REN sites, DdeI (1100 bp) and NruI 
(1199 bp), were conveniently located 5’ and 3’ of R390 codon, respectively 
(Figure 4.8).  The NruI site, together with the nucleotide changes required for 
the R390A mutation, were included in the PCR primer C4B-R (Table 4.3B) and 
the DdeI cloning site was incorporated into the primer C4B-F (Table 4.3B).  The 
99 bp PCR product was purified and cloned into pGEM-T Easy.  Two recombinant 
plasmids were obtained and digested with NruI and DdeI.  The REN digested 
plasmid DNAs were separated on a 5% polyacrylamide gel, and the presence of 
the expected 99 bp fragment confirmed that the correct HSV-1 NruI-DdeI insert 
had been cloned.  DNA sequencing of one of the pGEM-T Easy recombinants 
verified it contained the UL25 sequences specifying the R390A mutation.  The 
purified NruI-DdeI 99 bp fragment was subsequently ligated to the purified pFB-
UL25-C4A NruI-EcoRI 6855 bp fragment, containing the mutated residues N396A, 
Y398A, D400A and L402A, and to the pFB-UL25 EcoRI-DdeI 1092 bp fragment.  
The ligated DNA was electroporated into DH5α and the recombinant plasmids 
obtained were digested with NruI and EcoRI.  One of the recombinant plasmids, 
which produced the expected fragments of 1191 bp and 6855 bp, was selected 
for further analysis and renamed pFB-UL25-C4B.   
4.4 Loop mutants 
The disordered residues deleted in each of the six regions (L1-L6) are shown in 
Table 4.2. 
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4.4.1 L1 mutant construct (pFB-UL25-L1) 
A PCR product that contained a deletion of the nucleotides encoding the L1 
unstructured residues A249-D254, and included the cloning sites PstI (672 bp) 
and BsaWI (772 bp) flanking the deletion, was produced using the primers L1-F 
and L1-R (Table 4.3C).   Initial attempts to generate the required PCR product 
with L1-F and L1-R using the PCR-cycle1 cycle were unsuccessful.  The UL25 
fragment was successfully amplified after repeating the experiment using the 
PCR-cycle2 cycle, which increased the specificity by raising the annealing 
temperature from 58oC used during PCR-cycle1 to 68oC.  The purified 116 bp PCR 
product was sub-cloned into pGEM-T Easy and plasmid DNA was prepared from 
the recombinant bacteria obtained.  Recombinant plasmids containing the 
correctly mutated UL25 insert were identified by REN analysis and confirmed by 
sequencing the DNA samples. The purified HSV-1 100 bp PstI-BsaWI insert was 
subsequently ligated to the pFB-UL25 EcoRI-NruI 6855 bp, EcoRI-PstI 664 bp and 
BsaWI-NruI 409 bp fragments and the DNA was electroporated into DH5α.  
Plasmid DNAs prepared from ten recombinant bacterial clones and the control 
pFB-UL25 DNA were digested with EcoRI and XbaI.  Three plasmids produced the 
expected EcoRI-XbaI fragments, 2121 bp and 5907 bp, giving the same pattern of 
digestion as the control pFB-UL25 plasmid.  One of these plasmids was used for 
subsequent analysis and was renamed pFB-UL25-L1 (Figure 4.9).    
4.4.2 L2 mutant construct (pFB-UL25-L2) 
To remove the DNA sequences specifying the unstructured residues in L2 two 
overlapping oligonucleotides, L2-F and L2-R, were designed (Table 4.3C).  The 
annealed fragment contained the cohesive ends of the cloning sites AatII (1020 
bp) and DdeI (1067 bp), an additional NotI (1051 bp) site and a 33 bp deletion 
that removed the sequences encoding the unstructured residues R335–G345 of L2 
(Figure 4.9).  The annealed 47 bp oligonucleotide was ligated to the purified 
pFB-UL25 NotI-XbaI 6253 bp, NotI-AatII 684 bp and DdeI-XbaI 1029 bp fragments 
and the ligation mixture was electroporated into DH5α.  Plasmid DNAs were 
prepared from six recombinant bacterial colonies and together with the control 
plasmid (pFB-UL25) were digested with NotI.  Each of the recombinant plasmid 
DNA samples produced two fragments of the expected size (7298 bp and 715 bp), 
 
 
 
 
UL25 Mutant Primer ID L1 – L3 Overlapping Oligonucleotides and Primers 
L1-F 
 
5’-TAATATTATCCCTGCAGGCGTGCGGCCGGCTGTATGTGGGCCAGCGCCACTATTCC-3’ 
                                 PstI 
pFB-UL25-L1 
L1-R 
 
5’-ATATGACCGGAGCGCGΔCCCGTGCGTGTTTCGGTACAGCAGGTAGAGACACAACACG-3’     
                  BsaWI 
L2-F 
 
5’-CCCCΔGTGGCGCACCACGACGACATAAACCGCGCGGCCGCCGCGTTCC-3’  
 AatII                                                                                   NotI                           DdeI 
pFB-UL25-L2 
L2-R 
 
5’-TGAGGAACGCGGCGGCCGCGCGGTTTATGTCGTCGTGGTGCGCCACΔGGGGACGT-3’ 
     DdeI                           NotI                                                                                          AatII 
L3-F 
 
5’-TAGGCATGCTGATTCCTGGAGCCGTCΔTCCGGATCCGACTCGGGGGCCATCAAGAGCGGAGACAACAATCTGG -3’ 
              NspI                                                            BamHI     
pFB-UL25-L3 
L3-R 
 
5’-ATATAGCAGTAAGACGTACTAGTGCTGCTTGGCGGGCCCCCGATGACATATCCACCACCCGCCGCGTCGACC-3’ 
                                                                                           ApaI              
Table 4.3C  The overlapping oligonucleotides and primers used to generate the UL25 mutant constructs listed  
 
The symbol Δ represents deleted UL25 sequences. The REN sites included in the primers are underlined and their respective names shown underneath.  Bases 
highlighted in bold are the silent base pair changes used to introduce REN sites without altering the protein sequence.  The bases highlighted in green are nucleotide 
changes used to adjust the percentage of G + C bases in a primer so that a pair of primers had an equal percentage. 
pFB-UL25-L1
8028 bp
UL25 ORF
BsaWI (772)
Deletion (A249-D254)
NruI (1181)
EcoRI (8)
XbaI (2129)
Pst I (672)
PstI (1224)
PstI (2141)
Pst I (7789)
 
pFB-UL25-L2
8013 bp
UL25 ORF
AatII (57)
AatII (1020)
DdeI (1067)
Deletion (P335-D345)
NotI (1051)
EcoRI (8)
Xba I (2096)
NotI (336)
 
 
Figure 4.9 Plasmid maps of pFB-UL25-L1 and pFB-UL25-L2   
The REN sites used in the construction and analysis of each plasmid are shown, together with the 
location of the deleted (unstructured) residues from the looped out regions.  The green-hatched 
arrow represents the HSV-1 sequences inserted in the pFBpCI backbone and the block green 
arrow represents the UL25 ORF.  Multiple cutting REN sites are coloured black and unique REN 
sites are highlighted in red.    
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confirming they contained an additional NotI site, which was present in the 
mutated UL25 insert.  One of the plasmids was selected for further study and 
renamed pFB-UL25-L2.    
4.4.3 L3 mutant construct (pFB-UL25-L3) 
A PCR product containing a 27 bp deletion of sequences specifying the nine 
unstructured residues (P417-A425) of L3, the cloning sites NspI (1252 bp) and 
ApaI (1474 bp) flanking the deletion, and an additional BamHI (1273 bp) site was 
produced using the primers L3-F and L3-R (Table 4.3C).  The purified PCR 
product was ligated to pGEM-T Easy and the DNA was electroporated into DH5α.  
Plasmid DNA was prepared from a series of recombinant bacterial clones and 
digested with BamHI, which does not cut pGEM-T Easy, and those containing the 
desired UL25 insert were linearised.  DNA sequencing of the positively identified 
recombinants confirmed that one encoded the required deletion.  The purified 
222 bp NspI-ApaI mutated fragment was ligated to the pFB-UL25 EcoRI-NspI 1244 
bp and ApaI-EcoRI 6553 bp fragments.  To detect the recombinant plasmids 
containing the mutated fragment, DNA was prepared from six bacterial clones 
and digested with BamHI.  Five of the recombinant pFB-UL25 plasmids produced 
the three expected BamHI fragments of 838 bp, 1259 bp and 5922 bp, verifying 
that they contained the UL25 insert with the additional BamHI site.  One plasmid 
was selected for further analysis and referred to as pFB-UL25-L3 (Figure 4.10).            
4.4.4 L4 mutant construct (pFB-UL25-L4) 
Overlapping oligonucleotides, L4-F and L4-R (Table 4.3D), were constructed that 
when annealed contained DrdI (1391 bp) and ApaI (1486 bp) cohesive ends, an 
additional XbaI (1434 bp) site and a deletion of 15 bp removing the codons of the 
five unstructured residues (P479-T483) of L4 (Figure 4.10).  The annealed 95 bp 
fragment was ligated to the purified pFB-UL25 EcoRI-DrdI 521 bp, DrdI-DrdI 862 
bp and ApaI-EcoRI 6553 bp fragments and the DNA was electroporated into 
DH5α.  Plasmid DNA samples from two recombinant bacterial clones were 
digested with KpnI and XbaI.  Only one produced the expected fragments KpnI-
KpnI 6427 bp, KpnI-XbaI 875 bp, XbaI-XbaI 698 bp and XbaI-KpnI 31 bp that 
pFB-UL25-L3
8019 bp
UL25 ORF
NspI (1252)
NspI (1687)
Deletion (P417-A425)
BamHI (1273)
EcoRI (8)
Xba I (2120)
Apa I (1474)
BamHI (14)
BamHI (2111)
 
pFB-UL25-L4
8031 bp
UL25 ORF
DrdI (1699)
Deletion (P479-T483)
XbaI (1434)
DrdI (1391)
DrdI (529)
EcoRI (8)
Xba I (2132)
Apa I (1486)
Kpn I (559)
Kpn I (2163)
 
 
 
 
Figure 4.10 Plasmid maps of pFB-UL25-L3 and pFB-UL25-L4 
 
The REN sites used in the construction and analysis of each plasmid are shown, together with the 
location of the deleted (unstructured) residues from the looped out regions.  The green-hatched 
arrow represents the HSV-1 sequences inserted in the pFBpCI backbone and the block green 
arrow represents the UL25 ORF.  Multiple cutting REN sites are coloured black and unique REN 
sites are highlighted in red.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.3D – The overlapping oligonucleotides used to generate the UL25 mutant constructs 
listed 
   
The symbol Δ represents deleted UL25 sequences. The REN sites included in the primers are 
underlined and their respective names shown underneath.  Bases highlighted in bold are the silent 
base pair substitutions used to introduce or eliminate REN sites without altering the protein 
sequence.  The REN sites eliminated from UL25 are shown in grey.     
 
 UL25 Mutant Primer ID L4 – L6 Overlapping Oligonucleotides 
L4-F 
 
5’-CGGTCGAGCTGACCCAGCTATTTCCCGGCCTGGCCGCCCTGTGTCTAGACGCCCAGGCGGGGCGGΔCGG 
      DrdI                         no PvuII site                                                           XbaI 
 
CGGGTGGTGGATATGTCATCGGGGGCC-3’ 
                                                          ApaI pFB-UL25-L4 
L4-R 
 
5’-CCCGATGACATATCCACCACCCGCCGΔCCGCCCCGCCTGGGCGTCTAGACACAGGGCGGCCAGGCCGGG 
ApaI                                                                                                             XbaI   
                                                                
AAATAGCTGGGTCAGCTCGACCGCC-3’ 
      no PvuII site                         DrdI 
L5-F 
 
5’-CGCCAGGCGGCGCTGGTGCGCCTCACCGCCCTCGAGCTCATCAACCGCACCΔCCCACCCCT-3’ 
ApaI                                                                               XhoI                                                     BstXI 
pFB-UL25-L5 
L5-R 
 
5’-GTGGGΔGGTGCGGTTGATGAGCTCGAGGGCGGTGAGGCGCACCAGCGCCGCCTGGCGGGCC-3’ 
     BstXI                                                XhoI                                                                                    ApaI 
L6-F 
 
5’-TTGTACTTTTTATGTCTGGGGTTCATTCCACAGTACCTGΔTAGT-3’ 
NspI                                                                                                     XbaI   
pFB-UL25-L6 
L6-R 
 
5’-CTAGACTAΔCAGGTACTGTGGAATGAACCCCAGACATAAAAAGTACAACATG-3’ 
      XbaI                                                                                                              NspI    
L6sub-F 
 
5’-TTGTACTTTTTATGTCTGGGGTTCATTCCACAGTACCTG GCGGCCGCT TAGT-3’ 
NspI                                                                                                     NotI                XbaI   
pFB-UL25-L6sub 
L6sub-R 
 
5’-CTAGACTAAGCGGCCGCCAGGTACTGTGGAATGAACCCCAGACATAAAAAGTACAACATG-3’ 
      XbaI                   NotI                                                                                                          NspI 
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indicated the pFB-UL25 DrdI-DrdI 862 bp fragment was inserted in the correct 
orientation.  This plasmid was subsequently named pFB-UL25-L4.     
4.4.5 L5 mutant construct (pFB-UL25-L5) 
Overlapping oligonucleotides, L5-F and L5-R (Table 4.3D), were produced that 
when annealed contained the ApaI (1501 bp) and BstXI (1561 bp) cohesive ends, 
an additional XhoI (1531 bp) site, and a deletion of 9 bp encoding the 
unstructured residues (R511–N513) of L5 (Figure 4.11).  The 60 bp annealed 
product was ligated to the pFB-UL25 XbaI-ApaI 7400 bp, BstXI-NspI 144 bp and 
NspI-XbaI 433 bp fragments and the DNA was electroporated into DH5α.  Plasmid 
DNAs prepared from six recombinant bacterial isolates were digested with XhoI, 
with two producing fragments of 5880 bp, 1378 bp, 622 bp and 157 bp, which 
confirmed that they contained the additional XhoI site.  One was selected and 
subsequently renamed pFB-UL25-L5.  
4.4.6 L6 mutant constructs (pFB-UL25-L6 and pFB-UL25-L6sub) 
L6 consists of three unstructured residues (S578-V580) located directly at the 
carboxyl terminus of the UL25 ORF.  Initially, the mutant construct pFB-UL25-L6 
was created that contained a deletion of sequences encoding S578-V580.  
Preliminary complementation studies indicated that the pUL25-L6 failed to 
complement the growth of ΔUL25MO.  To determine if alanine residues located 
at all three codons elicited the same functional impact as the deletion mutant, 
pFB-UL25-L6sub encoding the amino acid substitutions S578A and V580A in the 
UL25 ORF was generated. 
4.4.6.1 pFB-UL25-L6 
The primers L6-F and L6-R (Table 4.3D) were annealed to give an oligonucleotide 
that included a deletion of the 9 bp encoding the unstructured residues of L6, 
and the cloning sites NspI(1714) and XbaI(1756) flanking the deletion (Figure 
4.12).  The annealed 42 bp fragment was ligated to the pFB-UL25 EcoRI-BstXI 
1562 bp, BstXI-NspI 144 bp and EcoRI-XbaI 5901 bp fragments and the ligated 
DNA was electoporated into DH5α.  Recombinant plasmid DNA was prepared 
from the bacterial isolates and digested with NotI, those containing the 
pFB-UL25-L5
8037 bp
UL25 ORF
Deletion (R511-N513)
XhoI (1531)
BstXI (1561)
BstXI (2075)
NspI (1705)
EcoRI (8)
XbaI (2138)
ApaI (1501)
XhoI (153)
XhoI (2153)
XhoI (8033)
 
 
 
 
 
Figure 4.11  Plasmid map of pFB-UL25-L5 
The REN sites used in the construction and analysis of each plasmid are shown, together with the 
location of the deleted (unstructured) residues from the looped out regions.  The green-hatched 
arrow represents the HSV-1 sequences inserted in the pFBpCI backbone and the block green 
arrow represents the UL25 ORF.  Multiple cutting REN sites are coloured black and unique REN 
sites are highlighted in red.    
   
 
 
 
 
 
 
 
pFB-UL25-L6
7649 bp
UL25 ORF
Not I (336)
NspI (1252)
BstXI (1570)
Not I (1753)
Deletion (S578-V580)
XbaI (1765)
EcoRI (8)
 
pFB-UL25-L6sub
7658 bp
UL25 ORF
Not I (336)
NspI (1252)
BstXI (1570)
Not I (1753)
XbaI (1765)
EcoRI (8)
 
 
 
 
Figure 4.12 Plasmid maps of pFB-UL25-L6 and pFB-UL25-L6sub 
 
The REN sites used in the construction and analysis of each plasmid are shown, together with the 
location of the deleted (unstructured) residues in pFB-UL25-L6.  The block green arrow represents 
the UL25 ORF.  Multiple cutting REN sites are coloured black and unique REN sites are highlighted 
in red.    
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expected UL25 insert were linearised and produced a fragment of 7649 bp.  One 
of these recombinants was selected for further analysis and named pFB-UL25-L6.  
4.4.6.2 pFB-UL25-L6sub 
This mutant was constructed in the same manner as pFB-UL25-L6, using the 
overlapping oligonucleotides, L6sub-F and L6sub-R (Table 4.3D) that specified 
the amino acid substitutions S578A and V580A and contained an internal NotI site 
(Figure 4.12).  Recombinants containing the mutated UL25 insert and the 
additional NotI site were identified by the production of two NotI fragments of 
1417 bp and 6241 bp.  One of these recombinants was selected for further 
analysis and named pFB-UL25-L6sub. 
4.5 Combination mutant (pFB-UL25-C1L2) 
As referred to in Section 1.4, pUL25 and pUL17 interact to form the C-capsid- 
specific component (CCSC) (Trus et al., 2007).  Specific residues in pUL25 have 
been speculated to be the sites of the protein that interact with the capsid 
during the formation of the CCSC (A. Steven, personal communication).  The 
predicted amino acids included H348, R362 and G363 from C1 and H323 and 
G324, which lie in the extended L2 region of pUL25 (Table 1.4).  Substitutions 
affecting two of the residues, R362A and G363A, were encoded in the UL25 gene 
within pFB-UL25-C1, whereas pFB-UL25-L2 has a deletion in UL25 that removes 
the codons specifying the unstructured residues R335-G345 that are adjacent to 
H323 and G324 in L2.  To determine the functional impact of these mutations in 
combination, a construct containing both the C1 and L2 mutated residues was 
generated.  The purified fragments pFB-UL25-C1 DdeI-XbaI 1047 bp, pFB-UL25-L2 
EcoRI-DdeI 1059 bp and pFB-UL25 EcoRI-XbaI 5907 bp were ligated and the 
ligated DNA was electroporated into DH5α.  Recombinant plasmid DNA was 
prepared from the bacterial isolates and analysed by REN digestion and DNA 
sequencing.  One of the plasmids, pFB-UL25-C1L2 (Figure 4.13), had the correct 
REN pattern and the expected UL25 sequence containing the desired mutations.    
 pFB-UL25-C1L2
8013 bp
UL25 ORF
AatII (57)
AatII (1020)
DdeI (1067)
Deletion (P335-D345)
NotI (1051)
C1 substitutions
L2 deletion
EcoRI (8)
Xba I (2147)
Not I (336)
 
 
 
 
 
Figure 4.13 Plasmid map of pFB-UL25-C1L2 
The REN sites used in the construction and analysis of the plasmid are shown and the positions of 
two of the fragments used to generate the complete plasmid are indicated.  The block grey arrow 
represents the pFB-UL25-L2 AatII-DdeI fragment (L2 deletion) that contained the deleted 
(unstructured) residues from pFB-UL25-L2.  The second fragment contained the mutated residues 
from pFB-UL25-C1 in the DdeI-XbaI fragment from this plasmid (C1 substitutions) and is denoted 
by the hatched grey arrow.  The green-hatched arrow represents the HSV-1 sequences inserted in 
the pFBpCI backbone, with the UL25 ORF highlighted by the block green arrow.  Multiple cutting 
REN sites are coloured black and unique REN sites are highlighted in red.  
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4.6 Complementation assay 
This assay determines the ability of proteins supplied in trans to complement 
the growth of a mutant virus lacking a functional version of the protein, under 
conditions non-permissive for input virus replication.  The yield of the progeny 
virus is subsequently determined by titrating the virus under permissive 
conditions.  Vero cells were transfected with either pFB-UL25, the empty vector 
pFBpCI or individual mutated pFB-UL25 plasmids and subsequently infected with 
ΔUL25MO (Section 2.2.7.3).  After incubation at 37oC for 24 h the cells were 
harvested and the viral yields were determined on 8-1 cells and expressed as a 
percentage of the yield obtained from positive control cells containing pFB-UL25 
(Figure 4.14).  Eight of the 17 mutants analysed had a minimal effect on the 
ability of the protein to support virus growth, giving yields of over 40% of the wt 
pUL25 positive control level in the complementation assay.  The remaining nine 
mutant proteins displayed significantly lower levels of complementation that 
were 5% or below that of the positive control sample.  For each of the 
complementation assays performed, a duplicate set of cell monolayers from the 
experiment was harvested and the proteins contained in the cell lysates were 
separated by SDS-PAGE on 10% polyacrylamide gels.  The proteins were blotted 
onto nitrocellulose membrane and incubated with primary anti-pUL25 antibody.  
The blot containing the N-terminally truncated pUL25 proteins was screened 
with anti-pUL25 RAb335, which was raised against pUL25 residues 342-580.  
Whereas, the other blots were screened with anti-pUL25 MAb166, which 
recognises an epitope located between pUL25 residues 59-133.  Although no 
loading control was used to determine the quantities of the proteins expressed 
in each sample, Western blot analysis confirmed the expression of pUL25 in each 
of the cell lysates analysed, confirming that the cells had been successfully 
transfected with the recombinant plasmid.  A representative image for each of 
the samples analysed during complementation analysis is shown Figure 4.15. 
4.7 Discussion 
UL25 must interact with its essential protein partners to ensure production of 
functional capsids and hence infectious virions.  Eight of the UL25 mutant 
proteins examined retained the ability to complement the growth of ΔUL25MO, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14 Complementation of ΔUL25MO by mutant UL25 proteins 
 
Vero cell monolayers in 24 well tissue culture dishes were transfected with a plasmid expressing a 
mutant UL25 protein.  As a positive control, cells in one well were transfected with pFB-UL25 
expressing the wt protein and as a negative control, cells in another well were transfected with the 
empty vector pFBpCI that did not express pUL25 instead of a plasmid expressing a mutant UL25 
protein.  Subsequently, each of the wells was infected with ΔUL25MO, and after virus absorption the 
cells were acid washed to remove residual viral particles from the cell surface.  Following incubation at 
37oC for 18 h, cells were harvested and the yield of ΔUL25MO determined on 8-1 cells.  For each 
plasmid, the average yield of the viral progeny obtained from three independent experiments was 
calculated and expressed as a percentage of the average yield obtained from ΔUL25MO-infected cells 
expressing pFB-UL25.  Error bars represent the standard deviation of the mean.  
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Figure 4.15 Western blot analysis of pUL25 in the complementation 
assays
Vero cell monolayers seeded in a 24-well dish were transfected with a 
plasmid expressing a mutant UL25 protein.  As a positive control cells in 
one well were transfected with pFB-UL25 expressing the wt protein and 
as a negative control, cells in another well were transfected with the 
empty vector pFBpCI that did not express pUL25.  Following incubation 
a 37oC for 18 h, cell lysates were prepared from the harvested cells and 
the proteins were separated by SDS-PAGE on 10% polyacrylamide gels 
and blotted onto nitrocellulose.  UL25 proteins in A, B and D were 
detected using primary MAb166 antibody and secondary hrp-conjugated 
anti-mouse antibody.  UL25 proteins in C were detected using primary 
RAb335 antibody and secondary hrp-conjugated protein A.    
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and reasonable virus yields of over 40% of the yield from the wt positive control 
sample were produced (Figure 4.14).  Several possibilities are suggested by these 
observations.  The corresponding wt residues of the mutated amino acids in 
pUL25-C1, -C2, -C3A, -L1, -L2, -L4, -L6sub and -C1L2 may not be essential for 
the interactions required during viral assembly.  Alternatively, the number of 
predicted functional residues mutated in each of the clusters, or the size of the 
deletion in the looped out regions, may be insufficient to produce a functional 
impact.  For instance, pUL25-C1 contained only three mutated residues of the 
nine predicted functional amino acids for C1, and pUL25-C2 contained four 
mutated residues out of the possible six for C2.  In addition, the mutated 
residues in the cluster regions may be tolerated as defined by SIFT analysis.  
Certainly, retrospective SIFT analysis on the amino acids mutated in pUL25-C1, 
pUL25-C2 and pUL25-C3A predicted that several of the alanine substitutions 
included in each of these constructs would be tolerated, and thus would be 
expected not to alter the protein’s function.  Ideally, if time had allowed, new 
C1 and C2 constructs would have been created that contained the additional 
mutated residues from the list of predicted functional amino acids for these 
regions.  In addition, SIFT analysis would have been used to potentially optimise 
the type of amino acid substitution performed at each of the target sites in the 
new constructs.    
Nine of the 17 mutant proteins analysed displayed significant reductions in the 
efficiency of complementation of the growth of ΔUL25MO, and virus yields of 5% 
or less of the level observed for the positive control sample were obtained 
(Figure 4.14).  These mutant proteins were pUL25-C3B, -C4A, -C4B, -L3, -L5, -L6 
and the three N-terminal deletion mutants, pUL25Δ1-45, pUL25Δ1-59 and 
pUL25Δ1-133.  Since the residues mutated in UL25 are located on the surface of 
the protein they are unlikely to affect the overall structure of the protein.  
Consequently, the reduction in complementation observed in ΔUL25MO-infected 
Vero cells expressing the individual mutant proteins listed above suggests that 
the wt residues mutated in each of the proteins, are crucial to the function of 
pUL25.  Two of the loop mutants, pUL25-L5 and pUL25-L6, with the smallest 
number of deleted residues (3 each), produced a profound effect on the ability 
of the protein to complement, and virus yields of less than 1% of the wt yield 
were obtained.  In contrast, ΔUL25MO-infected Vero cells expressing pUL25-L2 
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produced a mean complementation level of 68%, despite the protein having an 
11 amino acid deletion in L2.  The unstructured portions of the protein are 
assumed to relate to the molecule’s flexibility, which in turn influences the 
conformational parameters the protein requires to function effectively.  Since 
the large deletion of the unstructured residues in pUL25-L2 was tolerated, 
alterations in the flexibility of the protein appear to be localised with little long-
range impact on the function of the highly flexible pUL25 (Bowman et al., 2006).  
The level of complementation of ΔUL25MO by pUL25-C3A was comparable to the 
value obtained for the positive control.  However, by expanding the number of 
mutated residues within the C3 region of UL25 from the three in pUL25-C3A 
(G169A, S170A and G172A) to the six in pUL25-C3B, which contained the 
additional mutated residues G202V, R203A and K206A, the mean 
complementation efficiency was reduced from 92% to 2%, respectively.  A study 
is presently under way to determine if the two groups of mutated residues 
G169A, S170A, G172A plus G202V, R203A, K206A, contained in pUL25-C3B work 
in concert with each other or if the mutated amino acids G202V, R203A and 
K206A operate independently to produce the low levels of complementation 
observed with pUL25-C3B. 
The mutant pUL25-C1L2 (Section 4.5) had been created to examine the 
combined effects of the mutations contained in pUL25-C1 plus pUL25-L2 on the 
properties of pUL25.  A combination of the mutations was chosen since they 
either contained, or were close to, residues that were predicted to be the 
interaction sites on pUL25, which were involved in the formation of the CCSC 
(Trus et al., 2007).  In the complementation analysis the mutations in pUL25-
C1L2 had little effect on the protein’s ability to support viral growth, and virus 
yields of over 68% of the wt positive control level were produced.  However, the 
results do not conclusively rule out the possibility that these regions may be 
important during viral assembly.  The mutant pFB-UL25-C1 encodes mutations 
for only two of the possible three residues in C1 identified as significant for 
CCSC formation, while pUL25-L2 was chosen because the deleted amino acids in 
this protein were in close proximity to the two residues in L2 that were 
predicted to be the interaction sites for the formation of the CCSC on mature 
capsids.  Further experiments are required that specifically target the proposed 
interaction residues for CCSC formation on mature capsids.  Analysis of a single 
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mutant construct containing the appropriate SIFT selected substitutions at H348, 
R362, G363, H323 and G324 would help to clarify the functional significance of 
the amino acids identified. 
Complementation assays with pUL25-C4B and –C4A generated virus yields of less 
than 1% of the wt positive control level.  Since pUL25-C4A contained only four of 
the five mutated residues in pUL25-C4B, this demonstrated that one or more of 
the wt residues N396, Y398, D400 and L402 mutated in pUL25-C4A was 
functionally important.  The amino acids mutated in pUL25-C4A are located 
along a loop on the surface of UL25, which lies adjacent to the extended looped 
out region, L3 (Figure 4.16).  Since the pUL25-L3 protein also failed to 
complement the growth of ΔUL25MO, the combined results for pUL25-C4A and 
pUL25-L3 suggests that this whole area of the protein is essential for viral 
assembly.   
 
 
 
 
 
 
C terminus
Figure 4.16  Ribbon diagram of UL25nt
The location of the wt residues, N396, Y398, D400 
and L402, which are mutated in pUL25-C4A and 
and their proximity to L3 are illustrated.
N396
D400
L402
Y398
C terminus L3
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5 Ability of the mutant pUL25s to support DNA 
packaging  
5.1 Introduction 
As discussed in Section 1.3.5.2.5, UL25 has been shown to play an important role 
during the later stages of viral DNA packaging prior to the release of capsids into 
the cytoplasm.  The available evidence supports a model for DNA packaging in 
which the viral genome is inserted into the capsid in the direction of the L to S 
terminus (McVoy et al., 2000, Stow, 2001).  Stow (2001) used the original UL25 
null mutant, KUL25NS, to analyse HSV-1 DNA packaging in Vero and BHK cells in 
the absence of UL25 and showed that the proportion of encapsidated DNA 
present as full-length genomes was much lower than the values obtained in wt 
virus-infected cells.  Consequently, in KUL25NS-infected cells there was a 
significant overrepresentation of the L terminus and underrepresentation of the 
S terminus of the packaged HSV-1 genome (Figure 5.1).  The aim of the 
experiments carried out in this section was to determine the effect of each of 
the eight non-complementing mutant proteins pUL25-L3, -L5, -L6, -C3B, -C4A, 
Δ1-45, Δ1-59 and Δ1-133 on the ability of ΔUL25MO to encapsidate unit-length 
viral DNA in non-permissive U2OS cells.   
The UL25 mutant genes were initially cloned into the plasmid pFBpCI (Figure 
5.2), which had been selected on the basis that it could also be used as a 
baculovirus transfer vector.  Transfection of Vero cells with plasmid DNA was a 
convenient method of introducing the UL25 gene into cells for screening the 
expressed mutant UL25 proteins for their ability to complement the growth of 
ΔUL25MO.  However, the efficiency of transfection and the level of expression of 
the UL25 proteins in individual cells were variable.  To determine whether the 
mutant proteins altered the packaging phenotype of ΔUL25MO in non-permissive 
cells, a system was required in which the majority of the cells expressed the 
recombinant pUL25.  Various mammalian cell lines, in particular human 
osteosarcoma cell lines such as U2OS, have been reported to be efficiently 
transduced by a recombinant baculovirus containing a reporter gene under the 
control of the HCMV IE promoter (Condreay et al., 1999, Song et al., 2003).  
(b)
pST17
S K QBamHI Fragments
TRL IRL TRSIRSa a a
UL US
pBE1
Figure 5.1 The structure of the HSV-1 genome 
The HSV-1 genome is represented at the top and shows the positions 
of the unique (UL and US) and repeated regions (TRL, IRL, IRS and 
TRS).  The locations of the BamHI fragments S, K and Q are indicated 
and the positions of the a sequence are shown in red.  The expanded 
representation of the BamHI K (joint-spanning) fragment and the 
terminal fragments S and Q are shown along the bottom.   The shaded 
boxes represent the regions within these fragments that correspond to 
the inserts in the plasmids pBE1 and pST17.  32P-labelled pBE1 and 
pST17 were used as probes to determine the genomic location of the 
BamHI f ragments generated and analysed by Southern b lo t  
hybridisation during the DNA packaging assays carried out in Section 
5.3 (adapted from Stow, 2001).
pFBpCI
(5950 bp)
CMV enhancer
Tn7L
SV40 pa
Ampicillin
Tn7R
Gentamicin
Polyhedrin promoter
CMV promoter
EcoRI (1)
Xba I (51)
 
 
 
 
 
Figure 5.2 Plasmid map of pFBpCI 
The HCMV IE promoter and enhancer, polyhedrin promoter, ampicillin and gentamicin genes are 
represented by different coloured arrows.  The position of the right and left arms of the Tn7 
transposon (Tn7R and Tn7L, respectively) are shown by the black arrows, while the grey arrow 
represents the position of the SV40 polyadenylation signal (SV40 pa).  The positions of the unique 
EcoRI and XbaI sites are highlighted in red.     
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Furthermore, provided cells were infected with recombinant baculovirus at a 
high MOI, a reproducible number of transduced cells could be achieved.  An 
additional safety feature of this system is that recombinant baculovirus 
infections are contained, since mammalian cells are non-permissive for 
baculovirus replication (Kost et al., 2005).  To perform the packaging assay a 
series of recombinant baculoviruses were generated, each expressing one of the 
eight non-complementing mutant UL25 proteins under the control of HCMV IE 
promoter.  Two control recombinant baculoviruses were also constructed, one 
expressing the wt UL25 protein, AcWTUL25, and one expressing no foreign 
proteins, AcpCI.  
5.2 Generation of the baculovirus expressing the 
recombinant pUL25s 
The recombinant baculoviruses were produced using the Bac-to-Bac system (Life 
Technologies) and an overview of this procedure is shown in Figure 5.3.  Based 
on a method developed by Luckow et al. (1993), the system takes advantage of 
the site-specific transposition properties of the Tn7 transposon to generate 
recombinant bacmid DNA.  The bacmid was propagated in E.coli DH10Bac 
containing the helper plasmid pMON7124, which confers tetR to the bacterial 
cells and encodes a transposase enzyme providing the Tn7 transposition function 
in trans (Barry, 1988).  The mutated and wt UL25 genes were cloned into the 
baculovirus transfer vector pFBpCI downstream of the HCMV IE promoter, which 
controls the expression of the recombinant UL25 genes in mammalian cells 
(Figure 5.2).  The mini-Tn7 in pFBpCI contains the expression cassette, which is 
flanked by the right and left arms of Tn7 and includes the gmR gene.  Following 
transformation of E. coli DH10Bac with the recombinant pFBpCI, site-specific 
transposition occurs between the mini-Tn7 region from the recombinant plasmid 
gene and the receptor attTn7 sites in the baculovirus genome within the bacmid.  
Transposition of the recombinant gene to the attTn7 attachment site disrupts 
the expression of β-galactosidase from the LacZα gene in the bacmid, thereby 
allowing blue/white recombinant selection on medium containing the 
colourimetric substrate X-gal and the inducer IPTG.  Transformants are also 
selected for kmR, gmR and tetR, which confirms the presence of the bacmid, 
pFBpCI and the helper plasmid, respectively.   
Figure 5.3  Experimental outline used to generate the recombinant baculovirus
The recombinant baculovirus were generated using the Bac-to-Bac system (Life Technologies).
(A)  A wt or mutant UL25 gene was cloned into the baculovirus transfer vector, pFBpCI, 
downstream of the HCMV IE promoter within the mini-Tn7. 
(B)  The recombinant vector was electroporated into electrocompetent E. coli DH10Bac cells that 
contained the baculovirus shuttle vector, bMON14272, which encodes the LacZα gene possessing 
a mini-attTn7 site.
(C)  The helper plasmid pMON7124 provided the Tn7 transposition function in trans, allowing 
transposition of the UL25 gene into, and disruption of, the LacZα gene in the bacmid.  Bacteria, 
containing recombinant bacmids, were plated out onto L broth agar supplemente with tet, km and 
gm, which selects for bacteria carrying the bacmid, pFBpCI and the helper plasmid respectively.  In 
addition, the plates contained X-gal so that recombinant bacmids with the LacZα- phenotype could 
be identified.
(D)  The recombinant bacmid DNA was transfected into insect cells, resulting in the production of 
infectious recombinant baculovirus, which expressed the UL25 gene under the control of the 
HCMV IE promoter in mammalian cells.      
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Bacmid DNA encoding the modified UL25 gene was isolated from kmR, gmR and 
tetR bacteria using an adapted alkaline lysis procedure (Section 2.2.12.1).  To 
obtain infectious recombinant baculovirus, bacmid DNA was transfected into 
Sf21 cells (Section 2.2.12.2) and the cells were incubated at 28oC for three days.  
The progeny viruses were harvested and amplified to produce high-titre virus 
stocks, as described in Section 2.2.12.3.  Each of the recombinant baculoviruses 
generated and the proteins they express are listed in Table 5.1 (The N-terminal 
deletion mutants AcUL25Δ1-45, Δ1-59 and Δ1-133 were supplied by Dr V. 
Preston).  To confirm that each baculovirus expressed UL25 protein in 
mammalian cells, U2OS cells were infected with baculovirus expressing wt UL25 
or a mutant protein.  As a negative control a sample of cells was infected with 
baculovirus AcpCI.  After 24 h at 37oC, the cells were harvested and each sample 
was analysed for UL25 protein expression using the Western blotting technique 
described in Section 2.2.18.2.  The proteins expressed by AcUL25-C3B, -C4A,      
-L3, -L5 and –L6 were screened with anti-UL25 MAb166, which recognises an 
epitope located between pUL25 residues 59-133.  Since this epitope was not 
present in the N-terminally truncated proteins, the proteins expressed by 
AcUL25-Δ1-45, -Δ1-59 and -Δ1-133 were screened with anti-UL25 RAb335, which 
was raised against UL25 residues 342-580.  The images obtained for the Western 
blots are shown in Figure 5.4, and demonstrate that each UL25 recombinant 
baculovirus expressed a UL25 protein of the correct size. 
To confirm that the infection efficiency of each of the recombinant baculovirus 
in mammalian cells was similar, U2OS monolayers were infected with virus at 
MOI of 50 PFU per cell and prepared for immunofluorescence as outlined in 
Section 2.2.12.6.  To detect virus-infected cells in each sample, the mounted 
monolayers were probed with the appropriate anti-UL25 primary antibody at a 
concentration of 1:500 and secondary FITC-conjugated anti-mouse antibody at a 
concentration of 1:100.  To identify all of the cells in each sample the cell nuclei 
were stained with propidium iodide and then visualised using the confocal 
microscope.  The total number of cells and the number of cells infected with 
baculovirus were counted in a selected area of each coverslip.  For each 
recombinant baculovirus the proportion of virus-infected cells ranged from     
41% to 47% of the total number of cells counted (data not shown), verifying that 
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Figure 5.4  Western analysis of baculovirus- infected U2OS cell 
extracts for UL25 expression 
U2OS cells were infected with the baculovirus at an MOI of 50 PFU/cell 
and incubated overnight at 37oC.  Cell extracts were prepared and the 
proteins were separated by SDS-PAGE and then analysed by Western 
blotting.  No loading control was used during this experiment.  Blot (A) 
was screened with pr imary ant i-pUL25 MAb166 ant ibody at a 
concentration of 1:1000 and secondary hrp-conjugated anti-mouse 
antibody at 1:1000 dilution.  Blot (B) was screened with primary anti-
pUL25 RAb335 antibody at a concentration of 1:1000 and with 
secondary hrp-conjugated protein A antibody at 1:1000 dilution.  The 
white arrowheads indicate the position of the wt or truncated UL25 
proteins. 
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each virus stock showed a similar and therefore comparable efficiency of 
infection.    
  
Baculovirus Expressed HSV-1 UL25 Protein 
AcpCI None 
AcWTUL25 pUL25  
AcUL25-C3B pUL25-C3B  
AcUL25-C4A pUL25-C4A   
AcUL25-L3 pUL25-L3  
AcUL25-L5 pUL25-L5   
AcUL25-L6 pUL25-L6   
AcUL25Δ1-45 pUL25Δ1-45   
AcUL25Δ1-59 pUL25Δ1-59  
AcUL25Δ1-133 pUL25Δ1-133  
 
 
 
 
 
 
Table 5.1 List of recombinant baculoviruses 
 
5.3 Viral DNA packaging assay  
The DNA packaging assay of Stow (2001) was used to determine whether any of 
the mutant UL25 proteins expressed by the recombinant baculoviruses listed in 
Table 5.1 could alter the DNA packaging phenotype of ΔUL25MO in U2OS cells.  A 
summary of the assay is shown in Figure 5.5.  At 24 hpi the cells were harvested 
and total and DNase-resistant DNA samples were prepared as described in 
Section 2.2.14.1.  Since DNase I treatment should degrade all of the DNAs 
present in virus-infected cells, except the encapsidated viral DNA, the DNase-
resistant fraction represents the DNA that has been stably packaged.  DNA 
samples from both the total and DNase-resistant fractions were digested with 
BamHI.  The fragments were separated on a 0.8% agarose gel and analysed by 
Southern blot hybridisation (Section 2.2.15) using either 32P-labelled pBE1 or 
pST17 probes.  Figure 5.1 shows the genomic location of each of the BamHI 
fragments that hybridised to the HSV-1 sequences present in pBE1 and pST17.  
During the packaging process the replicated concatemeric viral DNA is cleaved 
Recombinant 
Baculovirus UL25MO
U2OS 
Cell
24 h @ 37oC
Cell Lysis 
DNA Extraction
Total DNA
Cell Lysis + 
DNaseI
Packaged DNA
(DNase-resistant) 
DNA Extraction
BamHI-digested and analysed 
by Southern blotting using 
32P-labelled pBE1 or pST17
Figure 5.5  Summary of the packaging assay
U2OS cells infected with a recombinant baculovirus and    UL25MO were 
incubated at 37oC for 24 h.  The cells were harvested and divided into two 
aliquots.  One aliquot of infected cells, which represented the total DNA 
fraction, was lysed and the DNA was extracted.  The other infected cell 
sample was lysed and treated with DNaseI prior to DNA extraction.  This 
fraction represented the packaged DNA.  Duplicate DNA samples from both 
the total and packaged fractions were digested with BamHI, the fragments 
were separated on a 0.8% agarose gel and then transferred by blotting onto 
nitrocellulose.  The DNA was hybridised to 32P-labelled pBE1 or pST17.
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into monomeric units, which, when digested with BamHI, give rise to the 
terminal BamHI S and Q fragments.  The pBE1 probe hybridises to the BamHI S 
fragment, which is located in the RL region of the L terminus, and the joint-
spanning BamHI K fragment of the HSV-1 genome.  The pST17 probe recognises 
the BamHI Q fragment, which is located in the HSV-1 RS region of the S terminus, 
and the BamHI K fragment.  In non-permissive cells infected with an HSV-1 UL25 
null mutant, viral DNA is cleaved and encapsidation of the DNA is initiated but 
fails to go to completion.  As a consequence, in packaged DNA digested with 
BamHI the L terminus (BamHI S) is overrepresented and S terminus (BamHI Q) is 
underrepresented relative to the joint-spanning fragment, BamHI K (Stow, 
2001).   
Representative phosphorimages of total and DNase-resistant DNA samples 
analysed by Southern blot hybridisation are shown in Figure 5.6.  Inspection of 
the images revealed that in ΔUL25MO-infected cells expressing any of the five 
UL25 mutant proteins, pUL25-L5, -C3B, Δ1-45, Δ1-59 and Δ1-133, the DNA 
packaging profile of ΔUL25MO was indistinguishable from the one obtained from 
the negative control sample, in which cells were co-infected with AcpCI and 
ΔUL25MO.  In the DNase-resistant samples the L terminal fragment (BamHI S) 
was present but the joint-spanning K fragment was detectable in considerably 
reduced amounts (Figures 5.6, B, lanes 2,4 and 6; F, lanes 2-5).  The S terminal 
fragment (BamHI Q) was also present at low levels in these DNA samples (Figure 
5.6 D, lanes 2, 4 and 6; C and D lanes, 2-5).  In contrast, in ΔUL25MO-infected 
cells expressing pUL25-L3, -L6 or –C4A the DNA packaging profile of ΔUL25MO 
was comparable to the pattern from positive control sample expressing the wt 
pUL25 protein, where both the BamHI S and Q fragments were detected in 
similar amounts in the DNase-resistant DNA samples (Figure 5.6 B and D, lanes 1, 
3, 5 and 7).  To quantify the results the amounts of radioactivity in the bands 
corresponding to the joint fragment and the L and S terminal fragments (BamHI 
K, S and Q, respectively) were measured in DNase-resistant samples.  When 
calculating the amount of radioactivity in BamHI S, the measurements included 
the major fragment, which had a single copy of the a sequence and the higher 
molecular weight fragments containing two or three copies.  The ratio of joint to 
terminal fragment was calculated for each recombinant baculovirus-infected cell 
sample from three independent packaging assays and the results are summarised 
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Figure 5.6 Southern blots of the packaging assays
U2OS monolayers were co-infected with the recombinant baculovirus 
indicated and   UL25MO.  At 24 hpi the cells were harvested and total and 
DNase-resistant DNAs were prepared.  Duplicate samples were digested 
with BamHI and the fragments were resolved by electrophoresis through 
0.8% agarose gel and transferred onto Hybond-XL membranes.  The 
membranes were hybridised to either 32P-labelled pBE1 (RL probe) or 
pST17 (RS) probe as shown.  The position of the joint-spanning (BamHI K) 
and terminal fragments (BamHI S and Q) detected are indicated.   
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in Table 5.2.  In cells co-infected with the negative control baculovirus, AcpCI 
and ΔUL25MO the DNA packaging profile was similar to the one previously 
reported by Stow (2001) for KUL25NS-infected cells alone, with a ratio of 3.5:1 
overrepresentation of the L terminal fragment, BamHI S, and a ratio of 0.6:1 
underrepresentation of the S terminal fragment, BamHI Q, relative to the joint-
spanning BamHI K fragment.  In addition, in ΔUL25MO-infected cells expressing 
pUL25-C3B, -L5, Δ1-45, Δ1-59 and Δ1-133 the BamHI digested packaged viral DNA 
samples produced ratios of the L and S terminal fragments relative to BamHI K 
that were similar to the ratios observed in the negative control sample (Table 
5.2), indicating that the mutant proteins expressed by AcUL25-C3B, -L5, Δ1-45, 
Δ1-59 and Δ1-133 failed to support encapsidation of full-length viral DNA in 
ΔUL25MO-infected cells.  By contrast, the ratios obtained from BamHI-digested 
packaged DNA from cells co-infected with ΔUL25MO and baculovirus expressing 
pUL25-C4A, -L3 or –L6, were comparable to the positive control, indicating that 
the defect in each of these proteins did not affect their ability to support 
packaging of full-length DNA.   
5.4 Pulse-field gel electrophoresis (PFGE) of 
encapsidated viral DNA 
To confirm that the genomic termini present in the DNase-resistance samples 
from ΔUL25MO-infected cells expressing pUL25-C4A, -L3 or –L6 resulted from 
encapsidation of mature unit-length genomes, each of the fractions were 
analysed by PFGE (Section 2.2.16) together with the DNase-resistant fraction 
from ΔUL25MO-infected U2OS cells expressing wt UL25.  PFGE is a technique 
used to separate large DNA molecules greater than 50 kb, which is the limit for 
the separation of DNA fragments by electrophoresis on standard agarose gels.  
U2OS monolayers were co-infected with ΔUL25MO and either AcWTUL25, AcpCI, 
AcUL25-L3, AcUL25-L6 or AcUL24-C4A, or singly infected with wt HSV-1, 
AcWTUL25 or ΔUL25MO.  At 24 hpi the cells were harvested, and DNase-resistant 
DNA was carefully prepared as described in Section 2.2.14.1 to minimise DNA 
shearing.  The DNAs were resolved by PFGE, transferred to Hybond-N membrane 
and hybridised to 32P-labelled HSV-1 pGX2, which contains the BamHI K 
fragment.  The phosphorimage obtained is shown in Figure 5.7 and reveals that a 
major band, corresponding to the full-length 152 kb HSV-1 genome, was 
 
 
Ratio relative to BamHI K  
Recombinant baculovirus Packaging competent Terminus Exp 1 Exp 2 Exp 3 
Mean ratio 
Mean ratio 
relative to 
AcWTUL25 
L  1.3 1.8 1.6 1.6 1.0 AcWTUL25 + S  0.9 1.0 1.0 1.0 1.0 
L  4.3 2.7 2.7 3.5 2.2 AcpCI - S  0.6 0.6 0.6 0.6 0.6 
L  3.5 4.7 1.2 3.1 1.9 AcUL25-C3B - S  0.7 0.5 1.1 0.7 0.7 
L  1.8 2.0 1.4 1.7 1.0 AcUL25-C4A + S  1.0 0.7 0.8 0.8 0.8 
L  2.3 2.1 1.8 2.0 1.3 AcUL25-L3 + S  1.1 0.7 0.9 0.9 0.9 
L  3.5 5.0 2.1 3.5 2.2 AcUL25-L5 - S  0.5 0.5 0.5 0.5 0.5 
L  1.8 1.0 1.1 1.3 0.8 AcUL25-L6 + S  1.0 0.7 0.9 0.9 0.9 
L  4.0 4.0 5.5 4.5 2.8 AcUL25-Δ1-45 - S  0.5 0.7 0.5 0.6 0.6 
L  6.5 6.4 9.2 7.4 4.6 AcUL25-Δ1-59 - S 0.7 0.6 0.4 0.6 0.6 
L  7.1 7.4 10.3 8.3 5.2 AcUL25-Δ1-133 - S  0.8 0.5 0.5 0.6 0.6 
 
 
Table 5.2 Quantification of the L and S terminal fragments encapsidated during packaging assays 
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Figure 5.7 PFGE analysis of packaged DNA
U2OS monolayers were co-infected with the recombinant 
baculovirus indicated and    UL25MO.  At 24 hpi the cells were 
harvested and DNase-resistant DNA was prepared, using a 
gentle method without phenol extraction to reduce shearing.  
After the DNA molecules had been separated by PFGE, the 
DNA was blotted onto Hybond-N membrane and hybridised to 
32P labelled pGX2, which contains the HSV-1 BamHI K 
fragment.  The position of the 152 kb viral genomes are 
indicated by the black arrowheads. 
5 kb
10 kb
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detected in packaged DNA from cells infected with either the wt HSV-1 virus 
(lane 3) or co-infected with AcWTUL25 and ΔUL25MO (lane 6).  In addition, a 152 
kb band was also observed in the packaged DNA from cells co-infected with 
ΔUL25MO and AcUL25-L3, –L6 or –C4A (lanes 8, 9 and 10).  In contrast, no full-
length encapsidated DNA was evident in the negative control sample from cells 
co-infected with AcpCI and ΔUL25MO (lane 7), or in the other control samples 
from cells infected with either AcWTUL25 or ΔUL25MO alone (lanes 4 and 5).  
5.5 Discussion 
The ratio of L and S terminal fragments to joint fragment detected in BamHI 
digested packaged DNA samples from ΔUL25MO-infected U2OS cells expressing 
pUL25-L3, -L6 or -C4A were similar to values obtained for mutant-infected cells 
expressing the wt protein.  The results suggested that unit length genomes were 
encapsidated in ΔUL25MO-infected cells expressing these mutant proteins.  
These observations were confirmed by PFGE analysis of the packaged DNA 
extracted from cells co-infected with ΔUL25MO and AcUL25-L3, -L6 or –C4A, 
which showed that full-length HSV-1 DNA molecules were present in these 
samples.  The evidence presented here indicates that the UL25 mutant proteins, 
pUL25-C4A, -L3 and –L6, do not disrupt viral assembly during DNA packaging but 
at some stage after encapsidation.  In contrast, in ΔUL25MO-infected cells 
expressing pUL25-C3B, pUL25-L5, pUL25Δ1-45, pUL25Δ1-59 or pUL25Δ1-133, the 
L terminal region from the HSV-1 genome was overrepresented and the S 
terminal region was underrepresented.  These results signified that the mutated 
residues contained in pUL25-C3B, the unstructured region of L5 (residues 511-
513) and the first 45 residues in the N-terminal portion of UL25, are critical for 
HSV-1 packaging of unit-length DNA.   
Using the imaging program Chimera (http://www.cgl.ucsf.edu/chimera/), five 
of the six residues that were mutated in pUL25-C3B were located in or near a 
deep cleft situated in the C3 region of UL25 and their position on the molecule is 
indicated in Figure 5.8.  The image shows that four of the residues mutated in 
pUL25-C3B are situated directly in the crevice, with G169, S170 and G172 
present on one side of the cleft and R203 lying directly opposite, while the fifth 
residue (R202) lies along the ridge at the entrance to the cleft.  It is easy to 
G169
S170
G172
G202
R203
Figure 5.8 The C3 cleft of UL25 
The image shows a solid surface representation of wt pUL25 
and indicates the locations of the five residues in the C3 cleft 
that were mutated in pUL25-C3B.  Four of the amino acids 
are situated directly in the crevice, with R203 lying on the 
opposing face from G172, S170 and G169.  The fifth residue, 
G202, is positioned along the ridge at the entrance to the 
cleft.
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envisage an essential protein partner of pUL25, which is required during DNA 
packaging, docking with pUL25 at this region and interacting directly with the 
important residue(s) that have been identified here.  The position of C3 relative 
to L5, which contains the unstructured residues deleted in pUL25-L5, is indicated 
in Figure 5.9.  On the view shown L5 is situated on the front face of the 
molecule, while C3 lies on the opposing side at the base of the protein, 
approximately 1800 from L5.  Since each of these regions appear to be some 
distance apart and on opposite sides of the structure, it is possible that the C3 
and L5 regions interact with different binding partners that are required during 
DNA packaging.   
Since the N-terminal region of pUL25 (residues 1-133) is not included in the 
crystallographic structure of the protein, the position of this region relative to 
L5 and C3 is unclear.  However, the predicted secondary structure for this 
portion of UL25 includes a long alpha helix (residues 48-110) preceded by a 45-
residue unstructured N-terminal loop, which may become structured following 
protein binding.   Although sequence analysis of this region revealed that the N-
terminal loop is the least conserved portion of the protein (Bowman et al., 
2006), from the data presented here it does appear to be essential for packaging 
the full-length genome.  This finding is supported by a recent report by Cockrell 
et al. (2009), who constructed an HSV-1 mutant expressing an N-terminally 
truncated pUL25 lacking the first 50 residues, and showed that failure of the 
virus to replicate in Vero cells was due to aberrant cleavage of the US end of the 
viral genome during packaging.   They also provided evidence that residues 1-50 
of the protein mediated capsid attachment of UL25 in vitro.   
The work presented here indicates that UL25 contains at least three distinct 
regions, the N-terminal portion, L5 and C3, which are critical for the protein 
interactions necessary for efficient encapsidation of unit-length viral DNA.   
However, further analysis is necessary to clarify if the mutations contained in 
pUL25-C3B, pUL25-L5 and pUL25Δ1-45 disrupt a single functional interface on 
the protein, or if each interacts with a different binding partner during viral DNA 
packaging.     
    
Figure 5.9 Ribbon diagram of UL25nt with C3 and L5
The position of L5 relative to the C3 region is indicated.  The 
location of C3 is highlighted by the broken circle.  On the 
view shown, C3 is located on the opposing face, 
approximately 180o from L5.  
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6 The effect of pUL25-L3, -L6 and -C4A on virus 
assembly in ΔUL25MO-infected U2OS cells  
6.1 Introduction 
The finding that the non-complementing mutant proteins, pUL25-L3, -L6 or -C4A, 
altered the DNA packaging phenotype of ΔUL25MO, allowing the mutant to 
encapsidate unit-length viral DNA, indicated that virus assembly was disrupted 
after DNA packaging.  The aim of the experiments described here was to 
determine at which point(s) during viral assembly these post-packaging blocks 
occurred.  Two different approaches were used, ΔUL25MO-infected U2OS cells 
expressing pUL25-L3, -L6 or –C4A were examined under the electron microscope 
to investigate the patterns of virus assembly, and fluorescent in-situ 
hybridisation (FISH) analysis was carried out on the cells to determine the 
distribution of virus DNA.    
6.2 Electron microscopic (EM) analysis 
U2OS cells were co-infected with ΔUL25MO and AcWTUL25, AcpCI, AcUL25-L3,    
-L6 or -C4A (Section 2.2.12.6).  At 24 hpi the cells were harvested and 
embedded in resin.  Thin sections of the virus-infected cells were prepared, 
stained with uranyl acetate and osmium tetroxide, and examined under the 
electron microscope (Section 2.2.17.1).  Representative images from the 
samples analysed are shown in Figure 6.1A-6.1F.  In the positive control sample, 
in cells co-infected with ΔUL25MO and AcWTUL25, C-capsids were found in both 
the nuclear and cytoplasmic compartments as expected (Figure 6.1A).  In the 
negative control sample, in cells co-infected with ΔUL25MO and AcpCI, DNA-
containing capsids were seen in the nuclei but not in the cytoplasm (Figure 
6.1B).    In ΔUL25MO-infected cells expressing either pUL25-C4A or pUL25–L3, 
the pattern of virus assembly resembled that of the negative control where DNA-
containing capsids were detected in the nuclei but not in the cytoplasm (Figure 
6.1C and D).  In contrast, in ΔUL25MO-infected cells expressing pUL25-L6 the 
distribution of virus capsids was similar to that observed in the positive control, 
and DNA-containing C-capsids were detected in both the nuclear and 
Figure 6.1A Cells co-infected with    UL25MO and AcWTUL25
Monolayers of U2OS cells were co-infected with 2 PFU/cell    UL25MO and 50 
PFU/cell AcWTUL25.  At 24 hpi cells were fixed and prepared for EM (Section 
2.2.17.1).  The nucleus (nuc), cytoplasm (cyt) and nuclear membrane are 
labelled.  As expected, in infected cells expressing wt pUL25, free A- and B-
capsids were located only in the nuclear compartment, while free C-capsids 
were present in the nuclear and cytoplasmic compartments.  C-capsids located 
in vesicles are highlighted by the green arrowhead.  The size bar represents 
500 nm. 
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Figure 6.1B Cells co-infected with    UL25MO and AcpCI
Monolayers of U2OS cells were co-infected with 2 PFU/cell    UL25MO and 50 
PFU/cell AcpCI.  At 24 hpi cells were fixed and prepared for EM (Section 
2.2.17.1).  The nucleus (nuc), cytoplasm (cyt) and nuclear membrane are 
labelled.  DNA-containing capsids (white arrowhead) were present in the 
nuclear compartment, but not the cytoplasm of infected cells.
cytnuc
nuclear membrane
Figure 6.1C Cells co-infected with    UL25MO and AcUL25-C4A
Monolayers of U2OS cells were co-infected with 2 PFU/cell   UL25MO and 50 
PFU/cell AcUL25-C4A.  At 24 hpi cells were fixed and prepared for EM (Section 
2.2.17.1).  The nucleus (nuc), cytoplasm (cyt) and nuclear membrane are 
labelled.  DNA-containing C-capsids (white arrowhead) were retained in the 
nucleus of infected cells.
cyt
nuc
nuclear membrane
Figure 6.1D Cells co-infected with    UL25MO and AcUL25-L3
Monolayers of U2OS cells were co-infected with 2 PFU/cell   UL25MO and 50 
PFU/cell AcUL25-L3.  At 24 hpi cells were fixed and prepared for EM (Section 
2.2.17.1).  The nucleus (nuc), cytoplasm (cyt) and nuclear membrane are 
labelled.  Free DNA-containing C-capsids (white arrowhead) were retained in 
the nucleus of infected cells.
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Figure 6.1E Cells co-infected with    UL25MO and AcUL25-L6
Monolayers of U2OS cells were co-infected with 2 PFU/cell   UL25MO and 50 
PFU/cell AcUL25-L6.  At 24 hpi cells were fixed and prepared for EM (Section 
2.2.17.1).  The nucleus (nuc), cytoplasm (cyt) and nuclear membrane are 
labelled.  DNA-containing C-capsids (white arrowhead) were present in the 
nuclear and cytoplasmic compartments of infected cells.  Some cytoplasmic 
capsids surrounded by dense material (blue arrowhead), but not in vesicles, 
were also observed.
Figure 6.1F Cells co-infected with    UL25MO and AcUL25-L6
Monolayers of U2OS cells were co-infected with 2 PFU/cell   UL25MO and 50 
PFU/cell AcUL25-L6.  At 24 hpi cells were fixed and prepared for EM (Section 
2.2.17.1).  The nucleus (nuc), cytoplasm (cyt) and nuclear membrane are 
labelled.  The enveloped C-capsids located in vesicles in the cytoplasm are 
indicated by the green arrowheads and a C-capsid located in the nucleus is 
labelled.
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cyt
nuc
C-capsid
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cytoplasmic compartments of infected cells (Figure 6.1E).  Interestingly, groups 
of cytoplasmic C-capsids in ΔUL25MO-infected U2OS cells expressing pUL25-L6 or 
the wt protein were frequently found embedded in dense material (Figure 6.1E), 
a feature not observed in Vero or U2OS cells infected with wt HSV-1.  In 
addition, enveloped virus particles were found in cytoplasmic vesicles in 
ΔUL25MO-infected U2OS cells expressing wt pUL25 and to a lesser extent in the 
mutant-infected cells containing pUL25-L6.  An image showing the enveloped C-
capsids seen in ΔUL25MO-infected cells expressing pUL25-L6 is shown in Figure 
6.1F.       
The finding that the nuclei of U2OS cells co-infected with ΔUL25MO and AcpCI 
contained DNA-containing capsids, in addition to A- and B-capsids, was in 
contrast to earlier findings by McNab et al. (1998), who failed to detect DNA-
containing capsids in the nuclei of UL25 null KUL25NS-infected Vero cells.  The 
data from the packaging assays and the PFGE analysis described in this thesis 
confirmed that virus DNA was packaged in U2OS cells co-infected with ΔUL25MO 
and AcpCI, although most of the encapsidated DNA was less than unit-length.  In 
view of the different results obtained for the HSV-1 UL25 null mutants, the 
pattern of capsid assembly of ΔUL25MO was compared with that of KUL25NS in 
Vero cells, together with wt HSV-1-infected Vero cells.  As expected, C-capsids 
were detected in the nuclei and cytoplasm of wt virus-infected cells.  However, 
in contrast to the previous results of McNab et al. (1998), DNA-containing capsids 
in addition to A- and B-capsids were detected in the cell nuclei of KUL25NS-
infected Vero cells and in the nuclei of ΔUL25MO-infected Vero cells (Figure 
6.2).  However, no cytoplasmic C-capsids were observed in cells infected with 
either mutant. 
6.3 Fluorescent in-situ hybridisation (FISH) analysis 
To substantiate the conclusions from the EM data for the three post-packaging 
mutants, pUL25-L3, -L6 and -C4A, the distribution of the virus DNA in the 
infected U2OS cells was analysed using FISH (Section 2.2.17.2).  U2OS cells were 
infected with ΔUL25MO and the recombinant baculoviruses as described above 
and the cells were prepared for FISH analysis.  FISH is technique that detects 
and localises specific DNA sequences within the cell by using a fluorescent DNA 
KUL25NS
    UL25MO
A-capsid
A-capsid
B-capsid
B-capsid
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Figure 6.2 Vero cells infected with KUL25NS or    UL25MO
Monolayers of Vero cells were infected with 2 PFU/cell KUL25NS (top) or   UL25MO 
(bottom).  At 24 hpi cells were fixed and prepared for EM (Section 2.2.17.1).  The 
nucleus (nuc), cytoplasm (cyt) and nuclear membrane are labelled.  The DNA 
containing capsids in the nucleus are indicated by the blue arrowheads and the A- and 
B-capsids are labelled. The size bar represents 250 nm.  
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probe.  The viral DNA probe used in this study consisted of HSV-1 sequences 
79,442-115,152, which lie outwith the UL25 ORF, to eliminate the possibility of 
detecting baculovirus DNA containing the HSV-1 UL25 gene in the cells.  To 
visualise the virus DNA, the HSV-1 DNA probe was labelled by nick translation 
with cy3-dCTP, and to highlight the cell nuclei the cells were counterstained 
with DAPI (4’, 6’-diamidino-2-phenylindole) (Everett & Murray, 2005).  A 
representative image obtained for each sample is shown in Figure 6.3.  As 
expected, co-infection of cells with ΔUL25MO and AcWTUL25 gave rise to 
fluorescently labelled virus DNA in both in the nuclear and cytoplasmic 
compartments of the cell (Figure 6.3A).  In the negative control sample, where 
cells were co-infected with ΔUL25MO and AcpCI, fluorescence from the labelled 
DNA was visible only in the nucleus as predicted (Figure 6.3B).  In virus-infected 
cells expressing pUL25-L3 or pUL25-C4A the viral DNA was detected only in the 
nuclei, whereas in samples expressing pUL25-L6, viral DNA was observed in both 
the nuclear and cytoplasmic compartments of the infected cells (Figure 6.3C, D 
and E).  These results support the data obtained from the electron microscopic 
study.   
6.4 Discussion 
DNA-containing capsids as well as A- and B-capsids were detected in the nuclei 
of both KUL25NS and ΔUL25MO-infected Vero cells.  The reason for the anomaly 
between the observations made by McNab et al. (1998) in KUL25NS-infected Vero 
cells and the results obtained during this study is unclear.  However, the 
presence of DNA-containing capsids in the nuclei of HSV-1 UL25 null-infected 
cells is in agreement with a recent report on the pattern of virus assembly of 
another HSV-1 UL25 deletion mutant, HSV-1-ΔUL25.  In the non-permissive rabbit 
kidney cell line RK13 infected with this mutant, numerous electron-dense DNA-
containing capsids were seen in the nuclei but not the cytoplasm (Kuhn et al., 
2008).  In addition, DNA-containing capsids were also detected in the nuclei of 
cells infected with a BHV-1 UL25 null mutant and in the nuclei of cells infected 
with a PrV UL25 null mutant (Desloges & Simard, 2003, Klupp et al., 2006, Kuhn 
et al., 2008).  The electron microscopic results on ΔUL25MO and KUL25NS are 
also consistent with the data from the DNA packaging experiments presented in 
this thesis and earlier findings by Stow (2001), showing that in the absence of 
Figure 6.3 Spread of viral DNA within the cell
Monolayers of U2OS cells were co-infected with 2 PFU/cell  UL25MO and 50 PFU/cell AcWTUL25 (A), 
AcpCI (B), AcUL25-C4A (C), AcUL25-L3 (D) or AcUL25-L6 (E).  At 24 hpi cells were fixed and  
prepared for confocal microscopy (Section 2.2.17.2).  The viral DNA was visualised by FISH using 
Cy3-labelled probe (orange) and the nuclei were stained with DAPI (blue).   
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pUL25 the cleaved HSV-1 DNA is encapsidated, although the packaged DNA is 
shorter that the full-length viral genomes.   
In ΔUL25MO-infected U2OS cells expressing the mutant proteins pUL25-L3, -L6 or    
–C4A, the UL25 null mutant acquired the capacity to encapsidate full-length viral 
DNA but failed to produce infectious virus particles.  The EM and FISH data from 
ΔUL25MO-infected cells expressing pUL25-C4A or pUL25-L3 demonstrate that the 
wt UL25 residues mutated in these proteins are essential for egress of mature C-
capsids from the nuclear compartment during infection.  In contrast, the three 
unstructured amino acids that were deleted in pUL25-L6 are critical for viral 
replication after nuclear egress and once the capsids have been released into 
the cytoplasm.  These results indicate that pUL25 has at least two further 
distinct roles to play during virus assembly in addition to DNA-packaging.   
Using Southern blot analysis Stow (2001) demonstrated that in non-permissive 
cells infected with KUL25NS less than unit-length DNA was stably packaged in 
the nuclear capsids and that these DNA-containing capsids were not translocated 
to the cytoplasm.  These observations led to the suggestion that pUL25 is 
important during nuclear egress.  However, a possible mechanism for the failure 
of the DNA-containing capsids to exit the nucleus in UL25 null-infected cells is 
that encapsidated full-length DNA may be necessary for the conformational 
changes required that allow more pUL17 and consequently pUL25 to bind, 
stabilising the structure and triggering primary envelopment.  The results 
obtained in this study with ΔUL25MO-infected U2OS cells expressing pUL25-C4A 
or pUL25-L3 revealed that after full-length DNA is packaged, pUL25 is required 
for egress of capsids from the nucleus.   
In a non-permissive rabbit kidney cell line (RK13) infected with a PrV UL25 null 
mutant, although capsids failed to exit the nucleus, DNA-containing capsids were 
found in close association with the INM (Klupp et al., 2006).  These results 
suggest that the lack of pUL25 does not affect the transport machinery required 
to relocate capsids to the site of primary envelopment at the INM, but does 
affect the ability of the capsids to bud into the INM.  In contrast, in RK13 cells 
infected with the HSV-1 UL25 mutant, HSV-1-ΔUL25, DNA-containing capsids 
were dispersed throughout the nuclei and were not found frequently lining the 
INM (Kuhn et al., 2008).  Similarly, in ΔUL25MO-infected cells expressing either 
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pUL25, pUL25-C4A, -L3 or –L6, and in the negative control sample C-capsids were 
dispersed throughout the nuclear compartment and did not appear to be 
specifically associated with the INM during infection (Figure 6.1A-6.1E).  In 
addition, since no capsids were observed in the perinuclear space this suggested 
that there was a defect during primary envelopment in virus-infected cells 
expressing pUL25-C4A or -L3.  Therefore, it is not clear whether C-capsids 
trapped in the nuclei of virus-infected cells expressing either pUL25-C4A or 
pUL25-L3 were unable to be transported to the site of envelopment, or lacked 
the ability to interact with the proteins essential for primary envelopment, 
pUL31 and/or pUL34, or other viral or cellular proteins required during this 
process.  As discussed in Chapter 4, the residues mutated in pUL25-C4A and 
pUL25-L3 lie in close proximity to one another, along a loop on the surface of 
UL25nt and illustrated in Figure 4.17.  Since both regions lie in the same area of 
pUL25 and ΔUL25MO has a similar phenotype in U2OS cells expressing either 
pUL25-C4A or pUL25-L3, it is conceivable that each mutated region disrupts the 
same functional interface of the protein.  Potentially, one or more of the wt 
residues that were mutated in pUL25-C4A could be directly involved in the 
interactions that are required during primary envelopment.  In contrast, the 
region that is deleted in pUL25-L3 may operate indirectly, by changing the 
conformation of the protein and blocking the ability of pUL25 to establish new 
interactions that are critical during egress.  Since HSV-1-C4A and –L3 have 
recently been constructed in the lab, it would be interesting to determine 
whether these two mutant viruses complement, which would clarify if the C4 
and L3 regions of pUL25 do indeed constitute a single interaction site. 
In ΔUL25MO-infected cells expressing pUL25-L6, some of the C-capsids located in 
the cytoplasm were surrounded with a dense material that may reflect the 
presence of tegument (Figure 6.1E).  None of these capsids were enveloped and 
located inside vesicles, which would be expected following secondary 
envelopment.  Since cytoplasmic C-capsids were often detected in clusters 
embedded in dense material, a feature that was not observed in wt HSV-1-
infected Vero or U2OS cells or in U2OS cells co-infected with ΔUL25MO and the 
negative control baculovirus, AcpCI, it is possible that some of the material 
associated with cytoplasmic C-capsids could be aggregates of pUL25.  In U2OS 
cells the UL25 gene in the recombinant baculovirus is under the control of the 
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powerful HCMV IE promoter, therefore higher levels of pUL25 may be present in 
the U2OS cells than in wt virus-infected Vero cells.  Although envelopment of C-
capsids was observed in cells expressing pUL25-L6, there were fewer enveloped 
virus particles both inside the cell and on the cell surface than in ΔUL25MO-
infected U2OS cells expressing wt pUL25.  Consistent with these observations, 
the mutant-infected cells expressing pUL25-L6 contained more angularised 
capsids in the cytoplasm than cells expressing the wt protein.  Since the original 
complementation experiments had been performed in non-permissive ΔUL25MO-
infected Vero cells expressing pUL25-L6, the presence of enveloped particles in 
ΔUL25MO-infected U2OS cells did raise some concern that pUL25-L6 may 
complement the growth of the mutant virus in these cells.  However, subsequent 
complementation analysis confirmed that the defect in pUL25-L6 was also 
apparent in U2OS cells expressing the pUL25-L6 mutant protein (M. Murphy, 
personal communication).  In addition, electron microscopic studies with a new 
mutant HSV-1-UL25-L6 virus that had been generated in our lab corroborated the 
findings with ΔUL25MO-infected U2OS cells expressing the pUL25-L6 mutant 
protein (V. Preston, personal communication).  
L6 is made up of three unstructured residues that are located directly at the C-
terminus of pUL25, which may become structured during the correct protein-
protein interaction.  Interestingly, these last three residues of pUL25 (S578, 
A579 and V580) form a potential class I PDZ domain-binding motif.  The 
sequence requirements for the different PDZ-binding motifs are outlined in 
Table 6.1.  PDZ domains are modular protein interaction domains that are 
approximately 90 amino acids long, which bind the C-termini of target proteins 
in a sequence-specific manner.  Their structural features allow them to mediate 
specific protein-protein interactions that underlie the assembly of large protein 
complexes involved in signalling and subcellular transport (Ham & Hendriks, 
2003, Hung & Sheng, 2002).  They are amongst the most common protein 
domains represented in sequenced genomes and have been recognised in 
numerous proteins from organisms as diverse as bacteria, plants, yeast, 
Drosophilia and metazoans (Ponting, 1997).  Interestingly, the three C-terminal 
residues from one of the head stabilising proteins of bacteriophage λ, gpW, 
which are thought to be unstructured, display sequence specificity for a Class     
II PDZ domain-binding motif and are critical for the protein’s            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             X = unspecified amino acid          φ = a hydrophobic amino acid   
PDZ Binding Motifs 
Class C-terminal Sequence 
Class I X-S/T-X-φ-COOH 
Class II X-φ-X-φ -COOH 
Class III X-D/E-X-φ-COOH 
Class I - UL25 loop 6 L-S-A-V-COOH  
Table 6.1 Classes of PDZ domain-binding motifs 
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activity (Maxwell et al., 2000).  The PROSITE bioinformatics program 
(http://www.expasy.org/prosite/) searches a given protein sequence for 
patterns that reflect protein domains, including PDZ domains.  Since pUL25 
contains sequences that form a PDZ domain-binding motif and evidence indicates 
that pUL36 interacts with pUL25 (Coller et al., 2007, Pasdeloup et al., 2009), 
PROSITE was used to search the protein sequences of HSV-1 strain 17 syn+ pUL36, 
and pUL37 for PDZ domains.  However, no potential PDZ domain sequences were 
found in either tegument protein.   
Intriguingly, a sequence alignment of alphaherpesviruses pUL25 homologues 
showed that 75% contained potential Class I or II PDZ binding motifs at the C-
terminus (Table 6.2).  In addition, across the alpha-, beta- and 
gammaherpesviruses subfamilies, approximately 73% of the C-terminal 
sequences of the UL25 homologues analysed also contained either Class I or II 
potential PDZ binding motifs.  The other L6 construct generated, pFB-UL25-
L6sub, consisted of substitutions S579A and V580A that, together with A579, 
formed a potential Class II PDZ-binding motif at the C-terminus of UL25 (L-A-A-A-
COOH).  The mutant protein expressed by pFB-UL25-L6sub during 
complementation analysis retained the ability to support the growth of 
ΔUL25MO, producing complementation yields of 80% in comparison to the wt 
positive control (Figure 4.14).  Although the wt pUL25 contains a Class I PDZ 
binding motif there is evidence that single PDZ domains may recognise and bind 
to more than one class of PDZ binding motif (Ham & Hendriks, 2003, Sheng & 
Sala, 2001).  However, a mutant pUL25 containing sequences that do not form a 
PDZ domain-binding motif at the C-terminal L6 region would need to be 
generated and analysed in order to clarify the relevance of such a motif during 
HSV-1 replication.   
    
  
Alphaherpesviruses C-terminal sequence  PDZ binding motif  
HSV-1 L-S-A-V-COOH Class I 
HSV-2 L-S-V-A-COOH Class I 
HHV-3 A-S-T-P-COOH - 
SuHV-1 F-A-A-A-COOH Class II 
CeHV-1 L-S-A-A-COOH Class I 
CeHV-2 L-S-T-A-COOH Class I 
CeHV-9 T-S-V-A-COOH Class I 
CeHV-16 L-S-T-A-COOH Class I 
 
BoHV-1 
 
T-S-A-V-COOH Class I 
BoHV-5 T-S-A-V-COOH Class I 
EHV-1 T-S-A-M-COOH Class I 
EHV-4 T-S-A-M-COOH Class I 
GaHV-1 Q-R-G-V-COOH - 
GaHV-2 I-S-T-L-COOH Class I 
MeHV-1 V-S-A-P-COOH - 
PsHV-1 V-T-I-A-COOH Class I 
 
Table 6.2 Potential PDZ binding-domains at the C-terminus of alphaherpesvirus UL25 
homologues 
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7 Interaction of mutant pUL25s with the capsid-
binding domain of pUL36 
7.1 Introduction 
The aim of the experiments described in this section was to determine the 
ability of the UL25 mutant proteins, pUL25-C4A, L3, -L5 and -L6 to interact with 
the CBD of HSV-1 pUL36 (pUL36cbd) identified by Coller et al. (2007).  These 
workers showed that the carboxyl terminus of the UL36 tegument protein is 
functionally conserved in HSV-1 and PrV and is a capsid-binding domain.  Using a 
mutant virus screen they found that pUL25 was essential for association of the 
pUL36cbd with nuclear capsids.  The results from co-immunoprecipitation 
experiments confirmed that pUL25 interacted directly with the CBD and the full 
length pUL36 (Coller et al., 2007, Pasdeloup et al., 2009).  To investigate 
whether any of the mutant UL25 proteins failed to interact with pUL36cbd, 
which consists of the 62 carboxyl-terminal residues of the tegument protein, a 
GST pull-down assay was set up.  An outline of the GST-gene fusion system and 
the GST pull-down assay is described in Section 2.2.19.     
7.1.1 Construction of GST-UL36cbd expression plasmid 
 A DNA fragment specifying the HSV-1 pUL36cbd (amino acids 3104–3164) was 
cloned into the plasmid pGEX-2TNMCR in frame with the GST gene, enabling the 
GST tag to become fused to the N-terminal region of the expressed pUL36cbd 
(Everett et al., 1997).  The DNA fragment encoding the pUL36cbd was generated 
by PCR using the HSV-1 cosmid Cos14, which contained the entire UL36 ORF, as a 
DNA template, and the primers 36cbd-F and 36cbd-R that incorporated the 
cloning sites EcoRI and BamHI, respectively,  (Table 7.1) (Cunningham & Davison, 
1993).  In addition, an internal NruI site was introduced by silent mutagenesis 
into the nucleotide sequence of 36cbd-F.  The 198 bp PCR fragment, which was 
amplified using the PCR-cycle1 (Section 2.2.1.2), was purified and ligated to 
pGEM-T Easy.  The ligated DNA was electroporated into DH5α and plasmid DNA 
was prepared from the isolates obtained.  Since NruI does not digest pGEM-T 
Easy sequences, the recombinant pGEM-T Easy plasmids were identified by the 
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presence of the single NruI site located in the sequences encoding pUL36cbd.  
DNA samples from these plasmids were sequenced using the M13 sequencing 
primers (Table 4.1), and one was identified that contained the desired PCR 
product.  The HSV-1 insert was released from the pGEM-T Easy recombinant by 
digestion with EcoRI plus BamHI, and the purified HSV-1 fragment was then 
ligated to the 4921 bp pGEX-2TNMCR EcoRI-BamHI fragment.  The ligated DNA 
was electroporated into electrocompetent DH5α and plasmid DNA was prepared 
from the isolates obtained.  Since NruI does not cut pGEX-2TNMCR, only 
recombinant plasmid DNAs containing the HSV-1 insert (pGEX-UL36cbd) were 
linearised with NruI.  One plasmid isolate containing a single NruI site was 
selected and used in protein expression experiments.   
 
 
Primer ID pUL36cbd Primers  
36cbd-F 
 
5’-TGGAATTCCCCGTATCGGCAAACGCAGTTCTGTCGCGACGCTACGTGC-3’  
           EcoRI                                                               NruI 
36cbd-R 
 
5’-TAGGATCCGCCCAGTAACATGCGCACGTGATGTAGGCTGGTCAGCACG-3’   
          BamHI 
Table 7.1 The primers used to generate the PCR fragment encoding pUL36cbd 
 
7.1.2 GST pull-down assay 
To express the desired proteins, electrocompetent E. coli BL21 were 
electroporated with either pGEX-UL36cbd, which encoded the GST tagged 
pUL36cbd, or pGEX-2TNMCR, which encoded the GST protein alone, as described 
in Section 2.2.19.1.  Initially, the expression of GST and pGST-UL36cbd in the 
transformed E. coli BL21 cells was poor, but by increasing the IPTG 
concentration from 0.1mM to 0.2 mM and by extending the incubation period for 
IPTG induction from 2 h to 3 h at 37oC, both proteins were detected at levels 
sufficient for analysis (Figure 7.1).   
The GST pull-down assays were carried out according to the method described in 
Section 2.2.19.3.  Essentially, the soluble extracts containing bacterially 
expressed GST or pGST-UL36cbd (bait proteins) were mixed with Glutathione-
Sepharose 4B beads.  The GST protein bound beads served as a control to 
Figure 7.1 Expression of GST and pGST-UL36cbd in E. coli
Western blot analysis of E. coli BL21 lysates expressing GST (lanes 1 and 2) or 
pGST-UL36cbd (lanes 3 and 4).  E. coli BL21 transformed with pGEX2TNMCR or 
pGEX-UL36cbd were grown at 37oC to an O.D of 0.4-0.6 and either harvested 
(uninduced samples) or treated with 0.2mM IPTG for 3 h at 37oC (induced samples).  
Bacterial lysates were prepared, the proteins were separated by SDS-PAGE and 
analysed by Western blotting using anti-GST antibody.  The arrow head indicates the 
protein band that corresponds to the predicted size of GST (26 kDa) in lane 2 or 
pGST-UL36cbd (32 kDa) in lane 4.
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confirm that there was no non-specific binding of the target protein lysates to 
the GST tag during the assay.  The beads with the bound bait proteins were 
concentrated and washed extensively to remove any non-specifically bound 
proteins.  Duplicate samples of pre-cleared baculovirus-infected Sf21 cell 
lysates, containing expressed wt pUL25, pUL25-C4A, -L3, -L5, or -L6, were 
subsequently mixed with the GST or the pGST-UL36cbd charged beads.  A 
negative control lysate sample, derived from AcpCI-infected Sf21 cells, was 
included.  After the samples had been incubated at 4oC for 1.5 h, the beads 
were washed extensively.  The proteins were eluted from the beads, separated 
by SDS-PAGE and analysed by Western blotting, using anti-GST antibody or anti-
pUL25 MAb166 as primary antibodies followed by secondary anti-goat hrp-
conjugated antibody and anti-mouse hrp-conjugated antibody, respectively.  
Since the detergent concentration and the concentration of fusion and target 
proteins applied can affect the proteins pulled down during the assay, these 
conditions were optimised prior to experimental analysis.  Aliquots of the 
baculovirus-infected cell extracts were mixed with Glutathione-Sepharose 
beads, the beads were removed and the extracts were analysed by SDS-PAGE to 
estimate the amount of pUL25 present in each of the extracts so that equivalent 
concentrations of each target protein could be used in the assay (data not 
shown).  Similarly, aliquots of the bacterial extracts were mixed with 
Glutathione-Sepharose beads, the beads were washed and the eluted proteins 
were analysed by SDS-PAGE to determine the amount of bait protein in the 
extract.   
A control experiment was performed to ensure that the expressed wt pUL25 
specifically bound to pGST-UL36cbd beads and not to GST charged glutathione 
beads.  AcWTUL25-infected and AcpCI-infected Sf21 protein samples were each 
incubated with beads charged with GST or pGST-UL36cbd, and the results of the 
protein interaction assays are shown in Figure 7.2.  The appropriate bait protein 
was detected in all samples (Figure 7.2 blot A, lanes 1-4).  In the GST pull-down 
assay using target protein samples with, or without, pUL25, no pUL25 band was 
detected in the protein blot probed with anti-pUL25 MAb166 (Figure 7.2 blot B, 
lanes 2 and 4), confirming that pUL25 did not bind to GST.  Similarly, in a pGST-
UL36cbd pull-down assay using target protein samples with no pUL25 probed 
with MAb166, no band of the expected size of pUL25 was observed in the blot 
Figure 7.2 GST pull-down assay to determine the specificity of binding of wt pUL25 to 
pGST-UL36cbd 
The GST pull-down assay was carried out according the method described in Section 2.2.19.3.  
AcWTUL25-infected U2OS cell extracts containing wt pUL25 (lanes 1 and 2) and AcpCI-infected 
U2OS cell extracts (lanes 3 and 4) were incubated with Glutathione beads charged with pGST-
UL36cbd (lanes 1 and 3) or GST (lanes 2 and 4).  The beads were washed and the co-precipitated 
proteins were analysed by SDS-PAGE followed by Western blotting.  Blot A was stained with anti-
GST antibody at a concentration of 1:2000 followed by the secondary anti-goat hrp-conjugated 
antibody diluted at 1:80,000.  Blot B was stained with anti-pUL25 MAb166 at a concentration of 
1:1000 followed by seondary anti-mouse hrp-conjugated antibody diluted at 1:1000.
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(Figure 7.2 blot B, lane 3).  However, a protein with a molecular weight of 
approximately 62 KDa was present when the AcWTUL25-infected cell sample was 
used in a pGST-UL36cbd pull assay (Figure 7.2 blot B, lane 1), confirming that 
the CBD of pUL36 interacted with wt pUL25.           
The results of the GST pull-down assay to determine whether pGST-UL36cbd 
formed stable interactions with the target mutant proteins, pUL25-C4A, -L3, -L5 
or –L6, are shown in Figure 7.3.  The pGST-UL36cbd was detected in the pGST-
UL36cbd pull-down assay protein samples eluted from the beads and analysed by 
Western blotting using anti-GST antibody, confirming the presence of the fusion 
protein (Figure 7.3 blot A).  Similarly, the GST protein was present in GST pull-
down assay protein samples eluted from the beads (Figure 7.3 blot B).  To 
determine the ability of the mutant UL25 proteins to form stable interactions 
with the GST fusion protein, duplicate pGST-UL36cbd and GST pull-down protein 
samples eluted from the beads were separated by SDS PAGE, and analysed by 
Western blotting using anti-pUL25 MAb166 antibody.  As expected, in the pGST-
UL36cbd pull-down assay a band of the predicted size for pUL25 (62 KDa) was 
present in the wt pUL25 protein extract but not in the negative control extract 
lacking pUL25, confirming that the UL25 MAb166 reacted specifically with pUL25 
(Figure 7.3 blot C, lanes 1 and 2).  In addition, a band of approximately 62 KDa 
was also detected in each of the mutant protein extracts eluted from the beads 
in the pGST-UL36cbd pull-down assay (Figure 7.3 blot C, lanes 3-6).  No protein 
bands of the size of pUL25, however, were observed in the GST blot.  The results 
indicate that wt and mutant UL25 proteins formed stable interactions with 
pGST-UL36cbd.   
7.2 Discussion 
The data presented here indicate that the mutations present in pUL25-C4A, -L3, 
-L5 and –L6 do not disrupt the interaction of UL25 with the CBD of pUL36.  
Although the GST pull-down assay is an important instrument for determining 
protein interactions, the results have to be interpreted carefully.  The presence 
of the GST tag may alter the conformation of the fusion protein in a manner that 
exposes or conceals potential interaction sites.  In addition, the amounts of 
fusion and target protein applied in the assay may not reflect physiological 
Figure 7.3 GST pull-down assay to determine the interaction of pUL25-L3, -L5, -
L6 and -C4A with pGST-UL36cbd 
The GST pull-down assay was carried out according the method described in Section 
2.2.19.3.  Pre-cleared baculovirus-infected U2OS cell extracts containing either wt 
pUL25, no pUL25, pUL25-L3, -L5, -L6 or -C4A (lanes 1, 2, 3, 4, 5 or 6, respectively in 
blots A, B, C or D) were incubated with Glutathione beads charged with pGST-
UL36cbd (blots A and C) or GST (blots B and D).  The beads were washed and the 
co-precipitated proteins were analysed by SDS-PAGE followed by Western blotting.  
Blots A and B were incubated with anti-GST antibody and blots C and D were 
incubated with anti-pUL25 MAb166 and subsequently with secondary hrp-conjugated 
antibody as described in Figure 7.2.
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concentrations of the proteins found in vivo.  Both of these factors may produce 
aberrant results that lead to incorrect conclusions about the absence or 
presence of an interaction.   
The wt residues mutated in pUL25-L5 are essential during packaging of full-
length viral DNA (Section 5.3).  Perhaps it is not surprising that pUL25-L5 and 
pUL36cbd interact, since the pUL25-L5 mutation would be predicted to affect a 
functional interface that interacts with the capsid.  The presence of pUL25 on 
capsids is required for efficient binding of the pUL36cbd onto capsids (Coller et 
al 2007), therefore, the pUL25 functional interface involved in capsid 
interactions and pUL36cbd-binding may be distinct.  The packaging assays 
performed during this study identified three distinct regions essential for 
encapsidation, the N-terminal portion of UL25 (residues 1-45), C3B and L5 
(Section 5.3).  Recent work has demonstrated that the N-terminal portion of 
pUL25, amino acids 1-50, contains a capsid-binding domain (Cockrell et al., 
2009).  In addition, the CCSC identified on C-capsids using cryo-electron 
microscopy and image reconstruction techniques was predicted to be a complex 
of pUL25 and pUL17, with additional contact points for pUL25 calculated to be 
on the triplexes and hexons (Trus et al., 2007).  Since pUL25 has been shown to 
interact directly with all three proteins, it is possible that the protein 
incorporates more than one capsid-binding interface, one of which could be 
associated with the L5 region (Ogasawara et al., 2001; Thurlow et al., 2006).  
Clearly, characterisation of a mutant HSV-1 expressing pUL25-L5 would resolve 
this.     
The post-packaging mutants pUL25-C4A, -L3 and –L6 would be expected to bind 
to capsids during encapsidation, since ΔUL25MO-infected cells expressing these 
proteins produced mature C-capsids (Section 5.3).  The wt residues mutated in 
pUL25-C4A and pUL25-L3 are essential for nuclear egress of C-capsids, while the 
pUL25-L6 mutation disrupts viral replication once the C-capsids have been 
released into the cytoplasm (Section 6.2).  Although each of these post-
packaging UL25 mutant proteins still interacted with pUL36cbd during the GST 
pull-down assay, an alternative pUL25 binding domain (pUL25 BD II) has recently 
been identified in HSV-1 pUL36 between residues 2037-2353 (Pasdeloup et al., 
2009).  In addition, the N-terminal portion of the protein has been reported to 
associate with capsids in virus-infected cells (Roberts et al., 2009).  It is possible 
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that either pUL25-C4A, -L3 or –L6 failed to bind to pUL36 at an alternative site.  
Certainly, the EM observations suggested that secondary envelopment was 
disrupted in ΔUL25MO-infected cells expressing pUL25-L6, since fewer enveloped 
viral particles were seen in the cytoplasm of these cells (Section 6.2), which may 
indicate a disruption during the earlier stage of tegumentation.   
Chapter 8                                                                                                                                        157 
8 General Discussion 
The overall aim of the work carried out in this thesis was to relate the function 
of pUL25 to the 3D structural information available for the protein.  Fourteen 
UL25 constructs were generated and a total of 17 UL25 mutant proteins were 
characterised to determine the effect of the mutations on the function of pUL25 
(Table 4.2).  The results of this study are summarised in Table 8.1 and show that 
there were three different classes of pUL25 mutants that failed to complement 
the growth of the UL25 null mutant ΔUL25MO.  One category of mutant had 
lesions that affected the role of pUL25 during DNA packaging, whereas the 
mutants in the two other groups had no effect on the DNA packaging function of 
the protein.  Interestingly, the post-packaging mutants disrupted a pUL25 
function required either for the exit of C-capsids from infected nuclei or during 
virus assembly after C-capsids were released into the cytoplasm.  The two novel 
phenotypes displayed by ΔUL25MO in non-permissive cells expressing the post-
packaging mutant proteins demonstrates for the first time that pUL25 is not only 
important for DNA encapsidation but also has essential roles at later stages of 
virus maturation.  
Three regions of pUL25, C3, L5 and the N-terminal domain from residues 1-45, 
were identified as critical for the encapsidation of full-length viral genomes.  
The UL25 encoded gene product is predicted to stabilise the maturing capsid by 
attaching to binding sites that become available during DNA packaging, and 
recent work by Trus et al. (2007) suggested that pUL25 attaches to C-capsids by 
interacting with different proteins, VP5 present in the peripentonal hexon, the 
triplex subunit, Ta, and pUL17.  Studies using mutant viruses or immunological 
assays have provided further evidence that pUL25 interacts with VP5, VP19C and 
pUL17 (Newcomb et al., 2006, Ogasawara et al., 2001, Pasdeloup et al., 2009, 
Thurlow et al., 2006).  While additional work is necessary to confirm that C3, L5 
and the N-terminal domain represent distinct functional interfaces, it is possible 
that the three regions identified here represent each of the potential UL25 
capsid-binding sites proposed by Trus et al. (2007).  Indeed, Cockrell et al. 
(2009) recently confirmed that the N-terminal portion of UL25 (residues 1-50) 
constitutes a capsid-binding domain.  To determine if any of the mutant UL25 
proteins disrupted the interaction with wt pUL17, the proteins were expressed in 
 UL25 protein Complement ΔUL25MO 
 
Full-length DNA Packaging  
 
Virus location 
(EM) 
Viral DNA location 
(FISH) 
Interaction with  
UL36 CBD 
pUL25 + + cytoplasm cytoplasm + 
pUL25-C1 +     
pUL25-C2 +     
pUL25-C3A +     
pUL25-C3B +     
pUL25-C4A - + nucleus nucleus + 
pUL25-C4B -     
pUL25-L6sub +     
pUL25-L1 +     
pUL25-L2 +     
pUL25-L3 - + nucleus nucleus + 
pUL25-L4 +     
pUL25-L5 - -   + 
pUL25-L6 - + cytoplasm cytoplasm + 
pUL25Δ1-45 - -    
pUL25Δ1-59 - -    
pUL25Δ1-133 - -    
pUL25-C1L2 +     
 
Table 8.1 Summary of the characteristics of the UL25 proteins 
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U2OS cells co-infected with AcWTUL25 or individual mutant AcUL25 recombinant 
baculoviruses and AcUL17 or were singly infected with each virus and 
immunoprecipitation assays were performed.  Although acceptable amounts of 
the wt and mutant UL25 proteins were generated by the recombinant 
baculovirus in these cells, the levels of pUL17 expressed were substantially less 
than those of pUL25 and an interaction between the two wt proteins could not 
be demonstrated with UL17 MAb (data not shown).  It was unclear why the levels 
of pUL17 under the control of the HCMV IE promoter were low, although this was 
a reproducible finding.  Unfortunately, there was insufficient time to investigate 
this further and complete the experiments.  Mutant HSV-1 viruses encoding the 
C3B or L5 mutant proteins are currently being constructed in the laboratory.  
The availability of these mutant viruses will allow the levels of mutant pUL25 
present on purified capsids from mutant virus-infected cells to be compared 
with purified wt B-capsids and help to determine if the mutant pUL25s bind to 
capsids.  In addition, immunoprecipitation assays can be carried out on the 
mutant virus-infected cells to establish whether the mutant pUL25s interact with 
pUL17. 
Recent immunoprecipitation experiments have shown that pUL25 binds to pUL6, 
which is the structural unit that comprises the dodecameric portal and where 
the viral DNA is inserted during packaging (Pasdeloup et al., 2009).  Although 
pUL25 has been demonstrated to lie adjacent to the pentons, its association 
with pUL6 indicates that protein may also be located at the unique vertex 
occupied by the portal, which is consistent with pUL25’s function during DNA 
packaging (Newcomb et al., 2006, Pasdeloup et al., 2009).  In addition to its 
predicted indirect role of stabilising the maturing capsid during DNA packaging, 
pUL25 may also bind directly with packaging machinery at the portal to ensure 
full-length viral genomes are encapsidated.  It is therefore possible that C3, L5, 
the N-terminal region of pUL25, or a combination of these regions, is required 
for the interaction of the protein with pUL6.   
Although the UL25 mutant ts1249 has an uncoating defect at the NPT, the 
mutant also displays a packaging defect if ts1249-infected cells are grown at the 
PT to allow uncoating of the viral genome prior to incubation at the NPT.  The 
ts1249 phenotype is the result of the replacement of the negatively charged 
glutamic acid at position 233 in pUL25 with a positively charged lysine residue.  
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To determine if this mutation was structurally linked to the functional interfaces 
C3 and L5 involved in DNA packaging or to any of the other predicted functional 
clusters or unstructured portions of UL25, the ts1249 E233K mutation was 
located with respect to these regions on the UL25nt crystal structure using the 
Chimera structural imaging program (http://www.cgl.ucsf.edu/chimera).  The 
glutamic acid residue, which is highly conserved among the alphaherpesvirus 
UL25 homologues, was found on the surface of pUL25 near a looped out region 
that is distinct from L1-L5.  Since the glutamic acid residue does not lie close to 
any of the clusters identified by Bowman et al. (2006), it is unlikely that the 
ts1249 mutation affects the same functional interface as the ones identified 
here.   
The residues mutated in pUL25-C4A and -L3 disrupted the function required for 
nuclear egress of C-capsids when the proteins were expressed in ΔUL25MO-
infected cells.  As discussed in Chapter 6, the mutated regions of C4 and L3 may 
fail to interact with the transport machinery required to move C-capsids to the 
site of primary envelopment or affect the ability of the capsids to bud into the 
INM.  The obvious binding partners for pUL25 at this point during virus assembly 
are the proteins that are essential during primary envelopment, pUL31 and 
pUL34.  However, it is possible that other viral or cellular protein partners are 
required by pUL25 at this stage of the HSV-1 growth cycle, with a prime 
candidate viral protein being pUL36, although the point at which pUL36 
associates with the capsid is controversial.  Coller et al. (2007) showed that the 
transiently expressed pUL36cbd-GFP fusion protein bound to capsids in the 
nuclei of virus-infected cells.  The small size of the CBD (62 amino acids), 
however, enabled the fusion protein to passively diffuse through nuclear pores.  
Whether full-length pUL36 enters the nucleus and binds to nuclear capsids during 
infection is debatable.  In three separate studies it was reported that pUL36 was 
excluded from the nucleus, present in reduced levels in the nucleus relative to 
the cytoplasm, or evenly distributed throughout the nucleus and the cytoplasm 
(Klupp et al., 2002, Klupp et al., 2006, McNab & Courtney, 1992).  Experiments 
using cell fractionation and capsid purification suggested that full-length HSV-1 
pUL36 was associated with intranuclear HSV-1 capsids (Bucks et al., 2007).  
However, a subsequent study reported that no large proteins indicative of pUL36 
were detected in preparations of purified nuclear HSV-1 capsids (Trus et al., 
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2007).  The idea that pUL36 attaches to capsids in the cytoplasm is supported by 
observations using UL36 null mutants.  Ultrastructural analysis of non-permissive 
cells infected with an HSV-1 pUL36 deletion mutant, KΔUL36, revealed an 
accumulation of unenveloped nucleocapsids in the cytoplasm, with no obvious 
defects in DNA packaging or nuclear egress (Desai, 2000).  In addition, a similar 
phenotype has been described for the PrV pUL36 deletion mutant PrV-ΔUL36F 
(Fuchs et al., 2004).  Consistent with these findings, a recent study 
demonstrated that removal of the entire HSV-1 UL36 ORF did not prevent 
efficient egress of capsids from the nucleus (Roberts et al., 2009).  Electron 
microscopic analysis of UL36 null mutant ARΔUL36-infected U2OS cells confirmed 
that this mutant had the same phenotype in these cells as reported previously 
(data not shown) (Roberts et al., 2009).  Therefore, in the light of the phenotype 
displayed by the UL36 null mutants, it is unlikely that expression of the mutant 
C4 or L3 proteins in ΔUL25MO-infected cells affects pUL25’s interaction with 
pUL36 in the nucleus and at a stage that would influence nuclear egress of C-
capsids.  This conclusion is supported by the results of an interaction assay using 
the pGST-UL36cbd fusion protein showing that these two UL25 mutant proteins 
retained the capacity to interact with the C-terminal end of pUL36. 
 
An alternative explanation for the phenotypes observed in ΔUL25MO-infected 
cells expressing C4 and L3 mutant proteins, is that there may be additional 
capsid-binding sites for pUL25 that are distinct from those required during DNA 
packaging.  Consistent with this idea is the suggestion by Trus et al. (2007) that 
there is a ‘hidden’ population of pUL25 present on C-capsids, in addition to the 
pUL25 associated with CCSC at the pentons.  It is possible that binding of this 
alternative UL25 protein population to C-capsids, for example at the portal, 
triggers the appropriate exit machinery necessary for the mature capsids to 
leave the nucleus.  Since HSV-1-UL25-C4A and -L3 mutants have subsequently 
been generated, it is now feasible to determine the amounts of pUL25 present 
on the C-capsids purified from mutant virus-infected cells in comparison to the 
level of the protein on C-capsids from wt HSV-1 infected cells.  
Characterisation of pUL26-L6, which is the sole member of the third class of 
pUL25 mutants, led to the identification of unstructured wt residues that are 
essential for virus assembly following nuclear egress of C-capsids.  In thin 
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sections of ΔUL25MO-infected cells expressing pUL25-L6 examined under the 
electron microscope, more naked capsids were seen in the cytoplasm and fewer 
enveloped virus particles were observed in comparison to mutant-infected cells 
expressing the wt pUL25.  These results suggest that the wt residues mutated in 
L6 are important for virus assembly at some point between tegumentation and 
secondary envelopment.  One possibility is that the unstructured residues in the 
L6 region of pUL25 may be required for the interaction of pUL25 with pUL36.   
However, the results of a GST pull-down assay using the fusion protein pGST-
UL36cbd indicated that the pUL25-L6 mutant protein interacted with the C-
terminal end of pUL36 (Chapter 7).  Since there is another pUL25 binding site 
available on pUL36 (BD II), it is possible that the L6 protein fails to bind to this 
site or potentially a third site at the N-terminus (Pasdeloup et al., 2009, Roberts 
et al., 2009).  If this were the case, it would suggest that the large UL36 
tegument protein (335.8 KDa) requires more than one attachment site in order 
for it to function properly.  As a consequence of this partial binding of the pUL36 
to capsids, reduced amounts of the protein may be present on the capsid or 
pUL36 may be incorrectly folded on the capsid.  This in turn could lead to a 
reduced number of enveloped virus particles as a result of slower transport of 
capsids to the site of secondary envelopment in comparison to ΔUL25MO-fected 
cells expressing wt pUL25, and/or inefficient envelopment (Desai, 2000, Fuchs 
et al., 2002a).  Further studies of the interactions of the other pUL25 binding 
domains of pUL36, BD II and the predicted domain at the N-terminus, with the 
packaging competent mutant proteins (pUL25-C4A, -L3 and –L6) identified here 
may help to clarify when and where pUL36 attaches to the capsid in infected 
cells, and whether these mutant proteins have impaired interaction with pUL36. 
The functional screens used in the current study did not investigate whether any 
of the mutant proteins generated affected the release of the virus genome from 
the capsid and it is possible that the L6 mutation, like ts1249, disrupts two 
different functions of pUL25.  Although the L6 residues do not lie near the 
ts1249 mutation, they could affect the same function but not necessarily the 
same interface.  There are several possible explanations for the uncoating 
phenotype of ts1249.  The ts1249 E233K mutation could destabilise a critical 
interaction site of pUL25 with, for example, the nucleoporins CAN/Nup214 or 
hCG1.  Support for this idea has come from observations that ts1249 capsids 
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produced at the PT fail to bind to isolated nuclei at the NPT but associate with 
them at the PT (Dr. D. Pasdeloup, personal communication).  An alternative 
explanation for the phenotype of ts1249, which is similar to the pUL36 mutant 
tsB7 phenotype (Section 1.3.1.2), is that the interaction between pUL25 and 
pUL36 is altered in the ts1249-infected or tsB7-infected cells, leading to failure 
to release virus DNA from the capsid or the inability to expose UL25-NPC binding 
sites.  The UL36 protein is a large protein and it is possible that it could interact 
with several functional interfaces of pUL25.  Experiments are underway in the 
lab to determine if the HSV-1-UL25-L6 mutant virus has an uncoating defect 
using the same approach that was used to investigate whether capsids lacking 
pUL36 were able to initiate infection (Roberts et al., 2009). 
The ET analysis used by Bowman et al. (2006) has proved to be an extremely 
powerful tool for identifying important functional interfaces on the pUL25 
structure.  Two of the four predicted functional ET clusters (C3 and C4) were 
found to be essential for the function of the protein, with the mutational 
analysis of selected residues in C4 identifying a novel function for pUL25 during 
the egress of capsids from the nucleus.  Further mutagenesis of the two other ET 
clusters, C1 and C2, is necessary in order to investigate the functions of these 
predicted interfaces.  SIFT analysis of the potentially functional amino acids in 
the C1 and C2 constructs generated here, calculated that two of the alanine 
substitutions in each of the C1 and C2 mutant proteins may be tolerated and, 
therefore, are unlikely to disrupt the function of the mutant proteins they 
expressed.  In addition, only three of the nine possible functional residues were 
mutated in the C1 construct created.  The tactical approach used to determine 
the functional significance of the unstructured amino acids in L1-L6 by creating 
deletion mutants was validated following analysis of the two L6 proteins, one of 
which encoded a deletion while the other contained missense mutations.  The 
deletion of the wt residues in pUL25-L6 altered the function of the protein 
significantly, whereas the substitution of the same wt residues in pUL25-L6sub 
produced no major defect when expressed in ΔUL25MO-infected cells.  By 
deleting unstructured residues, three of the six disordered regions targeted were 
shown to be essential for the protein’s function, enabling two new important 
roles to be identified for pUL25 in addition to DNA packaging. 
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Further analysis of the mutant viruses that have either been generated, HSV-1-
UL25-C4A, -L3 and -L6, or is in progress, HSV-1-UL25-C3B and –L5, will help to 
confirm and extend the phenotypes identified during this study.   
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